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A B STR A C T
The eosinophil is a proinflammatory leukocyte that is present in the circulation and in 
tissues in low levels in healthy individuals. In atopies, levels of this cell are markedly 
elevated and eosinophilic inflammation is believed to underlie the pathophysiological 
changes in affected tissues. Eosinophils have been linked with the aetiology of numerous 
diseases, notably asthma, rhinitis and dermatitis. The targeting of eosinophil trafficking 
and activation presents a potential target for therapy of allergic disease. The mechanisms 
regulating the trafficking and activation of eosinophils are complex and are potentially 
modulated by numerous cytokines, chemokines, lipid mediators and low molecular 
weight bioactive peptides. However, the molecules and mechanisms that selectively 
regulate trafficking and activation of eosinophils remain/unclear. Notably , the cytokines 
eotaxin (chemotactic cytokine) and IL-5 have been shown to have important roles in 
eosinophil trafficking and activation and may selectively regulate eosinophilic responses 
at basal states and during inflammation. Furthermore, these cytokines co-operate to 
regulate eosinophilia. Currently, the relationship between IL-5 and eotaxin for regulation 
of eosinophil trafficking and activation has not been fully elucidated.
In order to determine the roles of, and relationship between, eotaxin and IL-5 for 
eosinophil trafficking in the circulation and in the skin, recombinant cytokines were 
administered to mice intravenously and instilled into the skin, and the levels of 
eosinophils in each of these compartments monitored. Both IL-5 and eotaxin potently 
induced blood eosinophilia when administered intravenously. Moreover, they acted in 
co-operation. Intravenous IL-5 mobilised eosinophils from the bone marrow, while i.v. 
eotaxin acted independently of this compartment. IL-5 and eotaxin also potently induced 
tissue eosinophilia when administered to the skin and their collective actions were 
synergistic. IL-5 also acted in synergy with two other C-C chemokines, M IP -la  and 
RANTES, but not with the lipid mediators, PAF and LTB4. These results suggest that 
IL-5 may selectively amplify intracellular signals activated by CCR3 ligands.
The role of eotaxin and IL-5 in the regulation of selective eosinophilia and activation in 
the lung was also examined by employing recombinant vaccinia viruses (rVV) engineered 
to express eotaxin and IL-5 in situ. rVV-HA-IL-5 and rVV-HA-eotaxin potently induced 
pulmonary eosinophilia in naive mice and co-infections at equivalent viral titres resulted in 
a synergistic response. However, rW -HA-IL-5- and rVV-HA-eotaxin- induced airways 
eosinophilia only resulted in the induction of airways hyperreactivity and elevated levels 
of major basic protein in the BALF after aeroallergen provocation, and this response was 
CD4-dependent. Thus, IL-5 and eotaxin in conjunction with other inflammatory
mediators released during antigen processing and CD4 T-cell activation are required to 
promote eosinophil activation and airways hyperreactivity.
IL-5- and eotaxin- deficient mice were also employed to investigate the role of, and 
relationship between, each of these cytokines in eosinophilic trafficking at base line and 
during allergic responses. Under these conditions eosinophil levels in the bone marrow, 
blood and tissues were monitored in response to systemic delivery of eotaxin and IL-5 or 
allergen. By employing IL-5 deficient mice, this cytokine was found to be essential for 
the homing and migration of eosinophils into tissues in response to specific chemotactic 
stimuli (ie. eotaxin and IL-5) at base line^Iow ever, IL-5 was not required for eosinophil 
homing to allergic sites of inflammation in the skin or lung. These results suggest that 
other molecules are released at sites of inflammation that can take the place of LL-5 in 
promoting eosinophil trafficking into tissues. IL-5 was also not required for the 
development of blood eosinophiiia in response to i.v. eotaxin. Thus, two mechanisms 
may exist to regulate eosinophiiia in the circulation. Eotaxin regulated eosinophil 
recruitment to sites of allergic inflammation in the skin and controled the action of IL-5 on 
eosinophil differentiation in the bone marrow. Eotaxin was not required for eosinophil 
trafficking to the lungs during late-phase responses to aeroallergen inhalation.
The role of EL-5 and eotaxin in the development of eosinophil-mediated airways 
hyperreactivity was also studied by using IL-5- or eotaxin- deficient mice. Due to the 
close association between IL-5 and eosinophiiia, the role that each factor plays 
individually in the development of allergic disease remains unknown. By amplifying 
pulmonary eosinophiiia in IL-5 deficient mice by adoptive transfer of eosinophils or by 
i.v. administration of eotaxin, the individual roles of IL-5 and eosinophils in the 
development of airways hyperreactivity following aeroallergen provocation was 
examined. Airways hyperreactivity was induced in IL-5 deficient mice following 
sensitisation and aeroallergen provocation and the degree of reactivity correlated with the 
presence of major basic protein and the number of eosinophils in the airways. This 
relationship between eosinophil numbers in the airways, major basic protein levels and 
airways hyperreactivity was also observed in wild type mice. However, airways 
hyperreactivity was significantly reduced and qiifcsl PB B I  in IL-5 deficient mice. The 
i.v. adoptive transfer of donor eosinophils and the i.v. administration of eotaxin 
selectively amplified the accumulation of eosinophils in the airways which directly 
correlated with the level of airways hyperreactivity. Furthermore, although airways 
hyperreactivity developed in the absence of IL-5, this molecule played a significant role in 
amplifying the induction of airways hyperreactivity. Airways hyperreactivity was not 
significantly attenuated in sensitised and aeroallergen challenged eotaxin deficient mice.
In an attempt to define the elemental signals required for the trafficking of eosinophil into 
sites of allergic inflammation, the requirements'!^ IL-5, IL-4, TNF-a and IL -lß  in
\ a>p  r o
eosinophil recruitment during allergic cutaneous late-phase reactions was examined in 
mice using anti-cytokine mAbs and cytokine (or receptor) deficient mice. Eosinophil 
recruitment to sites of allergen provocation in the skin is dependent on IL-4 and TNF-a in 
IL-5 deficient mice, but not in wild type mice. These results suggest that IL-5 may have 
overlapping function with IL-4 and TNF-a and may promote eosinophil recruitment to 
sites of allergen provocation by activating adhesion systems at the vascular endothelium. 
Furthermore, eosinophil recruitment at sites of inflammation was dependent on ICAM-1 
and VCAM-1 and thus, IL-4, TNF-a and IL-5 may activate these adhesion pathways.
In conclusion, IL-5 and eotaxin play fundamental roles in the regulation of eosinophil 
function. Notably both cytokines can regulate eosinophil differentiation, as well as blood 
and tissue/ eosinophilia. In particular, the migration of eosinophils is regulated by a
CR3 which
provides a mechanism that synergistically and selectively potentiates eosinophilia. 
Modulation of IL-5 and^^a?dn^ignalling may provide a significant advance in the 
treatment of eosinophil derived pathophysiology in allergic disease.
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CHAPTER I
INTRODUCTION
l
1.1 IN T R O D U C T IO N .
The eosinophilic leukocyte has been implicated as a primary effector cell in the 
pathogenesis of allergic inflammatory diseases such as asthma, rhinitis and dermatitis, in 
addition to inflammatory bowel disease and certain disorders of the nervous system 
(Gleich and Adolphson, 1986; Walsh and Gaginella, 1991). The severity and high 
frequency of allergic diseases in society, particularly asthma, has led to extensive 
investigations into the mechanisms regulating the recruitment and activation of 
eosinophils at sites of inflammation. To specifically target the action of the eosinophil in 
disease pathology, it is necessary to further elucidate the complex mechanisms that are 
involved in the recruitment and activation of this cell at sites of inflammation. 
Characterisation of these mechanisms will also aid in the further understanding of the role 
of eosinophils in numerous other physiological responses, such as the hosts 
resistance/defence against some parasites (particularly helminths), wound healing, tissue 
remodelling and anti-tumourogenesis (Lowe e ta l, 1981; Todd et al., 1991; Wong etal., 
1993; Wardlaw et al., 1995).
1.2 EO SIN O PH ILS AND A TO PIC  A LLER G IC  DISEASES.
The association of eosinophils with atopic inflammatory diseases, such as asthma, 
rhinitis and dermatitis is well documented (Bruijnzeel et al., 1989; Bousquet et al., 1990; 
Naclerio et al., 1994; Leiferman, 1994). Furthermore, there is increasing evidence that 
eosinophilic inflammation underlies the pathophysiological changes that are associated 
with these diseases (Reed, 1986; de Vries, 1994, Oddera et al., 1996).
Atopic asthma is a chronic inflammatory disorder of the lung that is primarily 
characterised by chronic airways inflammation, reversible airways obstruction and 
airways hyperreactivity to inhaled spasmogens, such as ß-methylcholine and histamine 
(Bochner et al., 1994). Although the exact cause of atopic allergy (particularly asthma) 
remains unknown, eosinophilic inflammation is currently thought to underlie 
pathophysiological changes that are characteristically seen in susceptible individuals 
(Bousquet et al., 1990; Wardlaw et al., 1994; Martin et al., 1996). This is particularly 
evident in clinical asthma and experimental animal models of asthma where there are 
strong correlations between eosinophilic inflammation, the induction of airways 
hyperreactivity to inhaled spasmogens and disease severity (Bradley et al., 1991; Elwood 
et al., 1991).
Elevated levels of activated eosinophils are present in bronchial biopsies, bronchoalveolar 
lavage fluid (BALF) and in the peripheral blood of patients with asthma (Bochner et al., 
1994). Clinical observations have also shown a correlation between eosinophil numbers
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in the circulation and in the BALF of asthmatics and the severity of disease (Bousquet et 
al, 1990; Walker et al., 1991). There are, however, some clinical and experimental 
studies that have not found a direct correlation between the levels of eosinophils in the 
BALF and airways hyperreactivity (Djukanovic et al., 1990; Ishida et al., 1990; Banner 
et al., 1996).
Atopic dermatitis is a chronic eosinophilic inflammatory disease of the skin which shares 
many similarities with asthma. Large amounts of eosinophil granular proteins have been 
found in biopsies of skin lesions and sufferers of this disease commonly have elevated 
levels of circulating eosinophils and IgE (Rajika, 1975; Leiferman et al., 1985, 1990; 
Cheng et al., 1997). Elevated levels of serum IgE are seasonal and can be related to the 
presence of specific environmental allergens (de Vries, 1994). Atopic individuals exhibit 
hypersensitivity to specific environmental allergens and usually experience a severe, often 
organ-specific allergic reaction within minutes of allergen exposure. Antigen-induced 
crosslinking of two or more IgE molecules, that are bound to mast cells and basophils via 
the high affinity IgE receptor (Fcyll) are thought to trigger the release of various 
inflammatory mediators [such as histamine and platelet activating factor (PAF)] that drive 
the inflammatory response.
Atopic individuals may also experience a delayed non-specific hypersensitivity reaction 
that occurs within 6 hours after allergen exposure and lasts up to 12 hours. In atopic 
dermatitis the delayed response is characterised by a cutaneous blanch reaction, while in
individuals with asthma this responses takes the form of a spasmodic narrowing of the
,\n one second^
airways with an associated reduction in forced expiratory volume (FEV^. This 
hypersensitivity reaction is commonly termed the late-phase response (LPR) and is 
characteristically accompanied by a pronounced infiltration of inflammatory cells into the 
site of allergen exposure. In asthma, the late-phase response is most notably 
characterised by the presence of activated eosinophils and of T-lymphocytes, although 
other inflammatory cells such as macrophages and neutrophils may also be present. 
Notably, the T-lymphocytes are CD4 positive and are of a Th2 phenotype (de Vries,
1994; Wardlaw et al., 1995).
1.3 THE ROLE OF EOSINOPHILS IN PATHOGENESIS OF ALLERGIC 
DISEASE.
Upon activation, eosinophils have been shown to secrete a multitude of proinflammatory 
mediators [reactive oxygen species, lipid mediators (leukotrienes and PAF) and cationic 
proteins] and cytokines that have the potential to induce tissue damage and dysfunction 
(Bruijnzeel, 1989; Gleich, 1990, Gleich et al., 1994).
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Four eosinophil cationic proteins have been characterised [major basic protein (MBP), 
eosinophil peroxidase (EPO), eosinophil cationic protein (ECP) and eosinophil derived 
neurotoxin (EDN)]. These proteins are found in the cytoplasmic granules of the 
eosinophil (Wardlaw et al., 1995) and through a process termed degranulation, they are 
directionally released into the extracellular environment. Elevated levels of cationic 
proteins are present in the affected tissues of a number of eosinophilic diseases (Dor et 
al., 1984; Hisamatsu et a i, 1995; Leonardi et al., 1995). Furthermore, a correlation 
between the levels of these cationic proteins in the B ALF and the clinical symptoms of 
asthma has been demonstrated (Frigas et al., 1981; Wardlaw et al., 1988). Some of 
these cationic proteins (EPO and MBP) have been shown to be potent cytotoxins for the 
nasal and respiratory epithelium, inducing cilliostasis and tracheal epithelial denudation, 
in vitro (Ayars et al., 1989; Motojima et al., 1989; Tagari et al., 1992). In studies 
involving primates, the direct instillation of recombinant human MBP to the lung was 
able to enhance airway hyperresponsiveness to ß-methylcholine. Moreover, this effect of 
MBP was dose dependent and required an intact epithelium (Flavahan et a l, 1988;
Gundel et al., 1991). Cytotoxic concentrations of MBP are found in airways of 
asthmatics and at sites of inflammation in other allergic diseases (Gleich et al., 1979). 
Studies in rats have also show a role for MBP in the induction of epithelial-dependent 
airway hyperreactivity (Coyle et al., 1994). MBP-induced airways hyperreactivity in
rats may be dependent on the generation of i-kinins, such as bradykinin (Coyle et al.,
i = { m m u A o t e ö c V i \ j e
However, MBP and other cationic proteins may induced airways hyperreactivity by 
multiple mechanisms. MBP and EPO may enhance vagally mediated bronchoconstriction 
by acting as allosteric inhibitors of muscarinic M2 receptors (Gleich et al., 1995), in 
additon MBP may also activate platelets, neutrophils, mast cells and basophils to release 
numerous proinflammatory cytokines and lipid mediators (O'Donnel et al., 1983; 
Rohrbach et al., 1990; Moy et al., 1990).
1.4 MECHANISM OF EOSINOPHIL TRAFFICKING AND 
DEGRANULATION.
Clinical observations and investigations in animal models of allergy are slowly 
elucidating the complex mechanisms involved in the trafficking of eosinophils in 
inflammatory diseases. During an allergic response eosinophils must traffic from the 
bone marrow compartment to the site of inflammation. Eosinophil migration and 
activation are regulated by 6 key events: 1. Inflammatory stimuli at the site of 
inflammation initiate a series of signalling events that leads to the differentiation of a 
committed eosinophil/basophil precursor cell within the bone marrow (or in the 
circulation) into mature eosinophils; 2. Eosinophils residing in the bone marrow enter
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the blood stream; 3. Inflammatory mediators (specific cytokines and lipid mediators) 
released at the sites of inflammation upregulate the expression of specific adhesion 
molecules on the vascular endothelium and on the eosinophil and prime this cell for 
chemotactic and degranulatory responses; 4. At sites of inflammation, activated 
eosinophils bind to complementary adhesion molecules on the vascular endothelium and 
undergo diapedesis; 5. Eosinophils directionally migrate towards the site of 
inflammation (chemotaxis) in response to chemotactic signals elicited by cytokines, 
chemokines and lipid mediators that are produced at the site of inflammation. In addition, 
locally produced cytokines prolong eosinophil survival by inhibiting apoptosis; 6. 
Signalling events involving specific inflammatory mediators, such as allergen-specific 
immunoglobulins, activate eosinophils resulting in the release of oxygen radicals, lipid 
mediators and cytotoxic cationic proteins which promote tissue dysfunction and disease 
pathology.
1.4.1 Eosinophil differentiation.
As with all cells of the lymphomyeolid lineage, eosinophils are derived from 
haemopoietic stem cells which reside in the bone marrow (Wardlaw et al., 1995). In a 
complex mechanism of interaction, potentially involving interleukin (IL) -6, IL-11, EL- 
12, granulocyte-colony stimulating factor (G-CSF), leukemia-inhibitory factor (LIF) and 
steel factor, haemopoietic stem cells are committed into multipotential CD34+ progenitors 
(Ogawa, 1994).
In the presence of IL-3 and/or granulocyte macrophage-colony stimulating factor (GM- 
CSF), CD34+ myeloid progenitor cells undergo committed differentiation into CD34+ 
basophil/eosinophil myeloid progenitor cells. The intravenous administration of IL-3 and
oN
GM-CSF synergistidly stimulates an increase in eosinophil/basophil precursor levels in 
the circulation (Donahue et al, 1988). However, the involvement of IL-3 and/or GM- 
CSF in the generation of eosinophil precursor cells is not mandatory, as mature 
eosinophils are found in mice with impaired IL-3 and GM-CSF function (Nishinakamura 
et al., 1996). Although eosinophil/basophil progenitor cells are predominantly found in 
the bone marrow, these cells are also present in the circulation, particularly in atopic 
individuals (Denburg et al., 1983, 1985a, 1985b).
In the presence of either IL-3, IL-5 or GM-CSF individual basophil/eosinophil 
precursors cells may undergo differentiation/proliferation to form homozyf ou^colonies 
of either the basophil or eosinophil lineage or heterozygous basophil/eosinophil colonies. 
Generally, IL-3 and IL-5 preferentially direct and stimulate the differentiation of human 
basophil/eosinophil precursor cells towards the basophil and eosinophil lineages, 
respectively (Sanderson et al., 1985; Meyer et al., 1989; Valent et al., 1989). In
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contrast, GM-CSF does not appear to be selective in its action on the differentiation of 
basophil/eosinophil progenitor cells and gives rise to mixed colonies when added to 
peripheral blood-derived basophil/eosinophil precursor cells in vitro (Denburg e ta l,  
1991).
In the murine system, IL-5 is a potent inducer of basophil/eosinophil progenitor 
differentiation towards the eosinophil lineage in culture, giving rise to almost pure 
eosinophil colonies (Sanderson et a l, 1985). In contrast, IL-3 appears to act primarily as 
a mast cell growth factor (Ihle et a l, 1983). Both IL-3 and GM-CSF are regarded as 
multi-haemopoietins and are potentially involved in the committed-differentiation of many 
different myeloid lineages (Metcalfe, 1993). IL-5 on the other hand appears to be 
primarily an eosinophil differentiation factor (Denburg et a l, 1994). Notably, IL-5 also 
plays a key role in the later stages of eosinophil differentiation. However, mice 
genetically altered for the over expression of this cytokine exhibit pronounced blood and 
tissue eosinophilia (Clutterbuck et a l, 1989; Dent e ta l, 1990; Tominaga et a l, 1991; 
Shalit et a l, 1995). This indicates that IL-5 may also directly or indirectly (via the 
stimulation of other signalling molecules) influence early myeloid progenitor commitment 
towards the eosinophil lineage. In contrast, mice expressing high levels of IL-3 or GM- 
CSF exhibit only mild blood eosinophilia and have high levels of cells of other myeloid 
lineages, such as neutrophils and macrophages (Chang et a l, 1989; Johnson et a l,
1989). Interestingly, mice genetically altered for functional loss of IL-5, IL-3 and GM- 
CSF possess morphologically mature eosinophils, albeit at lower levels (Nishinakamura 
et al., 1996). This suggests there is a degree of redundancy in the action of these three 
cytokines in basal eosinophil development. IL-5, EL-3 and GM-CSF may have a more 
important role in enhancing eosinophil production during inflammation where levels of 
each of these cytokines are elevated (Walker et a l, 1992).
Studies by Perez et al., (1993) supports the existence of an IL-5, IL-3 and GM-CSF 
independent pathway for eosinophil proliferation. The cell-free pleural washings from 
rats given an injection of platelet-activating factor (PAF) into the pleural cavity stimulated 
murine haemopoietic eosinophil proliferation in vitro and this response was not inhibited 
by neutralising antibodies to IL-5, IL-3 or GM-CSF given alone or in combination to the 
cell culture. The role of cytokines in eosinophil differentiation is summarised in figure 
1. 1.
1.4.2 Eosinophil Priming.
Circulating eosinophils in atopic individuals are morphologicaEy and functionally 
dissimilar to those in the circulation of non-atopics (Kermal et a l, 1990; Griffin et al., 
1991). Eosinophils from atopic individuals are characteristically hypodense and may be
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Figure 1.1 Eosinophil differentiation.
Haemopoietic stem cells undergo differentiation into CD34+ myeloid progenitor 
cells in a complex interaction that is thought to involve IL-6, IL-11, IL-12, G-CSF, 
LIF and Steel factor. In the presence of GM-CSF and IL-3 this cell population 
undergoes committed differentiation into an eosinophil/basophil progenitor cell. 
Eosinophil/basophil progenitor cells differentiate toward eosinophil or basophil 
lineages and this process is probably regulated by LL-5, IL-3 and GM-CSF 
(Wardlaw et al., 1995).
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separated from those of a healthy individual by Percoll density gradients (Fukuda et al, 
1985). Associated with this change in eosinophil density is the enhancement of 
numerous eosinophil functional responses, including mobility (chemotaxis), cellular 
adhesion and terminal effector function (ie. degranulation) (Carlson et al, 1991;
Warringa et al, 1992a; Li et al, 1996). The enhanced chemotactic responses of 
eosinophils isolated from atopic individuals to PAF is well documented with cells 
showing strong chemotactic responses at concentrations of this molecule that are 
suboptimal for eosinophils from a healthy donor (Morita, et al, 1989; Warringa et al, 
1992a). Hypodense eosinophils isolated from the blood of atopies also exhibit strong 
chemotactic responses to IL-8, IL-4 and N-formyl-methionyl-leucyl-phenylalanine 
(fMLP) (Eda et a l, 1993; Warringa et a l, 1993; Dubois et a l, 1994). In contrast, 
eosinophils from normal donors respond only weakly or not at all to these molecules.
The hypodense phenotype is thought to be effected by mediators of inflammation such as 
PAF and the cytokines, DL-3, GM-CSF and IL-5 (Yukawa et al, 1989; Koenderman et 
al, 1996). Low density eosinophils are also found in individuals afflicted with the 
hypereosinophilic syndrome (HES), however, although eosinophil hypodensity has been 
associated with eosinophil# priming, this lower density phenotype does not always 
confer enhanced chemotactic responsiveness to PAF (Little and Casale, 1991).
1.4.2.1 The enhancement of eosinophil chemotaxis and migration by 
priming.
Allergic inflammation in thought to underlie disease pathology in atopies and is primarily 
characterised by elevated circulating levels and tissue infiltration of activated eosinophils 
and CD4+ T-lymphocytes. This population of T-lymphocytes secrete cytokines of a Th2 
type, including IL-4, IL-5 and IL-10. Th2 cells also produce GM-CSF and IL-3. 
Although weak chemotactic agents for non-primed human eosinophils in vitro, IL-5, IL-3 
and GM-CSF may have a major role in the priming of eosinophil function whilst in the 
circulation (Semhi et a l, 1992). IL-5 has been shown to selectively enhance the in vitro 
chemotactic responses of normal human eosinophils, but not neutrophils, to lipid 
mediators [PAF, leukotriene B4 (LTB4)], fMLP and chemokines of both C-C [Regulated 
upon activation in normal T-cells expressed and secreted (RANTES)] and C-X-C (IL-8) 
families, as measured in vitro with Boyden chambers (Sehmi et al, 1992; Schweizer et 
a l, 1994).
The ability of IL-5 to enhance the chemotactic responses of eosinophils to molecules, 
such as PAF, may involve the upregulation of chemoattractant receptors on the eosinophil 
(Kishimoto et al, 1996). The preincubation of normal human eosinophils with pico- 
molar concentrations of GM-CSF or IL-3 enhances the in vitro chemotactic response of 
these cells to LTB4 and PAF, respectively. Individually, both of these cytokines
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stimulate normal eosinophils to chemotactically respond to IL-8 and fMLP (Warringa et 
al., 1991). A role for IL-5 in the priming of eosinophils in vivo has also been shown. 
Eosinophils purified from allergic guinea pigs are more responsive to chemotactic stimuli 
(including PAF and LTB4) in vitro, than non-allergic controls (Coeffeir et al., 1994). 
Furthermore, the pretreatment of these allergic animals with anti-IL-5 mAh, before 
antigen challenge reduces the in vitro chemotactic responsiveness of eosinophils to PAF 
and LTB4.
In addition to enhancing chemotaxis, cytokines may prime eosinophils for enhanced 
adhesion to the vascular endothelium through the activation of adhesion systems. GM- 
CSF activates the functional adhesive state of vascular cell adhesion molecule-4 (VLA-4) 
on eosinophils without any apparent upregulation of expression (Paul-Sung et al., 1997). 
Both PAF and platelet factor-4 increase the adhesion of eosinophils to tissue culture 
plates coated with soluble intercellular adhesion molecule-1 (ICAM-1) and this process 
may involve the induction of the expression of lymphocyte function-associated antigen- 
l a  (LFA -la) and LFA-lß  on the eosinophil (Hayashi et al., 1994). Certain 
neuropeptides (substance P, neurokinin A, calcitonin gene-related peptide and 
cholecystokinin octapeptide) also have priming effects leading to enhanced chemotactic 
responsiveness of eosinophils to PAF and LTB4 in vitro. Interestingly, the priming 
ability of these neuropeptides was reported to only be active on eosinophils isolated from 
the blood of atopies (Nuamo and Agrawal, 1992).
1.4.2.2 Eosinophil cytotoxicity and cytokine priming.
The priming of eosinophils by cytokines does not only lead to enhanced 
chemotactic/migrational responses. In the presence of some cytokines eosinophils 
display hypersensitivity to degranulatory stimuli. IL-5, IL-3 and GM-CSF all enhance 
immmunoglobulin-dependent eosinophil degranulation in vitro, while IL-1, IL-2, IL-4, 
IL-6 and TNF-a appear to have no effect (Fugisawa et al., 1990). One cytotoxic 
property of eosinophils involves the generation and release of reactive oxygen species 
through a process termed respiratory burst. The stimulation of respiratory bursts in 
human eosinophils, induced by serum-treated zymosan particles, is also enhanced by the 
prior exposure of the cells to either IL-5, IL-3 or GM-CSF (Van de Brüggen et al., 1993; 
Koenderman et al., 1996).
1.4.3 The role of adhesion molecules in eosinophil trafficking.
The preferential accumulation of eosinophils, but not neutrophils, at sites of inflammation 
is a hallmark of many atopic inflammatory diseases. For eosinophils to migrate from the 
circulation into inflamed tissues in response to chemotactic signals they must cross the
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vascular endothelium. In order to do this eosinophils utilise a number of adhesion 
systems that are activated by inflammatory cytokines and lipid mediators. Eosinophil 
transendothelial migration is thought to regulated by the selectin and 
integrin/immunoglobulin families in concert with unidirectional chemotactic gradients 
generated at the site of inflammation (reviewed by Hogan and Foster, 1996).
I.4.3.1 The role of selectins in eosinophils adhesion to the vascular 
endothelium.
Selectins are a family of fucosylated carbohydrate ligand-binding adhesion molecules that 
include L-, P- and E- subtypes (named according to their expression on leukocytes, 
platelets and endothelial cells), all of whom share a common N-terminal lectin and 
epithelial growth factor like domains (Wardlaw et al, 1995).
L-selectin is expressed on all circulating leukocytes including eosinophils, while both E- 
and P-selectins are expressed primarily on endothelial cells following cytokine activation 
(Bevilacqua et al, 1987; Tedder et al, 1995). The initial tethering of eosinophils to, and 
their subsequent rolling along, the vascular endothelium during early events of 
transendothelial migration has not been fully characterised, but may involve adhesion 
processes that utilise L-selectin and P-selectin (Wardlaw et al, 1994). Antibodies against 
L-selectin block eosinophil adhesion to cytokine activated endothelial cells in vitro (Knol 
et al, 1994). Interestingly, although neutrophils reportedly use L-selectin to tether to the 
activated endothelium, the adhesion of neutrophils and eosinophils to the vascular 
endothelium through this molecule has been shown to involve* different mechanisms 
(Knol et al, 1994). This suggests that the binding of L-selectin to its ligand(s) at the 
vascular endothelium is cell specific.
A role for L-selectin in eosinophil tethering and rolling along the vascular endothelium 
has been demonstrated in rabbit mesenteric venules in vivo (Sriramarao et a l, 1994). 
Interestingly, PAF, IL-5 and IL-3 all induce the shedding of L-selectin from eosinophils 
in vitro (Smith et al, 1992; Needley et al, 1993). The shedding of L-selectin by these 
cytokines co-incides with the upregulation of another adhesion molecule, Mac-1, on the 
surface of the eosinophil. Mac-1 may enhance anchoring and transmigration of the 
eosinophil through activated endothelium by interaction with the counter ligand, ICAM-1 
(Zimmerman et al, 1992; Ebisawa et al, 1992). It has also been suggested that the 
shedding of L-selectin and the subsequent upregulation of Mac-1 on the eosinophil is 
probably induced by physical interactions between this leukocyte and the endothelium 
(Ebisawa et a l, 1992). Eosinophils isolated from the BALF of asthmatic patients 
following aeroallergen provocation have decreased levels of membrane associated
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L-selectin in comparison to eosinophils isolated from the blood of the same individuals 
(Georas et al, 1992) and thus, the shedding of L-selectin may be necessary for 
transmigration to occur (Wardlaw et al, 1994).
The role of E-selectin and P-selectin in eosinophil binding to the vascular endothelium is 
not clear. Tissue culture plates coated with recombinant P- or E- selectins bind 
eosinophils and adherence is inhibited by the addition of antibodies raised against the 
respective selectin (Weller et al, 1991; Wein et al, 1995). Other in vitro studies, 
however, do not support a physiological role for E-selectin in the adherence of 
eosinophils to the activated endothelium (Sriramarao et al, 1996). Notably, E-selectin 
only weakly binds eosinophils under conditions of shear force which mimic the dynamics 
of blood flow. Conversely, there is strong evidence to suggest that P-selectin is involved 
in the recruitment of eosinophils to nasal polyps, possibly by promoting the initial 
tethering of eosinophils to the vascular endothelium at this site (Symon et al, 1994; 
Wardlaw et a l, 1994).
I.4.3.2 The role o f integrins and immunoglobulin family adhesion 
molecules in eosinophil transmigration.
Following the initial tethering and rolling of leukocytes along the vascular endothelium, 
stronger cell adhesion needs to take place for transmigration to occur (Zimmerman et al, 
1992). Both the integrin and the immunoglobulin families of adhesion molecules are 
thought to participate in this process of firm adherence of eosinophils to the endothelium 
(reviewed in Wardlaw et al, 1995).
1.4.3.2.1 The integrins.
The integrins are a superfamily of a /ß  heterodimeric transmembrane glycoproteins that 
function as adhesion molecules in cell-cell and cell-substratum interactions. Adhesion 
molecules from this superfamily are predominantly expressed on the surface of 
leukocytes and bind to counter ligands that are expressed on the surface of endothelial 
cells and other leukocytes (Haas and Plow, 1994; Hoire et al, 1997). Eosinophils 
express the ß2 integrins, LFA-l(CDlla/CD18) and Mac-1 (CD1 lb/CD 18) and the 0C4 ßi 
integrin, VLA-4. Importantly, VLA-4 is expressed on eosinophils, but not on 
neutrophils, suggesting a key role for this molecule in the selective migration of 
eosinophils into inflamed tissues in atopic disease (Nourshargh, 1993).
There are two known ligands for VLA-4, fibronectin and VCAM-1 (Elices et al, 1990) 
This suggests that VLA-4 may be involved in eosinophil adhesion to the vascular 
endothelium as well as migration within tissues. VLA-4 and L-selectin both mediate the
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rolling of eosinophils along venules (Sriramarao et al., 1994). In contrast, neutrophils 
are thought to predominantly use L-selectin in this phase of the migrational process. 
Eosinophils isolated from the blood of allergic asthmatics, but not those isolated from 
normal individuals, spontaneously transmigrate through IL-lß- or TNF-a- stimulated 
monolayers of human umbilical vascular endothelial cells (HUVEC). Transmigration 
may reflect cytokine activation of eosinophils in asthmatics, since normal eosinophils 
primed with either IL-5, IL-3 or GM-CSF also undergo spontaneous transendothelial 
migration in this in vitro system. Thus, transendothelial migration not only requires 
activation of the endothelium, but also of the eosinophil.
Studies using IL-4-stimulated HUVEC also showed that eosinophils isolated from 
individuals with atopic dermatitis spontaneously transmigrate through monolayers in 
comparison to eosinophils isolated from normal donors (Moser et al., 1992b). 
Furthermore, in contrast to IL -lß or TNF-a, the stimulation of HUVEC with IL-4 does 
not promote spontaneous neutrophil transmigration. Eosinophil transmigration through 
IL-4-activated monolayers of HUVEC was inhibited by anti-CD 11/CD 18 and anti-VLA-4 
mAbs (Moser et al., 1992b). Although GM-CSF is known to control the adhesive 
properties of VLA-4 on the eosinophil, transmigration through IL -lß  activated 
monolayers of HUVEC was inhibited only by anti-CD 11/CD 18 mAb, but not anti-VLA-4 
mAb (Moser et al., 1992a; Paul Sung et al., 1997). This indicates that eosinophil 
transmigration can occur independently of VLA-4 and that in different cytokine 
environments eosinophils may use different adhesion pathways during transendotheiiai 
migration. IL-lß appears to promote transmigration via the CD11/CD 18 adhesion 
pathways while IL-4 promotes transmigration via both CD 11/CD 18 and VLA-4 adhesion 
pathways. These studies also indicated the complementary adhesion molecules for both 
CD 18/CD 11 and VLA-4 are present on the atopic eosinophil. The observation that IL-4 
may activate VLA-4 on the eosinophil, but not on the neutrophil, implies that this 
cytokine plays a role in the selective trafficking of eosinophils during allergic 
inflammation (Moser, 1994).
A role for VLA-4 in the mechanism of eosinophil! accumulation in vivo has also been 
demonstrated. Pretreatment of guinea pigs with anti-VLA-4 mAb was shown to inhibit 
the accumulation of eosinophils in the skin is response to LTB4 or PAF and during 
passive cutaneous anaphylaxis, as well as in the nasal mucosa following antigen 
inhalation (Weg et al, 1993; Terada et al., 1996).
I.4.3.2.2 Immunoglobulin superfamilv.
ICAM-1 and VCAM-1 are two members of the immunoglobulin superfamily of adhesion 
molecules that regulate eosinophil adhesion in vivo. ICAM-1 is weakly expressed on the
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endothelium at non-inflamed sites and its expression is upregulated on endothelial cells 
by inflammatory cytokines (IFNy, IL -lß and TNF-a) and lipopolysacharide (LPS) 
(Acevedo et al., 1993). ICAM-1 acts as a ligand for both LFA-1 and Mac-1 and this 
interaction is potentially involved in the trafficking of numerous type of leukocytes 
(eosinophils, neutrophil and lymphocytes) (Marlin and Springer, 1987). ICAM-1 is 
involved in the adhesion of eosinophils to EL-1 (isotype undefined)-, TNF-a- orLPS- 
stimulated endothelial cultures by a mechanism involving CD 18-dependent interactions 
(Lamas et a l, 1988).
In contrast to ICAM-1, VC AM-1 is not detectable on resting endothelial cells. However, 
as with ICAM-1 the expression of VCAM-1 is upregulated in the presence of IFNy,
IL-lß and TNF-a. IL-4 also stimulates the expression of VCAM-1 on cultured 
endothelial cells, although this cytokine has little effect on ICAM-1 expression (Shimizu 
et a l, 1992). VCAM-1 binds the VLA-4 which is expressed on eosinophils but not 
neutrophils. The selective expression of this molecule on eosinophils suggests that the 
VC AM-1/VLA-4 pathway plays a prominent role in regulating eosinophilic inflammation 
in allergic disease (Nakajima et a l, 1994; Jahnsen, 1995; Tanimukai et al., 1995).
The expression of ICAM-1 on the vascular endothelium is upregulated in inflamed tissues 
of allergic individuals following allergen provocation (Kyan-Aung et al., 1991; Montefort 
et al., 1994). Increased ICAM-1 expression in the pulmonary vasculature of asthmatic 
patients has also been reported, although only in patients suffering from intrinsic and not 
extrinsic disease (Bentley et al., 1993, 1994). VCAM-1 expression on the vascular 
endothelium is also elevated in numerous allergic diseases and often correlates with the 
number of infiltrating eosinophils (Jahnsen et al., 1995; Nakumura, 1996).
A role for VCAM-l/VLA-4 interactions, but not the ICAM-l/LFA-1 adhesion system, in 
allergen-induced accumulation of eosinophils in the lungs of mice has been demonstrated 
by using blocking antibodies to each of these adhesion pathways (Nakajima et al., 1994). 
Furthermore, the inhibition of VCAM-1 and VLA-4 function, but not that of ICAM-1 or 
LFA-1 (with inhibitory mAbs) caused an increase in blood eosinophil numbers, 
suggesting a role for VCAM-1 and VLA-4 in the adhesion of eosinophils to the vascular 
endothelium in inflamed tissues. However, other studies using a sephadex-induced 
pulmonary eosinophilia model in guinea pigs demonstrated that the accumulation of 
eosinophils in the BALF was dependent on both VLA-4 and CD18-mediated pathways 
(Das et al., 1995).
In summary, current literature suggests that eosinophils may potentially use both the 
ICAM-1/CD11/CD18 and the VCAM-l/VLA-4 cellular adhesion pathways in the process 
of transendothelial migration, however, the specific expression of VLA-4 on eosinophils
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indicates that adhesion systems utilising this molecule selectively regulate the migration of 
this leukocyte into inflamed tissues during allergic responses.
The role of adhesion molecules in eosinophil adhesion and transendothelial migration is 
summarised in figure 1.2.
1.4.4 Molecules regulating eosinophil trafficking in tissues.
The accumulation of eosinophils in specific tissues is a prominent feature of atopic 
asthma and dermatitis. The mechanism by which eosinophils directionally migrate 
through tissues is thought to be mediated by the local release of chemoattracts and the 
generation of chemotactic gradients. For many years researchers have been trying to 
identify the molecule(s) involved in the selective accumulation of eosinophils at sites of 
inflammation. Numerous molecules (lipid mediators, small molecular weight peptides, 
cytokines and chemokines) induce eosinophil chemotaxis in vitro and/or regulate 
trafficking of this leukocyte in vivo. However, the majority of these molecules also act 
as chemoattractants for other leukocytes, questioning their relative roles and importance 
in eosinophil trafficking in many disease states (Wardlaw et a l, 1995).
I.4.4.1 Small molecular weight peptides and eosinophil trafficking.
Numerous small molecular weight peptides, including fMLP, the eosinophil chemotactic 
factor-A (ECF-A) tetra-peptides (Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu) and histamine, 
are all chemotactic for eosinophils in vitro (Clark et al., 1975; Goetzl and Austen, 1976; 
Ogawa et al., 1981). Extensive research in the 1970s and early 1980s into the role of 
histamine and ECF-A in eosinophil function was undertaken as these molecules were 
considered to be prime candidates for the regulation eosinophil trafficking in eosinophilic 
disorders. Histamine and ECF-A were shown to selectively induce the chemotaxis of 
eosinophils in vitro (Clark et al., 1975; Turnbull et al., 1977). Furthermore, the 
administration of ECF-A to primates promoted the recruitment of eosinophils to sites of 
instillation (Turnbull et a l, 1977). Enthusiasm for these molecules as key regulators of 
eosinophil trafficking in vivo was reduced, however, after Wardlaw et al., (1986) 
showed that both of these molecules were relatively weak in vitro chemoattractants for 
human eosinophils in comparison to PAF.
C5a, a peptide derivative of complement, is also a potent eosinophil chemoattractant in 
vitro and promoted the accumulation of eosinophils in the skin of guinea pigs (Kay et al., 
1973; Faccioli et al., 1991; Pettipher et al., 1994). However, C5a may regulate the 
accumulation of eosinophils in guinea-pig skin through the generation of other eosinophil
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Figure 1.2 The role of adhesion molecules in eosinophil trafficking.
Transendothelial migration of eosinophils involves the tethering, rolling and 
anchoring of the eosinophils to the vascular endothelium, followed by 
diapedesis. Tethering (A) may be regulated by L- and P-selectin while (B) 
firm anchoring of the eosinophil to the vascular endothelium appears to 
involve Mac-l/ICAM-1, LFA-l/ICAM-1 and VLA-4/VCAM-1 interactions. 
Firm anchoring of eosinophils is associated with the shedding of L-selectin 
and precedes the active process of diapedesis.
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chemoattractants such as LTB4 (Pettipher et al, 1994). C5a is also a potent 
chemoattractant for neutrophils in vitro and in vivo (Fischer and Czametzki, 1982;
Collins et al., 1993; Teixeira et al., 1994).
I.4.4.2 The role o f lipid mediators in eosinophil trafficking .
The lipid mediators, PAF and LTB4, potently induce eosinophil chemotaxis in vitro and 
regulate the accumulation of this leukocyte at sites of administration in vivo (Czametzki 
and Mertensmeier, 1985; Bisgaard et al, 1986; Sun et al., 1991; e Sliva et al., 1991). 
However, these two lipids are not selectively chemotactic for eosinophils, acting in vitro 
as potent chemoattractants for a range of leukocytes, particularly neutrophils (Czametzki 
and Mertensmeier, 1985; Bruijnzeel et al., 1990).
1.4.4.2.1 Platelet-activating factor.
PAF, also known as PAF-acether, is a potent chemotactic agent for human eosinophils in 
vitro (Sigal et al., 1987; Tamura et al., 1987; Sun et al., 1991). Eosinophils isolated 
from the blood of atopies exhibit stronger chemotactic responses to PAF than eosinophils 
that are isolated from the blood of non-allergic individuals (Warringa et al., 1992a). The 
enhanced responsiveness of eosinophils from atopic individuals is thought to be related to 
a higher cell activation (priming) state (Warringa et al, 1992b). In support of this theory 
is the ability of IL-5, IL-3 and GM-CSF (all elevated at sites of allergic disease) to prime 
normal eosinophils for enhanced chemotactic responsiveness to PAF in vitro (Warringa et 
al., 1992b). IL-5 may enhance chemotactic responses to PAF by inducing the expression 
of the PAF receptor (Kishimoto et al., 1996).
PAF also induces the transmigration of eosinophils through monolayers of HUVEC in 
vitro (Sano et al., 1995). This response is enhanced by the activation of HUVEC with 
either IL-lß or IL-4, indicating that PAF may act in synergy with inflammatory cytokines 
to promote the accumulation of eosinophils in vivo. PAF also induces transmigration of 
neutrophils across EL-lß-stimulated HUVEC, though interestingly, not across IL-4 
stimulated cultures (Sano et al., 1995). This indicates that PAF may act in concert with 
IL-4 to promote the selective transendothelial migration of eosinophils in vitro and 
collectively both molecules may play an important role in the selective accumulation of 
eosinophils (but not neutrophils) into inflamed tissues.
The administration of PAF induces a localised eosinophilia in both primates and rodents 
(Arnoux et al., 1988; Coyle et al., 1988). In man, the injection of PAF induces 
eosinophilia at the site of administration in atopies, but not in non-atopic individuals 
(Henocq and Vargaftig, 1986,1988; Fadel et al., 1990). Similar observations have also
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been reported in mice where the intradermal administration of PAF leads to a localised 
eosinophilia in antigen-sensitised, but not in non-sensitised animals (Yukawa et al,
1992). This indicates that eosinophils become responsive to PAF only after priming with 
inflammatory mediators in mice and humans. In contrast, the inhalation of PAF by naive 
guinea pigs and primates leads to pulmonary eosinophilia (Lellouch-Tubiana et al, 1987; 
Coyle et al., 1988; Amoux et al, 1988; Sanjar et al, 1990; Wegner et al, 1992). While 
numerous reports indicate that PAF is a potent inducer of the accumulation of eosinophils 
in vivo, eosinophil accumulatory responses to the administration of this molecule are 
often delayed, peaking at 24-48 hours later and may involve the generation of other 
eosinophil chemoattractants (Sanjar et al, 1990; e Silva et al, 1991). Furthermore, PAF 
also induces the accumulation of mononuclear cells and neutrophils at sites of 
administration in vivo (e Silva et al, 1991).
Although a role for PAF in eosinophil trafficking during allergy has been demonstrated in 
various rodent models of allergic inflammation (Coyle et al, 1988; Etienne et al, 1989; 
Iwamoto et al, 1992), other studies have failed to show any significant role for PAF in 
eosinophil recruitment in vivo (Richards et al, 1991a; Johnson et al, 1992).
I.4.4.2.2 L TB a.
Although some studies have shown LTB4 to be a potent eosinophil chemoattractantjrc 
vitro others have indicated that its action is relatively weak (Uden et al, 1983; Bruizneel 
et al, 1993). These observations may be dependent not only on the species from which 
the eosinophils are isolated, but also on the activational state of the cells being assayed 
(Sun et a l, 1991). LTB4 is a weak in vitro chemoattractant for eosinophils isolated from 
normal human blood or the peritoneal cavity of monkeys (Sun et a l, 1991). In contrast, 
eosinophils isolated from the peritoneal cavity of guinea pigs exhibit strong chemotactic 
responses to LTB4 Interestingly, the converse is true for PAF (Sun et al, 1991). 
Although LTB4 is chemotactic for both eosinophils and neutrophils in vitro, this molecule 
is preferentially chemotactic for eosinophils when compared on a molar basis. Studies in 
guinea pigs, however, show the converse in vivo, with large numbers of neutrophils 
accumulating at skin sites of LTB4 administration (Czametzki and Mertensmeier, 1985). 
Unlike PAF, rather than enhanced chemotaxis to LTB45 eosinophils obtained from atopic 
patients are less responsive to this lipid mediator than are cells isolated from non-atopic 
individuals (Czametzki and Rosenbach, 1986).
IL-5, IL-3 and GM-CSF all have the ability to prime eosinophils that are isolated from 
normal donors, but not from atopies, for enhanced chemotactic responses to LTB4 
(Sehmi et al, 1992). Notably, pico-molar concentrations of GM-CSF primed 
eosinophils for enhanced chemotactic responses to LTB4 in vitro, while nano-molar
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concentrations of this cytokine had the opposite effect (Waringa et a l, 1991). Thus, the 
reduced chemotactic responsiveness of eosinophils from atopic individuals may be due to 
the exposure of these cells to elevated levels of GM-CSF.
Elevated levels of LTB4 and 20-hydroxy-LTB4 are found in the B ALF of asthmatics 
(Lams et al, 1988; Wardlaw et al, 1989). Furthermore, eosinophils isolated from the 
BALF of atopic patients following segmental antigen challenge have a reduced 
chemotactic response to LTB4 (but not fMLP) in comparison with eosinophils isolated 
from the blood of the same individuals (Kim et al, 1994). These observations suggest 
that previous exposure of BALF eosinophils to LTB4 results in desensitisation to this 
molecule (Kim et al, 1994).
Similar observations in vivo have also been reported. 20-hydroxy-LTB4 induced a 
significant accumulation of eosinophils at skin sites of administration in non-atopic 
asthmatics, but not in atopic asthmatics or normal individuals. This may indicate a role 
for LTB4 and 20-hydroxy-LTB4 in eosinophil trafficking in non-atopic asthma 
(Bruijnzeel et al, 1993). The exposure of rats to an aerosol of LTB4 induced a delayed 
pulmonary eosinophilia similar to that observed in actively sensitised rats following 
antigen inhalation (Richards et al, 1991a). Antigen-induced BALF eosinophilia in 
actively sensitised guinea pigs and rats was also inhibited by an LTB4 antagonist 
(Richards et al, 1991a, 1991b). Similarly, the treatment of sensitised mice with an 
inhibitor of LTB4 synthesis also inhibited antigen-induced BALF eosinophilia 
(Henderson et a l, 1996). Interestingly, LTB4 antagonists had no effect on the antigen- 
induced influx of eosinophils into the trachea of actively sensitised dogs (Johnson et al, 
1992). Thus, although this molecule appears to play a significant role in the 
accumulation of eosinophils at sites of allergic inflammation in rodents, it may be of less 
importance in eosinophil recruitment during allergic responses in other species.
I.4.4.3 The role of cytokines in eosinophil trafficking.
Accumulating evidence indicates an important role for cytokines, particularly members of 
a subfamily of cytokines known as chemokines, in the mechanisms of eosinophil 
trafficking in vivo (reviewed by Hogan and Foster, 1996). Numerous cytokines (IL-lß, 
IL-2, IL-4, IL-5, GM-CSF and TNF-a) and chemokines [eotaxin, RANTES, 
macrophage inflammatory protein-la (M IP-la), monocyte chemoattractant protein-3 
(MCP-3), MCP-4 and IL-8] are chemotactic for eosinophils in vitro and/or induce the 
accumulation of eosinophils at sites of administration in vivo. These molecules may also 
have important roles in regulating the accumulation of eosinophils at sites of allergic 
inflammation (Rot et al, 1992; Dahinden et al, 1994; Santz et al, 1995; Milne et al,
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1995; Lukacs et al, 1996a; Alam et al, 1996; Garcia et al, 1996a, 1996b; White et al, 
1997).
1.4.4.3.1 Non-chemokine cytokines.
1.4.4.3.1.1 IL-1 and IL-2.
IL-1 ß is rapidly produced in the nasal mucosa of individuals with atopic rhinitis 
following allergen exposure and elevated levels of this cytokine are also found in the skin 
lesions of patients with atopic dermatitis (Bochner et al, 1990; Bachert and Ganzer,
1993). IL-1 (subtype undefined) also plays an important role in the induction of 
pulmonary eosinophilia during allergic inflammation in guinea pigs (Watson, 1993). 
Administration of recombinant murine IL-lß to the skin of rats leads to a dose dependent 
accumulation of In1 11-labelled eosinophils (Sanz et al., 1995). The ability of IL -lß to 
induce the accumulation of eosinophils in vivo may involve the generation of secondary 
molecules such as PAF and IL-8, as PAF antagonist and anti-IL-8 mAb inhibited IL -lß- 
induced accumulation of eosinophils in the skin of rats. In vitro, IL -lß  induces the 
migration of eosinophils across cultured endothelial cells and may regulate migration by 
activating adhesion systems (Ebisawa et al, 1992).
IL-2 is a potent in vitro chemotactic agent for human eosinophils expressing CD25 (IL-2 
receptor) (Rand et al, 1991). This cytokine may also promote the accumulation of 
eosinophils in tissues, although no role for this molecule in this capacity could be 
demonstrated in a murine model of antigen-induced eosinophilic inflammation (Horn and 
Estridge, 1994). Milne et al., (1995) reported that the exposure of guinea pigs to an 
aerosol of IL-2 caused an elevation in the levels of both eosinophils and macrophages in 
the BALF 24 hours later. These investigators also demonstrated, with the use of anti-IL- 
5 mAb, that this response was IL-5 independent, unlike earlier studies in mice 
(Yamaguchi et al, 1990). Other experiments examining the effects of IL-2 
administration on the accumulation of eosinophils in guinea-pig skin failed to show any 
effect over a period of 3 hours suggesting that IL-2 does not act as an eosinophil 
chemoattractant.
1.4.4.3.1.2 IL-4 .
IL-4 is chemotactic for eosinophils that are isolated from the blood of atopies but not 
from the circulation of normal individuals and the intraperitoneal and intradermal 
administration of IL-4 in mice leads to the selective accumulation of eosinophils at sites of 
installation (Moser et al, 1993; Dubois et al, 1994). In a murine model of allergic 
airways eosinophilic inflammation, IL-4 deficiency was shown to selectively reduce the
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accumulation of eosinophils in pulmonary tissues in comparison to wild type animals 
(Brusselle et a l, 1994).
IL-4 also potently and selectively induces transendothelial migration of "primed" 
eosinophils, but not neutrophils, in vitro and this effect maybe mediated by the 
upregulation of the CDlla/CD18, CDllb/CD18 and VLA-4 adhesion systems (Moser et 
a l, 1992a). IL-4 has also been shown to selectively up regulate the expression of 
VCAM-1, but not ICAM-1 or E-selectin on isolated endothelial cells. These results 
further support the concept that this cytokine may participate in the selective migration of 
eosinophils (but not neutrophils) into inflamed tissues (Schleimer et al., 1992; Nakajima 
et a l, 1994).
Experiments in IL-4-deficient mice have also shown a role for this molecule in eosinophil 
trafficking in vivo. The accumulation of eosinophils in the airways of these mice was 
impaired during allergic airways inflammation in comparison to wild type mice (Hogan et 
a l, 1997), although, interestingly, tfag:migratmri-of-4£Qst.nophils into iung tissue-sand the 
development of blood eosinophilia was unaffected. This suggests that IL-4 may promote 
eosinophil migration into the airways.
1.4.4 .3.1.3 TNF-a.
TNF-a induces the migration of human eosinophils (but not neutrophils) in vitro, 
although, this response is through chemokinetic (random movement) rather than 
chemotactic (directional movement) mechanisms (Nagata et al., 1993). There is 
conflicting evidence on the ability of TNF-a to induce the spontaneous transmigration of 
eosinophils through monolayers of HUVEC. TNF-a induced the migration of both 
eosinophils and neutrophils through naked filters in vitro, however, only neutrophils 
migrated through these filters when they were covered with a monolayer of HUVEC 
(Bittleman et al., 1996). In contrast, other studies (Ebisawa et al., 1992) showed that 
TNF-a induced the migration of eosinophils through monolayers of HUVEC. Elevated 
levels of TNF-a are present in the B ALF of asthmatics and recently it was demonstrated 
that the instillation of recombinant guinea-pig TNF-a in to the lungs of guinea pigs 
induced a delayed pulmonary eosinophilia, 24-72 hours post administration. Together 
these observations suggest a role for TNF-a in the induction of pulmonary eosinophilia 
during allergic airways inflammation (Cembryznsha-Nowak et al., 1993; White et a l, 
1997).
The inhibition of TNF-a activity in vivo using a fusion protein (soluble TNF-a receptor 
linked to the Fc portion of antibody) reduced both neutrophil and eosinophil infiltration 
into the lungs of mice during antigen-induced airways inflammation (Lukacs et al.,
20
1995a). Similar experiments in guinea pigs also showed a role for TNF-a in eosinophil 
and neutrophil trafficking to sites of allergic inflammation (Renzetti et al., 1996). TNF-a 
may promote eosinophil and neutrophil accumulation in tissues through the activation of 
the ICAM-1 and E-selectin adhesion pathways (Tonnel etal., 1996). This cytokine, in 
synergy with IL-4, may also promote the selective accumulation of eosinophils at sites of 
allergic inflammation by activating the VCAM-1 adhesion system (Iademarco et al,
1995).
I.4.4.3.1.4 IL-3, GM-CSF and IL-5.
IL-3, GM-CSF and IL-5 are eosinophil-trophic cytokines that also act as chemoattractants 
for normal human blood eosinophils in vitro, but not for eosinophils isolated from the 
blood of atopies (Sehmi et al., 1992). Similar to TNF-a, the action of IL-5 on 
eosinophil migration in vitro is thought to be through the stimulation of chemokinesis 
rather than chemotaxis (Schweizer et al., 1996). Elevated levels of IL-5, IL-3 and GM- 
CSF are present in the B ALF and sera of both atopic and non-atopic asthmatics. 
Furthermore, the priming of normal human blood eosinophils with either 
IL-3 or IL-5 promotes enhanced chemotactic responses to PAF. Interestingly, the 
priming of eosinophils with IL-3 or IL-5 inhibits the migration of these cells in response 
to GM-CSF or IL-5 (Walker et al., 1992; Warringa et a l, 1992a; 1992b; Sehmi et al, 
1992). Receptors for each of these cytokines share a common ß-subunit and may be 
involved in cross (IL-3 and IL-5 on GM-CSF) or self desensitisation (IL-5 on IL-5) 
(Miyajima etal., 1993).
Of these three cytokines only IL-5 selectively promotes the accumulation of eosinophils 
in vitro with IL-3 and GM-CSF also inducing the accumulation of basophils and 
neutrophils (Sehmi et al., 1992; Yamaguchi et al., 1992). The administration of IL-5 
leads to the accumulation of eosinophils in both guinea-pig and human tissues at sites of 
administration (Terada et al., 1992; Iwama et al., 1993; Terada et al., 1993; Van 
Oosterhout et al., 1993). Elevated levels of IL-5 are found in the BALF of asthmatics 
following segmental allergen challenge and these levels often correlate with increased 
levels of eosinophils in the BALF (Sur et al., 1996). In various animal models of allergic 
inflammation, mAbs against IL-5 also reduce the accumulation of eosinophils in tissues at 
sites of allergen provocation (Gulbenkian et al., 1992; Mauser et a l, 1993; Kurup et a l, 
1994). It should be noted that while anti-IL-5 mAb reduced the accumulation of 
eosinophils in inflamed tissues during allergic responses, many of these animals also 
exhibit reduced circulating eosinophil levels following antibody treatment. This indicates 
that the suppression of tissue eosinophilia may not be through the inhibition of eosinophil 
chemotaxis, but due to the reduction in the available blood pool of this cell.
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IL-5 has pleotrophic actions on eosinophil function, regulating eosinophil differentiation, 
chemotaxis and survival. Thus, in many of these studies it may also be possible that the 
anti-IL-5 mAbs are inhibiting the differentiation of eosinophils in the bone marrow and 
the subsequent generation of blood eosinophilia. The immediate action of anti-IL-5 mAb 
in the inhibition of the accumulation of eosinophils in some of these studies, however, 
does suggest a role for IL-5 in eosinophil migration. Whether IL-5 acts directly as an 
eosinophil chemoattractant in vivo or stimulates the generation of a second messenger is 
yet to be established.
Notably, IL-5 deficiency greatly reduces pulmonary eosinophilia in a mouse model of 
allergic airways inflammation, but does not totally inhibit accumulation (Foster et a l,  
1996). Once again, this may reflect the lower circulating levels of eosinophils in these 
mice and their inability to mount a blood eosinophilia following multiple exposures to 
aeroallergen, rather than as a result of impaired eosinophil chemotaxis at sites of 
inflammation (Foster et al., 1996).
I.4.4.3.2 Role o f chemokines in eosinophil trafficking.
Recent and exciting developments in the elucidation of the mechanisms regulating 
eosinophil trafficking at sites of inflammation have implicated numerous chemokines 
(Reviewed by Kita and Gleich, 1996). Chemokines are a super family of low molecular 
weight cytokines (6-14 kDa) that share a degree of amino acid homology and are 
chemotactic for leukocytes. Chemokines are divided primarily into one of two families, 
C-X-C (also know as a ) or C-C (also known as ß) depending upon the proximity of the 
first two of four highly conserved cysten?residues within the amino acid sequence. More 
recently a third family of chemokines was defined with the discovery of IL-16 (also 
know as lymphotaxin) that does not contain the C-C or C-X-C structural motifs.
The C-X-C family of chemokines is typified by IL-8 (Cohen and Cohen, 1996). This 
chemokine has a broad range of effector functions on neutrophils. However, IL-8 is also 
chemotactic for human eosinophils in vitro, although it appears to be active only on cells 
isolated from atopies. This may reflect priming of eosinophils in these individuals since 
this cell from normal individuals only become responsive to IL-8 following exposure to 
IL-5, IL-3 or GM-CSF (Warringa et a l, 1991; Schweizer et a l, 1994).
Members of the C-C chemokine family include M IP -la  and ß, MCP-1, -2, -3 (and more 
recently MCP-4 and -5), RANTES and eotaxin. These molecules are typically 
chemotactic for monocytes, basophils, eosinophils and some T-lymphocyte subsets, but 
not for neutrophils (Kameyoshi et a l, 1992; Dahinden et a l, 1994; Liles and Van 
Voorhis, 1995). Of these chemokines, MCP-3, -4 and -5, RANTES, eotaxin and to a
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lesser extent M IP-la and MCP-2, are chemotactic for eosinophils and may function to 
promote eosinophil trafficking into inflamed tissues during allergic responses (Rot et al., 
1992; Dahinden et al, 1994; Jose et al, 1994a; Baggiolini and Dahinden, 1994; 
Baggiolini, 1996). Many of these chemokines can signal through common receptors 
expressed on the eosinophil and have the ability to self- and cross- desensitise (Dahinden 
e ta i,  1994; Noso et al., 1994).
1.4.4.3.2.1 Macrophage inflammatory protein-la.
M IP -la  is chemotactic for normal human eosinophils in vitro, although this molecule is 
not as potent as RANTES or C5a (Rot et al, 1992). Although elevated levels of M IP -la  
are found in the BALF of atopic asthmatics, anti-M IP-la mAb did not inhibit BALF- 
induced eosinophil chemotaxis in vitro (Alam et al., 1996). M IP -la  is a potent 
chemoattractant for murine eosinophils isolated from IL-5 transgenic mice and a role for 
this chemokine in the accumulation of eosinophils in a murine model of allergic airways 
inflammation has been demonstrated (Lukacs et al., 1995b; Rothenberg et al., 1996).
The pretreatment of antigen-sensitised mice with anti-M IP-la mAb inhibited the 
accumulation of eosinophils in allergic lungs by half (Lukacs et al., 1995b).
Furthermore, the chemotactic activity of homogenates of antigen sensitised mouse lungs 
was partially inhibited by anti-M IP-la mAb (Lukacs et al., 1996b). Thus, M IP -la  may 
be an important chemoattractant for murine eosinophils in vivo.
Interestingly, while M IP-la is not as potent as RANTES at inducing the chemotaxis of 
human eosinophils in vitro, this chemokine is far more potent than RANTES at inducing 
changes in transient intracellular free calcium levels in eosinophils (Rot et al., 1992). 
Furthermore, RANTES was shown to desensitise the effect of M IP-la on changes in 
intracellular calcium levels in eosinophils, although, interestingly M IP -la  did not 
desensitise eosinophils to RANTES. Other groups have shown that M IP -la  and 
RANTES cross desensitised eosinophils to each other (Van Riper et al., 1994). M IP -la  
and RANTES are ligands for C-C chemokine receptor 1 (CCR1) and CCR3, both of 
which are expressed on the surface of human eosinophils (Combadiere et al., 1995a). 
Discrepancies between the findings of these groups could be due to species differences 
and the level of expression of OCRs. M IP -la  may also have other actions on eosinophil 
function besides the induction of chemotaxis. Recently, M IP-la was shown to induce 
the production of reactive oxygen species by eosinophils (Kapp et al., 1994).
1.4.4.3.2.2 Monocyte chemoattractant protein-2, -3, -4 and -5.
MCPs 2 to 5 are all chemotactic for human eosinophils in vitro with varying efficacy. 
Early studies showed that MCP-3 and to a lesser extent MCP-2, induces the migration of
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eosinophils in modified Boyden chambers in vitro. These studies also demonstrated that 
MCP-2 and -3 and RANTES may signal through the same receptor(s) and cross 
desensitise respective responses on human eosinophils (Noso et al, 1994). MCP-3 and 
RANTES may signal through two types of CCRs expressed on eosinophils (Dahinden et 
al., 1994) and subsequent reports have shown that these molecules both signal through 
CCR1 and CCR3 (Combadiere et al., 1995b; Ponath et al, 1996a). Investigations have 
indicated a role for MCP-3 in the accumulation of eosinophils during allergic 
inflammation in both humans and mice. MCP-3 mRNA expression was elevated in the 
skin of atopies, but not normal individuals following allergen provocation at this site and 
correlated with the dermal infiltration of eosinophils (Ying et al, 1995). Elevated levels 
of cells expressing MCP-3 mRNA are also found in the lungs of both atopic and non- 
atopic symptomatic asthmatics relative to non-asthmatic controls (Humbert et al, 1997). 
Furthermore, the in vitro eosinophil chemotactic activity of BALF obtained from allergic 
asthmatics is partially inhibited by anti-MCP-3 mAb (Alam et al, 1996). Collectively 
these data suggest a role for this chemokine in eosinophil trafficking during allergy.
The recent discovery of MCP-4 (human) and MCP-5 (mouse) and the demonstration that 
they are chemotactic for eosinophils indicates a possible role for these molecules in the 
accumulation of eosinophils in inflamed tissues during allergy (Uguccioni et al, 1996; 
Garcia et al, 1996a; Jia et al, 1996). Although a role for MCP-4 in the accumulation of 
eosinophils in vivo has yet to be demonstrated, MCP-5 appears to be involved in 
eosinophil trafficking in mice. Airways eosinophilia during allergic inflammation in mice 
was significantly reduced by anti-MCP-5 mAb treatment (Jia et al, 1996). Further 
investigations will be necessary to dissect the mechanisms of action of these molecules in 
eosinophil trafficking.
1.4.4.3.2.3 RA NT E S .
Regulated upon activation in normal T-cells expressed and secreted or as more 
commonly know RANTES, is a potent in vitro chemoattractant for eosinophils and 
memory type T-lymphocytes (Kameyoshi et al., 1992). Elevated levels of this 
chemokine are present in the BALF of atopic asthmatics and the in vitro eosinophil 
chemotactic activity of the BALF from these patients is partially inhibited by anti- 
RANTES mAb (Alam et al, 1996). The intradermal administration of human RANTES 
also leads to a localised eosinophilia in dogs and Rhesus monkeys, but not in guinea 
pigs. This suggests that the action of this molecule on eosinophil chemotaxis is species 
specific (Meurer et al, 1993; Jose et al, 1994a; Ponath et al, 1996b).
Elevated mRNA levels for RANTES were seen in the BALF of antigen sensitised mice 
following antigen provocation in a model of allergic airways inflammation and correlated
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with the accumulation of eosinophils in pulmonary tissues (Gonzalo et al, 1996a). In 
similar studies, the chemotactic activity of the B ALF from antigen sensitised and 
challenged mice was inhibited in vitro in the presence of anti-RANTES mAb (Lukacs et 
al, 1996b). Increased numbers of cells expressing RANTES mRNA have been 
observed in atopic and non-atopic asthmatics, relative to non-asthmatic controls (Humbert 
et al, 1997). Other studies, however, failed to show a correlation between the elevated 
RANTES mRNA levels and the accumulation of eosinophils at skin sites of allergic 
inflammation (Ying et al, 1995).
I.4.4.3.2.4 Eotaxin.
Eotaxin is a novel eosinophil active C-C chemokine that is approximately 8.4 kDa in size. 
This chemokine was originally identified in the B ALF from actively sensitised guinea 
pigs following antigen provocation (Jose et al, 1994a). Eotaxin potently induces the 
selective accumulation of In111-labelled eosinophils when injected intradermally and is a 
selective inducer of pulmonary eosinophilia when administered by aerosol to guinea pigs 
(Griffiths-Johnson et al, 1993; Jose et al, 1994a). Murine and human homologues 
have since been characterised and both are potent eosinophil chemoattractants in vitro 
(Rothenberg eta l, 1995a; Ponath et al, 1996b).
Murine eotaxin has been shown to be chemotactic for eosinophils, but not 
monocytes/macrophage, lymphocytes or neutrophils, in vitro (Rothenberg eta l, 1995a). 
The accumulation of eosinophils in the skin of guinea pigs was amplified by the 
intravenous administration of IL-5 one hour prior to the intradermal injection of eotaxin 
(Collins et a l, 1995). It was suggested that IL-5 indirectly enhanced the chemotactic 
action of eotaxin by inducing a peripheral blood eosinophilia.
In contrast to experiments in guinea pigs, the instillation of eotaxin in the lungs of naive 
mice did not induce a pronounced accumulation of eosinophils in the airways, however, 
the instillation of eotaxin in the lungs of mice that are transgenic for the DL-5 gene induced 
a strong and selective pulmonary eosinophilia (Rothenberg et al, 1996). This indicates 
that IL-5 and eotaxin act cooperatively to traffic eosinophils into tissues. IL-5 may in part 
promote eosinophilf accumulation by enhancing the available blood eosinophil pool as 
IL-5 transgenic mice exhibit a pronounced blood eosinophilia (Tominaga et al, 1991). 
Eotaxin mRNA is constitutively expressed at low levels in many tissues of mice and 
guinea pigs (Rothenberg et a l, 1995b; Gonzalo et a l, 1996b). Increased mRNA 
expression of this chemokine is seen in the lungs of sensitised mice and guinea pigs 
following aeroallergen exposure (Rothenberg et al, 1995b). In sensitised mice, the 
kinetics of eotaxin mRNA expression in the lungs parallels the recruitment of eosinophils 
into this tissue following aeroallergen exposure (Gonzalo et al, 1996b) and recently,
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eotaxin was shown to regulate early eosinophil trafficking into allergic inflamed tissues in 
mice (Rothenberg, et al, 1997). Naive guinea pigs exhibit a higher constitutive level of 
eotaxin mRNA expression than mice, furthermore, guinea pigs also have a higher basal 
level of pulmonary residing eosinophils than mice, suggesting that this molecule may 
regulate basal level eosinophil trafficking (Rothenberg et al., 1995a, 1995b; Matthews et 
al., 1998). Eotaxin may also maintain the basal circulating eosinophil pool, since eotaxin 
deficient mice have reduced levels of eosinophils in the blood (Matthews et al., 1998).
Human eotaxin is as potent as RANTES at inducing human eosinophil chemotaxis in 
vitro, however, human eotaxin is much stronger than RANTES at inducing the 
accumulation of eosinophils when administered intradermally to Rhesus monkeys 
(Ponath et al, 1996b).
The potent and selective action of eotaxin on eosinophil migration suggests an important 
role for this molecule in eosinophil trafficking in vivo. Furthermore, eotaxin acts co­
operatively with IL-5 suggesting that these two cytokines are key regulators of 
eosinophilia during allergic inflammation.
1.4.5 Mechanisms of eosinophil activation and degranulation.
Eosinophil activation and degranulation at sites of allergic inflammation are thought to be 
central to the pathogenesis of asthma and dermatitis (Seminario and Gleich, 1994). Upon 
activation, eosinophils may secrete numerous cytokines (IL -la , IL-3, IL-4, IL-5, IL-6, 
TG F-a and ß, GM-CSF and TNF-a), chemokines (IL-8, M IP -la , eotaxin and 
RANTES) and lipid mediators (leukotriene C4, PAF, 15-hydroxyeicosatetraenoic acid, 
prostaglandins E\ and E2 and thromboxane B2) (reviewed in Wardlaw et al, 1994; 
Moqbel et al., 1994; Garcia et al., 1996b). Many of these molecules have direct effects 
on eosinophil priming, activation, trafficking, survival and degranulation and may 
function to amplify the inflammatory response (Jose et al., 1994a; Wardlaw et al, 1994; 
Cohen and Cohen, 1996). Eosinophils are also a rich source of numerous cytotoxic 
cationic proteins (MBP, EDN, ECP and EPO) (Wardlaw et al., 1995). These proteins 
are contained in the granules of the cell cytoplasm and in response to specific stimulus are 
released into the extracellular environment through a process termed degranulation. The 
stimulation of eosinophils may also lead to the generation of respiratory bursts which 
results in the release of reactive oxygen species that may contribute to tissue damage and 
the inflammatory process in atopic diseases such as asthma and dermatitis (Martin et al., 
1996)
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1.4.5.1 Molecules that are involved in eosinophil activation and 
degranulation.
Eosinophil degranulation is induced in vitro in the presence of immobilised 
immunoglobulins (IgG, IgA, slgA and IgE), cytokines (IL-5 and GM-CSF), chemokines 
(RANTES and M IP-la), PAF, complement peptides (C3a and C5a), fMLP, melanin 
and substance P (Khaliffe et al., 1985, 1986; Abu-Ghazaleh et a l, 1989; Kroegel et a l, 
1989, 1990; Fujisawa et al, 1990; Kita et al., 1992, 1994, 1996; Rot et al, 1992; 
Takafuji et al, 1994; Hoire and Kita, 1994; Daffem et al, 1995).
I.4.5.1.1 The role o f  immunoglobulins in eosinophil activation and de granulation.
Eosinophils isolated from atopic individuals undergo degranulation, releasing EPO, when 
incubated with specific antigen or anti-human IgE mAb (Tomassini et al., 1991). 
Immobilised IgGl or IgG3, but not IgE mAbs also induces the release of EDN from 
eosinophils (Kaneko et al., 1995). Different immunoglobulin isotypes have been shown 
to release individual eosinophilic granule proteins into the extracellular environment and 
may provide a key signal for eosinophil degranulation. The incubation of eosinophils 
isolated from atopic individuals with anti-IgE mAb leads to the release of EPO, but not 
ECP (Tomassini et al., 1991), while anti-human IgA induces the release of both EPO and 
ECP from these cells. In contrast, the incubation of eosinophils with anti-IgG mAbs 
preferentially trigger the release of ECP but not EPO. Thus, specific immunoglobulins 
may be involved in the selective release of specific eosinophil granule proteins, with the 
potential tolhlicit particular physiological effects in vivo.
Although in vitro studies indicate a role for immunoglobulins in eosinophil degranulation 
in vivo and that elevated levels of allergen specific immunoglobulins are present in the 
sera of atopies, airways dysfunction and by inference eosinophil degranulation, during 
allergic airways inflammation in mice occurred independently of this pathway (Hogan et 
a l, 1996). Some studies have shown a role for IgE in eosinophil mediated airways 
dysfunction following aeroallergen provocation (Hamelmann et al., 1997). In contrast, 
similar studies indicate that eosinophil mediated airways dysfunction occurs in IgE 
deficient mice (Mehlhop et al., 1997).
I.4.5.1.2 Immunoglobulin-independent regulation of eosinophil degranulation and 
activation.
Although IL-5, IL-3 and GM-CSF promote eosinophil degranulation, their role is in the 
priming of eosinophils for events leading to degranulation in response to immunoglobulin 
stimuli (Fugisawa et al., 1990). IL-3, IL-5 and GM-CSF are released at sites of
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inflammation and may enhance eosinophil survival during allergy through autocrine 
mechanisms and with regards to IL-5 and GM-CSF this process may involve the 
inhibition of eosinophil apoptosis (Rothenberg et a l, 1988; Stem et al, 1992; Czech et 
a l, 1993; Adashi et a l, 1995; Hu, 1997).
Eosinophils may also be degranulated by non-immunoglobulin stimuli and this 
mechanism may first depend on the activation or priming of the cell. PAF induces the 
release of ECP from eosinophils isolated from the blood of atopies, but not normal 
individuals (Eda et al., 1993; Turner et a l, 1994). In contrast to PAF, fMLP, C5a and 
C3a all induce the release of ECP from eosinophils from normal donors (Turner et a l, 
1994). PAF stimulates normal donor eosinophils to release EDN in vitro, as does 
recombinant human GM-CSF (Hoire and Kita, 1994). Interestingly, two cationic 
proteins that are released from eosinophils during degranulation (MBP and EPO) also 
potently induce non-cytolytic eosinophil degranulation (Kita et a l,  1995). This suggests 
that eosinophil degranulation at sites of allergic inflammation may be amplified by 
autocrine mechanisms.
I.4.5.1.3 A role for adhesion molecules in eosinophil de granulation.
Adhesion molecules may play a significant role in eosinophil degranulation. The 
degranulation of eosinophils by PAF or GM-CSF in vitro requires eosinophil adhesion 
and is inhibited by anti-CD 11 a/CD 18 (Mac-1) mAb. The binding of eosinophils to 
fibronectin augments degranulatory responses to fMLP in vitro. Eosinophil 
degranulation by fMLP requires cell adhesion to fibronectin and this is mediated by 
VLA-4 (Neeley et a l, 1994). Interesting, PMA-induced eosinophil degranulation does 
not require the eosinophil to be adherent (Hoire and Kita, 1994).
Unlike eosinophils in the circulation, those present in the sputum of atopic asthmatics 
express ICAM-1 (Hansel et a l, 1991). ICAM-1 expression is induced on eosinophils 
following exposure to either IL-3, IL-5 or GM-CSF, in combination with TN F-a and 
these cytokines are present in the BALF of atopic asthmatics (Hansel et a l, 1991; Czech 
et a l, 1993). Recently, the expression of ICAM-1 on eosinophils was shown to be 
important for the stimulation of eosinophil degranulation [as measured by EPX (EDN) 
release] by GM-CSF and TNF-a (Hoire et a l, 1997). In this study, the addition of anti- 
CD 18 mAb abrogated both eosinophil adhesion to human serum albumin coated tissue 
culture plates and GM-CSF and TNF-a-stimulated eosinophil degranulation.
Furthermore, both cell aggregation and degranulation, but not adhesion was shown to be 
dependent on ICAM-1. Thus, eosinophil-eosinophil or eosinophil-lymphocyte interaction 
via ICAM-1 may be required for eosinophil degranulation.
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Investigations to date suggest that eosinophils are stimulated to degranulate via two 
pathways, one dependent and the other independent of immunoglobulins. Furthermore, 
both of these pathways contain mechanisms for the selective release of individual granule 
proteins.
1.5 SUMMARY.
Eosinophil activation is thought to underlie the aetiology of allergic diseases. It is clear 
that the regulation of eosinophil trafficking and degranulation is a very complex process. 
Many of the molecules that have been shown to exert regulatory effects on the recruitment 
of eosinophils are not solely specific for this leukocyte and may have important roles in 
other immune processes. Current literature indicates that cytokines and chemokines are 
key regulators of eosinophilia and that these molecules provide attractive targets for 
therapeutic intervention in allergic inflammatory disease. Increasing evidence suggests 
that IL-5 and eotaxin may selectively regulate eosinophil recruitment, particularly during 
allergy, although many of these studies fail to define the precise roles of these molecules 
in this process. Recent reports also indicate that these two cytokines may act co­
operatively.
Two mechanisms underlie eosinophil degranulation that are immunoglobulin dependent 
and independent. Immunoglobulins in particular have been implicated in the regulation of 
eosinophil degranulation at sites of allergic inflammation, although an essential 
requirement for these molecules in this process remains controversial. Some molecules, 
such as IL-5 may play important role in both pathways of eosinophil activation . The 
elucidation of mechanisms that regulate eosinophil recruitment and activation, may 
provide new avenues for the improved management of allergic inflammatory diseases 
such as asthma.
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SPECIFIC AIMS OF THIS THESIS
1. To examine the relationship between interleukin-5 and eotaxin in the regulation of 
blood and cutaneous eosinophilia in mice.
2. To determine the relationship between interleukin-5 and eotaxin in regulating 
pulmonary eosinophilia and their role in airways dysfunction in mice.
3. To dissect the requirement of interleukin-5 in eosinophil trafficking in vivo.
4. To dissect the role of interleukin-5 in eosinophil trafficking and function during 
allergy.
5. To dissect the role of eotaxin in eosinophil trafficking and function in vivo and to 
determine its role in eosinophilic responses during allergy.
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CHAPTER II
THE RELATIONSHIP BETWEEN 
INTERLEUKIN-5 AND EOTAXIN IN THE 
REGULATION OF BLOOD AND CUTANEOUS 
EOSINOPHILIA IN MICE
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II.l INTRODUCTION.
The recruitment of eosinophils at sites of allergic inflammation is a complex process 
which potentially may be regulated by inflammatory cytokines (IL-lß, IL-3, IL-4, IL-5, 
GM-CSF and TNF-a) and chemokines (RANTES, MCP-3, M IP -la  and eotaxin). 
Despite this apparent complexity, it is clear from investigations with IL-5 deficient mice 
that the absence of IL-5 alone abolishes the pronounced tissue and blood eosinophilia 
normally generated by allergic responses and parasite infections (Kopf et a l, 1996; Foster 
et al, 1996). Furthermore, of the cytokines implicated in modulating eosinophilic 
inflammation only IL-5 and eotaxin have been identified to selectively regulate eosinophil 
trafficking (Kay et al., 1991; Jose et a l, 1994a; Rothenberg et al., 1995a; Gonzalo et al., 
1996a). Currently, it is unknown which of these cytokines provides the essential signal 
for eosinophil homing and migration into tissues.
IL-5 has been identified as a central mediator in the regulation of eosinophilic 
inflammation and in the aetiology of asthma and allergic disease (Coffman et al., 1989; 
Kay et a l, 1991; Hamid et a l, 1991; Robinson et al, 1992; Kopf et a l, 1996; Foster et 
al., 1996). EL-5 not only regulates the growth, differentiation and activation of 
eosinophils (Owen et a l, 1987; Rothenberg et al., 1988; Yamaguchi et a l, 1988; Lopez 
et al., 1988; Clutterbuck et a l, 1989; Fujisawa et al., 1990), but also provides an 
essential signal for the induction of eosinophilia during allergic inflammation (Coffman et 
al., 1989; Kopf et a l, 1996; Foster et a l, 1996). Investigations with IL-5 deficient mice 
have established the blood and airways eosinophilia and the subsequent development of 
lung damage and airways hyperreactivity, that occurs in response to aeroallergen, is 
dependent on IL-5 (Foster et a l, 1996). However, these investigations also indicate that 
other factors derived from the site of antigen presentation are required to amplify the IL-5 
signal for eosinophil migration and are essential for widespread eosinophilic inflammation 
in tissues.
Eotaxin, a member of the C-C branch of chemokines, has been recently identified as a 
novel chemotactic agent for eosinophils (Jose et a l, 1994a; Rothenberg et al., 1995a).
The potency and rapid action of eotaxin at inducing selective pulmonary and intradermal 
eosinophil recruitment suggests an integral role for this protein in the early phases of the 
signalling mechanism for eosinophil homing and tissue recruitment (Jose et al., 1994b; 
Rothenberg et a l, 1995a; Gonzalo et a l, 1996b). Eotaxin is constitutively expressed in a 
number of tissues and may regulate basal tissue homing of eosinophils. Increased 
production of eotaxin in response to antigen-stimulation, in association with the increased 
synthesis of cytokines and eosinophil chemoattractant chemokines, may regulate 
eosinophil tissue homing and accumulation to the site of inflammation (Jose et al., 1994b; 
Rothenberg et al., 1995a; Gonzalo et al., 1996b).
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Investigations with guinea pigs suggest that eotaxin and IL-5 may act cooperatively to 
promote the recruitment of eosinophils into tissues (Collins et al, 1995). The number of 
eosinophils recruited to sites of intradermal injection of eotaxin correlated with an increase 
in the number of circulating eosinophils induced by the systemic administration of IL-5.
In mice, eotaxin-induced recruitment of eosinophils to the lung and skin was only 
consistently observed in IL-5 transgenic mice, which have elevated levels of IL-5 and a 
pronounced basal blood eosinophilia (Rothenberg et al, 1996). Thus, during the 
inflammatory response, IL-5 may provide the signal for the release of a pool of 
eosinophils from the bone marrow, while eotaxin may elicit the signal for eosinophil 
localisation to the site of inflammation (Collins et al, 1995; Rothenberg et al, 1996). 
However, it is not clear whether the amplification of eotaxin-induced eosinophilia in the 
presence of increased levels of systemic IL-5 is directly due to this cytokine or to the 
concomitant increase in the number of circulating eosinophils.
In order to provide important insight into the molecular mechanisms regulating eosinophil 
homing and selective eosinophil trafficking during complex tissue responses to 
inflammatory stimuli, it is essential to gain a better understanding of the interaction 
between IL-5 and eotaxin. In order to further elucidate the relationship between IL-5 and 
eotaxin in eosinophil trafficking in vivo, these cytokines were assayed for their ability to 
induce tissue eosinophilia in skin, singularly or in combination, using a skin bioassay 
technique. In addition, these two cytokines were injected intravenously to determine their 
effect on circulating eosinophil levels. In this chapter, results suggest that eotaxin may 
have an important role in regulating blood eosinophilia and may act in synergy with IL-5 
to promote the selective accumulation of eosinophils into tissues.
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II.2 MATERIALS AND METHODS.
11.2.1 Animals.
Male mice (C57BL/6, 6-8 weeks of age) were used in all bioassay experiments.
11.2.2 Effect of i.v. IL-5 and/or eotaxin on circulating levels of 
eosinophils.
Mouse recombinant IL-5 was a generous gift from Professor Ian Young (John Curtin 
School of Medical Research, Australian National University) and was expressed and 
purified from the baculovirus expression system (Ingley et al., 1991). Mice were 
injected intravenously (i.v.) with eotaxin [0.03-2.4 nmol/kg (Pepro Tech Inc., Rocky 
Hill, NJ., USA.)], IL-5 (10-100 pmol/kg) or control vehicle [100 i^l of 10 mM 
PBS/0.1% BSA (< 0.1 ng/mg endotoxin), (pH 7.4)]. In some experiments mice were 
given an i.v. co-injection of eotaxin (1.2 nmol/kg) and IL-5 (100 pmol/kg) (at these 
concentrations both cytokines induced a blood eosinophilia of similar magnitude). Blood 
samples were taken before, at 30 minutes and hourly after the i.v. injection of eotaxin, 
IL-5, eotaxin with IL-5 or control vehicle for quantification of eosinophils.
Eosinophils/ml blood were determined by diluting blood 1/10 in Discombe's solution 
(Discombe, 1946) and counting positively staining cells 10 minutes later by light field 
microscopy using a haemocytometer.
11.2.3 Effect of i.v. IL-5 and/or eotaxin on bone marrow levels of 
eosinophils.
Mice were injected i.v. with IL-5 (100 pmol/kg), eotaxin (2.4 nmol/kg) or control vehicle 
[100 (il of 10 mM PBS/0.1% BSA (< 0.1 ng/mg endotoxin) (pH 7.4)]. At the peak of 
the blood eosinophilia (30 minutes for both IL-5 and eotaxin) mice were sacrificed by 
cervical dislocation and the right femurs removed into ice cold Hank's buffered salt 
solutions (HBSS). Epiphyses from both the proximal and distal ends of the femurs were 
removed and the bone marrow cavity lavaged with 2 mis of HBSS. The number of 
cells/ml of lavage fluid was determined by using a haemocytometer and 2 x 105 cells were 
cytocentrifuged and stained with Giemsa-May-Grunwald for differential cell counting. 
Routinely, 300-400 cells were counted per slide.
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11.2.4 Bioassay of eotaxin- and/or IL-5- induced accumulation of 
eosinophils in skin.
Mice were anaesthetised with ether, the dorsal skin shaved and then injected i.v. with 
IL-5 (100 pmol/kg) or control vehicle [100 fil of 10 mM PBS/0.1% BSA (< 0.1 ng/mg 
endotoxin) (pH 7.4)]. In some experiments mice were injected i.v. with eotaxin (1.2 
nmol/kg) or in combination with IL-5 (100 pmol/kg). After 1 hour mice were injected 
subcutaneously (s.c.) with 150 fil of air and the required concentration of eotaxin (1-80 
pmol/site), IL-5 (0.1-10 pmol/site) or a combination of both cytokines [IL-5 (10 
pmol/site) and eotaxin (5.0 pmol/site) at concentrations that induced maximal response 
(ECioo)] or control vehicle [100 |il HBSS/0.01% BSA (< 0.1 ng/mg endotoxin) (pH 
7.4)]. Two hours after the s.c. injection of cytokine(s) or control vehicle, mice were 
sacrificed by CO2 asphyxiation and the dorsal skin membrane [subcutaneous fascia 
(Lawman, 1984), approximately 18x18 mm] below the air pouch excised directly onto a 
glass slide. Slides were allowed to air dry before being fixed with 100% methanol and 
stained with May-Grunwald-Giemsa for differential cell counting. Eosinophils/mm2 were 
determined by counting 10 fields of view (x 250 magnification) with reference to a 
calibrated grid fitted to the microscope's optical lens. Blood samples were taken before 
i.v. injection of IL-5, 30 minutes after injection and hourly thereafter. Eosinophils/ml of 
blood were determined by the Discombe's method (see section II.2.2).
11.2.5 Determination of half maximal effective concentrations for 
eosinophil chemoattractants.
Dose response curves for the following eosinophil chemoattractants were performed 
using the skin bioassay technique (see section II.2.4) with the following modification. 
Mice were given an i.v. injection of 100 pmol/kg IL-5 in 0.1% BSA/PBS (pH 7.4) 30 
minutes (instead of 1 hour) prior to receiving a s.c. co-injection of 100 fil of 0.01% 
BSA/HBSS (pH 7.4) containing either M IP -la  [0.01-1 pmols (AUSTRAL biologicals, 
San Ramon, CA., USA.)], RANTES [0.01-10 pmols (R&D Systems, Minneapolis,
MN., USA.)], LTB4 [0.1-100 pmols (SIGMA Chemical Co., St Louis, MO., USA.)], 
PAF [0.1-100 pmols (Cayman Chemical Company, Ann Arbor, MI., USA.)] or VGSE 
[0.01-1000 pmols (A gift from Dr Caryl Hill, John Curtin School of Medical Research, 
Australian National University and was synthesised by the Biomolecular Resource 
Facility of the John Curtin School of Medical Research)] and 150 fil of air. Half 
maximally effective concentrations (EC50) of these molecules were determined from their 
respective dose response curves. EC50 = the dose of chemoattractant required for half 
maximal recruitment of eosinophils into the sites of inetallalipn (above background level 
of eosinophil recruitment induced by control vehicle). EC50 of eotaxin and IL-5 were
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determined from dose response curves generated as described in section II.2.4 and were 
confirmed using the modified skin bioassay technique as described above. &><* U--S
- 0*5 p**°\ fcf eoVo*\f\ =. *x* 5p<^o\.
II.2.6 Bioassay to determine the relationship between chem oattractants 
for the accumulation of eosinophils in the skin.
The relationship between various chemoattractants for the recruitment of eosinophils to 
the skin was analysed using the modified back patch bioassay (see section II.2.5).
Briefly, mice received an i.v. injection of IL-5 [100 pmol/kg in 0.1% BSA/PBS (pH 
7.4)] and 30 minutes later were s.c. co-injected with one of the following combinations of 
chemoattractants at their respective EC50 in 100 p.1 of 0.01 % BSA/HBSS (pH 7.4)+ 150 
|Lil air. IL-5 (0.5 pmol) with either eotaxin (2.5 pmol), MIP-loc (62.5 fmol), RANTES 
(0.5 pmol), LTB4 (1.0 pmol), PAF (0.5 pmol) or VGSE (0.5 pmol); or eotaxin (2.5 
pmol) with either PAF (0.5 pmol) or LTB4 (1.0 pmol). The accumulation of eosinophils 
in the dorsal skin membrane was determined 2 hours later (see section II.2.4).
36
II.3 RESULTS.
11.3.1 Effect of intravenous IL-5 and eotaxin on circulating and bone 
marrow eosinophil levels.
Intravenously administered IL-5 induced a rapid and sustained increase in circulating 
eosinophils (figure II.la). The peak was at the first time point of 30 minutes and 
eosinophil numbers fell to basal levels over 5 hours. This effect was eoncentration- 
dependent and a dose of 100 pmol/kg induced an eosinophilia that was equivalent to that 
observed during allergic pulmonary inflammation in mice (Foster et al., 1996). The rapid 
action of i.v. IL-5 in guinea pigs has been associated with the mobilisation of a bone 
marrow pool of eosinophils (Collins etal., 1995). This mechanism also appeared to be 
operating in the present experiments as the blood eosinophilia correlated with a fall in 
bone marrow eosinophil numbers (figure II.2).
The effect of i.v. administration of eotaxin on circulating levels of eosinophils has not 
been previously reported. In this investigation i.v. eotaxin potently induced a dose (0.03- 
2.4 nmol/kg) dependent blood eosinophilia (figure II.lb). The onset of eosinophilia was 
extremely rapid and blood levels were at least equivalent to that observed during 
eosinophilic inflammation in mice (Foster et al., 1996) and in response to i.v. IL-5 (figure 
n.la). However, eotaxin was approximately 3 fold less potent than IL-5 in inducing an 
equivalent eosinophilia. Notably, the increase in blood eosinophil numbers in response to 
i.v. eotaxin (figure II.lb) did not correlate with a significant reduction in the level of bone 
marrow eosinophils (figure II.2a). The co-administration of both eotaxin (1.2 nmol/kg) 
and IL-5 (100 pmol/kg) induced a blood eosinophilia significantly greater than that 
induced by either of these two molecules alone (figure II.2b).
11.3.2 Effect of subcutaneously injected eotaxin and IL-5 on the 
accumulation of eosinophils in the skin.
In mice, as previously observed (Gonzalo eta l, 1996; Rothenberg et al., 1996), eotaxin 
was a highly potent chemotactic signal for the selective and rapid recruitment of 
eosinophils to tissues. Within 2 hours, eotaxin (1.0-20 pmol/site) had induced a 
pronounced tissue eosinophilia which was highly dependent on concentration (figure 
II.3a). The effect of eotaxin was maximal at 5.0 pmol/site and subsequent increases in 
dose resulted in a concentration dependent reduction in the accumulation of eosinophils. 
Similar results were also obtained in mice with dilutions of crude supernatants from COS 
cells transfected with eotaxin cDNA and expressing eotaxin (Rothenberg et al., 1995a).
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Figure II. 1 The effect of i.v. administration of IL-5 or eotaxin on 
circulating eosinophil numbers in mice.
Mice were injected i.v. with IL-5 (10-100 pmol/kg), eotaxin (0.03-2.4 nmol/kg) or 
control vehicle [100 (J,l of 10 mM PBS/0.1% BSA (pH 7.4)]. Blood samples were taken 
before, at 30 minutes and hourly after i.v. injection of the cytokines or control vehicle for 
differential quantification of leukocytes, (a) IL-5 (10-100 pmol/kg) induced a dose 
dependent increase in circulating eosinophil levels, (b) Eotaxin (0.03-2.4 nmol/kg) 
induced a dose dependent increase in circulating eosinophil numbers. Results represent 
mean eosinophils/ml of blood ± SEM of groups of 5-6 mice. The significance of 
differences between experimental groups was analysed using the Student's unpaired t- 
test. Differences in means were considered significant if P < 0.05. (a) * P < 0.001 
compared with control vehicle at 30 minutes, (b) * P < 0.001 at 2.4 nmol/kg eotaxin 
compared with control vehicle.
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(a)
control vehicle i.v.
39
Figure II.2 Eosinophil numbers in the bone marrow of mice in the 
presence of i.v. IL-5 or eotaxin and the effect of the co-administration of 
these two cytokines of circulating eosinophil levels.
(a) The effect of i.v. injection of IL-5 (100 pmol/kg), eotaxin (1.2 nmol/kg) or control 
vehicle [100 fil of 10 mM PBS/0.1% BSA (pH 7.4)] on bone marrow levels of 
eosinophils. IL-5 but not eotaxin caused a reduction in bone marrow eosinophil 
numbers. Femurs were removed at the peak of the blood eosinophilic response (30 
minutes) and the bone marrow cavity lavaged with 2 mis of HBSS. The number of 
cells/ml of lavage fluid was determined and 2 xlO5 cells were cytocentrifuged and stained 
with Giemsa-May-Grunwald for differential cell counting. Results represent the mean 
number of bone marrow eosinophils ± SEM for groups of 4 mice, (b) Mice were injected 
i.v. with IL-5 (100 pmol/kg), eotaxin (1.2 nmol/kg), both IL-5 (100 pmol/kg) and 
eotaxin (1.2 nmol/kg) or control vehicle [100 p.1 of 10 mM PBS/0.1% BSA (pH 7.4)] and 
the levels of eosinophil in the blood determined 30 minutes later. Mice that received IL-5 
and eotaxin simultaneously i.v. had significantly higher eosinophil levels in the blood in 
comparison to treatment with an individual cytokine. Results represent mean 
eosinophils/ml of blood ± SEM of groups of 5-6 mice. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. (a) * P < 0.001 compared 
with control vehicle, (b) * P < 0.001 compared with IL-5 or eotaxin alone.
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Figure II.3 The effect of i.v. IL-5 on eotaxin- and IL-5- induced 
eosinophil recruitment into the skin of mice.
(a) Accumulation of eosinophils in dorsal skin membranes in response to subcutaneously 
injected eotaxin (1.0-80 pmol/site) or control vehicle [100 fil of HBSS/0.01% BSA (pH 
7.4)]. Eotaxin-induced eosinophil recruitment (determined 2 hours after s.c. eotaxin 
administration) was concentration dependent and was determined in the presence and 
absence of i.v. IL-5. Mice were injected i.v. with IL-5 (100 pmol/kg) or control vehicle 
[100 pi of 10 mM PBS/0.1% BSA (pH 7.4)] and 1 hour later eotaxin or control vehicle 
was injected subcutaneously. Eosinophil recruitment was maximal at 5.0 pmol/site 
eotaxin. (b) Accumulation of eosinophils in dorsal skin membranes was determined as 
described above for (a), however, mice were subcutaneously injected with IL-5 (0.1 to 
10.0 pmol/skin site) instead of eotaxin. IL-5-induced eosinophil recruitment was 
concentration dependent and was determined in the presence or absence of i.v. IL-5. 
Eosinophil recruitment was maximal at 10 pmol/site IL-5. Results represent mean 
eosinophils/mm2 ± SEM of groups of 6 mice. One dorsal membrane preparation was 
excised from each animal and prepared for differential cell counting. Ten fields per prepa­
ration were counted for eosinophil infiltration and the mean obtained. The significance of 
differences between experimental groups was analysed using the Student's unpaired t- 
test. Differences in means were considered significant if P < 0.05. (a) * P < 0.001 
compared to i.v. control vehicle at the same subcutaneous concentration of eotaxin. (b) * 
P < 0.001 compared to i.v. control vehicle at the same subcutaneous concentration of 
IL-5.
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The effect of eotaxin on eosinophil transmigration was significantly amplified by first 
inducing a blood eosinophilia by i.v. injection of IL-5 (100 pmol/kg) (figure II.3a) 1 hour 
prior to eotaxin injection (corresponding blood levels are show in figure II. la). These 
results, in part, may explain why some investigators see no or only poor chemotactic 
responses with eotaxin in the absence of systemic eosinophilia (Rothenberg et a l, 1996). 
Subcutaneously injected eotaxin or IL-5 did not induce a blood eosinophilia (results not 
shown). Interestingly, increased numbers of eosinophils in the blood in response to i.v. 
eotaxin did not significantly enhance responses to chemotactic stimuli in the skin (figure
l i f e .
The subcutaneous injection of IL-5 (1-10 pmol/site) also induced a concentration 
dependent tissue eosinophilia which was also amplified by i.v. injection of IL-5 (figure 
II.3b). Tissue eosinophilia induced by IL-5 (10 pmol/site) was equivalent to that 
produced by eotaxin (5.0 pmol/site) (figure II.3a). The s.c. co-injection of eotaxin (5.0 
pmol/site) and IL-5 (10 pmol/site) significantly amplified eosinophil recruitment at sites of 
administration in comparison to eotaxin or IL-5 alone (figure n.4a).
The relationship between the blood eosinophilia induced by eotaxin and/or IL-5 and the 
subsequent accumulation of eosinophils at s.c. sites of the administration of these 
chemoattractants was also examined (figure IL4). Interestingly, the i.v. injection of 
eotaxin (1.2 nmol/kg) induced a blood eosinophilia (figure n.lb), but did not amplify 
chemotactic responses to subcutaneously administered eotaxin (5.0 pmol/skin site) or IL- 
5(10 pmol/skin site) (figure II.4b). In contrast, i.v. injection of IL-5 (100 pmol/kg) 
significantly potentiated the chemotactic responses of eosinophils to either s.c. 
administered cytokine (figure II.4b). Furthermore, the i.v. injection of a combination of 
both IL-5 (100 pmol/kg) and eotaxin (1.2 nmol/kg) significantly amplified chemotactic 
responses to s.c. eotaxin (5.0 pmol/skin site) or IL-5 (10 pmol/skin site) (figure n.4b). 
The accumulation of eosinophils in the skin in response to s.c. eotaxin or s.c. IL-5 in the 
presence of both i.v. eotaxin and IL-5 was significantly greater than responses obtained 
solely with i.v. IL-5.
II.3.3 The relationship between cytokines, chemokines, lipid mediators 
and chemotactic peptide in the accumulation of eosinophils in skin.
M IP-la-, RANTES-, PAF-, LTB4- and ECF-A tetrapeptide (VGSE)- induced dose- 
dependent accumulation of eosinophils in mouse skin (figures II.5 and II.6). At higher 
doses of most of these molecules, an inhibition of the accumulation of eosinophils 
occurred, indicating that like eotaxin the chemotactic action of these molecules in vivo is 
tightly regulated. Inhibition of eosinophil chemotaxis at high doses of YGSE in vitro has 
previously been reported (Boswell et a l, 1976).
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Figure II.4 The effect of the s.c. co-administration of IL-5 and/or eotaxin 
on eosinophil recruitment into the skin and the effect of eotaxin and/or 
IL-5 i.v. on these eosinophilic responses in the skin.
(a) Mice were injected i.v. with IL-5 (100 pmol/kg) and then 1 hour later injected s.c. 
with either IL-5 (10 pmol/site) or eotaxin (5 pmol/site) or with a combination of both 
cytokines. The co-injection of IL-5 and eotaxin induced accumulation of eosinophils 
significantly greater than either of these cytokines alone, (b) The effect of i.v. injection of 
IL-5 (100 pmol/kg) or eotaxin (1.2 nmol/kg) or a combination of both cytokines on the 
accumulation of eosinophils in dorsal skin membranes in response to s.c. eotaxin (5 
pmol/site) or IL-5 (10 pmol/site). Maximal accumulation of eosinophils occurred in the 
presence of a combination of i.v. eotaxin and IL-5. Eotaxin, IL-5, eotaxin with IL-5 or 
control vehicle were injected into the skin 1 hours after i.v. administration of IL-5, 
eotaxin or control vehicle. Eosinophil recruitment into dorsal skin membranes was 
determined 2 hours after s.c. injection of eosinophil chemoattractants or control vehicle. 
Results represent mean eosinophils/mm2 ± SEM of groups of 6 mice. One dorsal 
membrane preparation was excised from each animal and prepared for differential cell 
counting. Ten fields per preparation were counted for eosinophil infiltration and the mean 
obtained. The significance of differences between experimental groups was analysed 
using the Student's unpaired Mest. Differences in means were considered significant if P  
< 0.05. (a) * P < 0.05 compared to eotaxin or IL-5 alone and (b) * P  < 0.01 compared to 
control vehicle i.v. and ** P  < 0.05 compared to i.v. IL-5. No significant difference was 
observed between i.v. control vehicle and i.v. eotaxin groups, in the presence of s.c. 
eotaxin or IL-5.
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Figure II.5 Dose response curves for M IP-a and RANTES and 
determination of half maximally effective concentrations for the 
accumulation o f eosinophils in skin.
M IP-la and RANTES potently induced the accumulation of eosinophils in skin. Mice 
were injected i.v. with IL-5 [100 pmol/kg in 100 ml of 10 mM PBS/0.1% BSA (pH 7.4)] 
and 30 minutes later were given a s.c. injection of (a) M IP -la  (0.005-1 pmol/skin site), 
(b) RANTES (0.05-10 pmol/skin site) or control vehicle [100 \i\ of HBSS/0.01% BSA 
(pH 7.4)]. Mice were sacrificed 2 hours after s.c. injections and the accumulation of 
eosinophils in the dorsal membrane determined. Results represent mean eosinophils/mm2 
± SEM of groups of 6 mice. One dorsal membrane preparation was excised from each 
animal and prepared for differential cell counting. Ten fields per preparation were 
counted for eosinophil infiltration and the mean obtained. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.01. < 0.05 and ** P <
0.001 when compared with control vehicle.
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Figure I I .6 Dose response curves for PAF, LTB4 and VGSE and 
determination of half maximally effective concentrations for the 
accumulation o f eosinophils in skin.
PAF, LTB4 and VGSE potently induced the accumulation of eosinophils in skin. Mice 
were injected i.v. with IL-5 [100 pmol/kg in 100 ml of 10 mM PBS/0.1% BSA (pH 7.4)] 
and 30 minutes later were given a s.c. injection of (a) PAF (0.1-100 pmol/skin site), (b) 
LTB4 (0.05-10 pmol/skin site), (c) VGSE (0.1-100 pmol/skin site) or control vehicle 
[100 p.1 of HBSS/0.01% BSA (pH 7.4)]. Mice were sacrificed 2 hours after s.c. 
injections and the accumulation of eosinophils in the dorsal membrane determined.
Results represent mean eosinophils/mm2 ± SEM of groups of 6 mice. One dorsal 
membrane preparation was excised from each animal and prepared for differential cell 
counting. Ten fields per preparation were counted for eosinophil infiltration and the mean 
obtained. The significance of differences between experimental groups was analysed 
using the Student's unpaired t-test. Differences in means were considered significant if P 
< 0.01. *P < 0.05 and ** P < 0.001 when compare with control vehicle.
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The order of potency of these chemoattractants on a molar basis was, MIP-loc (EC50 = 
0.05 pmol) > RANTES (EC50 = 0.25 pmol) > VGSE (EC50 = 0.5 pmol) = IL-5 (EC50 = 
0.5 pmol) = PAF (EC50 = 0.5 pmol) > LTB4 (EC50 = 1 pmol) > eotaxin (EC50 = 2.5 
pmol). The co-administration of eotaxin and IL-5 at their respective EC50, induced the 
accumulation of eosinophils in the skin at 2 hours to levels greater than that induced by 
maximally effective concentrations of either cytokine alone or a calculated additive effect 
determined by combining the levels of eosinophil accumulation by each of these 
molecules at their respective EC50, less the control value (figure n.7a). The co-injection 
of IL-5 and other members of the C-C-chemokine family, namely, M IP -la  (figure II.7b) 
and RANTES (figure II.7c) at their respective EC50, also induced a potent eosinophilia in 
the skin that was synergistic (figure II.7). As with IL-5 and eotaxin, the accumulation of 
eosinophils in response to IL-5 and M IP-la or IL-5 and RANTES was greater than that 
induced by either of these cytokines alone at maximally effective concentrations or when 
compared to a calculated additive level of eosinophil accumulation.
To determine whether it was the action of IL-5 or the C-C-chemokine which inferred 
synergy on the accumulation of eosinophils in skin and whether this synergy could be 
referred to other non-cytokine eosinophil chemoattractants, IL-5 or eotaxin were co­
injected with LTB4 (figure II.8a), PAF (figure II.8b) or VGSE (figure II. 8c), each at their 
respective EC50. Interesting, the synergistic action of IL-5 on the accumulation of 
eosinophils induced by either eotaxin, M IP -la  or RANTES, did not extend to the two 
lipid mediators (figure 11.8a and figure ll.b) or to VGSE (figure 11.8c). Similarly, the 
lipid mediators did not act synergistically with each other (figure II.9c) or with eotaxin 
(figures II.9 a and II.9b) to promote the accumulation of eosinophils at sites of 
administration in the skin.
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F igu re  II.7  IL-5 acts synergistic ally with the C-C-chemokines, eotaxin, 
M IP -la  and RANTES to promote the accumulation of eosinophils in skin.
Mice were given an i.v. injection of IL-5 (100 pmol/kg) and 1 hour later injected s.c. with 
IL-5 and either eotaxin, M IP-la  or RANTES, each at EC50. Mice were sacrificed 2 
hours post s.c. injection and the accumulation of eosinophils in the dorsal membrane 
determined. IL-5 (0.5 pmol/skin site) in combination with (a) eotaxin (2.5 pmol/skin 
site), (b) M IP -la  (0.0625 pmol/skin site) or (c) RANTES (0.25 pmol/skin site) induced 
the accumulation of eosinophils in the skin at levels greater than that induced by either of 
the molecules at maximal effective concentration or what would be expected by the 
additive effect of both molecules in isolation at EC50 less control levels. Results represent 
mean eosinophils/mm2 ± SEM of groups of 5 mice. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. (a) * P < 0.02 compared to 
eotaxin or IL-5 alone at ECioo> (b) * P < 0.02 compared to IL-5 or M IP-la alone at 
EC 100 and (c) P < 0.02 compared to IL-5 or RANTES alone at ECioo*
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Figure II.8 IL-5 does not act synergistically with PAF, LTB4 or VGSE to 
promote the accumulation of eosinophils in skin.
Mice were given an i.v. injection of IL-5 (100 pmol/kg) and 1 hour later injected s.c. with 
EC50 of IL-5 (0.5 pmol/skin site) and either PAF (0.5 pmol/skin site), LTB4 (1.0 
pmol/skin site) or VGSE (0.5 pmol/skin site). Mice were sacrificed 2 hours post s.c. 
injection and the accumulation of eosinophils in dorsal skin membranes analysed. IL-5 in 
combination with (a) PAF, (b) LTB4 or (c) VGSE induced the accumulation of 
eosinophils in the skin at sites of co-administration at levels that was equivalent to that 
induced by either molecule at EC 100 or when compared with a level that was calculated by 
the addition of levels of eosinophil accumulation induced by both molecules alone at EC50 
less the control level. Results represent mean eosinophils/mm2 ± SEM of groups of 5 
mice. The significance of differences between experimental groups was analysed using 
the Student's unpaired r-test. Differences in means were considered significant if P  < 
0.05. No significant differences were detected between EL-5 at EC50 in combination with 
(a) PAF, (b) LTB4 or (c) VGSE at EC50 and IL-5, (a) PAF, (b) LTB4 or (c) VGSE alone 
at EC 100.
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Figure II.9 Eotaxin and PAF or LTB4 or PAF and LTB4 do not act 
synergistically to promote the accumulation of eosinophils in skin.
Mice were given an i.v. injection of IL-5 (100 pmol/kg) and then 1 hour later were 
injected s.c. with eotaxin (2.5 pmol/skin site) and either PAF (0.5 pmol/skin site) or 
LTB4 (1.0 pmol/skin site) each at EC50. Another group were injected i.v. with IL-5 and 
then one hour later were injected s.c. with PAF (0.5 pmol/skin site) and LTB4 (1.0 
pmol/skin site) each at EC50. Mice were sacrificed 2 hours post s.c. injection and the 
accumulation of eosinophils in the dorsal skin membrane determined, (a) Eotaxin in 
combination with PAF or (b) eotaxin in combination with LTB4 induced the accumulation 
of eosinophils at sites of administration in the skin at levels that were equivalent to that 
induced by the EC 100 value of (a) eotaxin or PAF or (b) LTB4 and the expected levels that 
were calculated by the addition of the levels of eosinophil accumulation induced by each 
molecule at EC50 less the control level, (c) The co-administration of PAF (0.5 pmol/skin 
site) and LTB4 (1.0 pmol/skin site) induced the accumulation of eosinophils in the skin to 
levels that were equivalent to that induce by EC100 of these molecules alone and the 
calculated expected levels. Results represent mean eosinophils/mm2 ± SEM of groups of 
6 mice. The significance of differences between experimental groups was analysed using 
the Student's unpaired r-test. Differences in means were considered significant if P < 
0.05. No significant differences were found between groups that received co-injections 
of EC50 of chemoattractants and the groups that received these respective molecules alone 
at maximally effective concentrations.
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II.4 DISCUSSION.
The selectivity and kinetics of tissue expression of eotaxin, suggest a central role for this 
chemokine in the early phases of eosinophil homing during allergic inflammation (Jose et 
al, 1994a; Rothenberg etal, 1995b; Collins et al, 1995; Gonzalo eta l,  1996b). Both 
eotaxin and IL-5 induced a blood eosinophilia when administered i.v. (figure n. 1). The 
inability of i.v. eotaxin to mobilise bone marrow eosinophils, in contrast to IL-5, 
suggests the existence of two distinct eosinophil pools which can be mobilised in 
response to these cytokines. IL-5 appears to mobilise a bone marrow eosinophil pool, 
while eotaxin may sequester eosinophils that are residing in tissues into the circulation 
(figure II.2). During allergic cutaneous inflammation two phases (peaks at 6 and 24 
hours) of tissue eosinophilia are observed (Iwamoto et al, 1992). Previous reports 
indicate that the first phase of eosinophilia can occur independently of IL-5, while the 
second phase is significantly reduced in the presence of anti-IL-5 mAb (Iwamoto et al, 
1992). The expression of eotaxin occurs early in the inflammatory response and can be 
induced in cultured endothelial cells, alveolar epithelial cells and T-cell clones (Thi and 
Th2 clones) by cytokines (Rothenberg etal,  1995a; Gonzalo et al, 1996b). Taken 
together, these results suggest that eotaxin secreted from inflammatory cells or tissue sites 
in the early phases of the inflammatory response may be able to initiate and supplement 
tissue eosinophilia by sequestering, into the circulation, eosinophils which are migrating 
through non-inflamed tissues. This mechanism would utilise the eosinophil pool already 
participating in immune surveillance and provide a mechanism for an immediate response 
to allergic inflammation or parasite infection in tissues. Eosinophilic inflammation could 
then be amplified and sustained over the course of the inflammatory response by 
eosinophils mobilised by IL-5 from the bone marrow. The observation that i.v. co­
administration of both IL-5 and eotaxin causes blood eosinophilia to a level that is greater 
than that induced by either of these cytokines alone further suggests that these two 
cytokines may act in synergy during allergy to enhance the circulating eosinophil pool. 
Recently, IL-5 was also shown to mobilise eosinophils from the bone marrow and 
promote eosinophilic responses to s.c. eotaxin, supporting this concept (Collins et a l , 
1995).
Eotaxin is a potent eosinophil chemoattractant in vivo (Jose et al, 1994a). Eotaxin 
potently induced the accumulation of eosinophils in the skin at sites of administration at 
doses ranging from 0.1-10 pmol/site and had an inhibitory effect at higher doses (figure 
Ü.3). The narrow range in which eotaxin stimulates eosinophilia suggests that 
chemotactic signals for the selective migration of a cell type are discretely regulated at the 
site of inflammation. The rapid action of eotaxin on eosinophil trafficking in the skin (2 
hours) also suggests that this molecule promotes the accumulation of eosinophils directly 
by acting as a chemotactic agent, although it is possible that this chemokine may also
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stimulate the release of other preformed chemoattractants from cells at the site of 
administration. Following the completion of experiments in this Chapter, eotaxin was 
shown to regulate eosinophil recruitment to the allergic inflamed lungs of mice 
(Rothenberg et al., 1997). Eosinophil recruitment was significantly reduced during the 
early stages (18 hours) of allergic inflammation. Interestingly, no difference in the 
accumulation of eosinophils during later stages (48 hours) of the inflammatory reaction of 
the allergic response was reported. These reports support the hypothesis that eotaxin is 
an important molecule for the rapid recruitment of eosinophils to sites of allergic 
inflammation.
Similar to eotaxin, IL-5 was found to potently induce the accumulation of eosinophils in 
the skin; suggesting that IL-5 secreted in tissue compartments can act as a chemoattractant 
for eosinophils as well as enhance other chemotactic signals for the accumulation of 
eosinophils in vivo (Wang et al., 1989; Iwama et a l, 1993; Coeffier et al., 1994; Collins 
et al., 1995). Notably, it was demonstrated that eotaxin and IL-5 act cooperatively to 
enhance the accumulation of eosinophils in tissues (figure II.4).
Intravenous IL-5 was also shown to enhance the accumulation of eosinophils in tissues in 
response to eotaxin. Interestingly, despite eotaxin's potent induction of blood 
eosinophilia, i.v. eotaxin did not enhance the accumulation of eosinophils in the skin in 
response to itself or IL-5 (figure n.4b). This indicates that elevated blood levels of 
eosinophils alone are not sufficient to enhance eosinophil recruitment into tissues in 
response to chemoattractants. The ability of i.v. IL-5 to enhance eosinophil recruitment 
into tissues may involve the priming of this cell in the circulation, promoting migration in 
response to s.c. eotaxin (or IL-5), in addition to elevating the circulating eosinophil pool. 
Thus, IL-5 may have more than one functional role in the promotion of eosinophil 
recruitment. IL-5 and eotaxin cooperatively induced blood eosinophilia and enhanced the 
accumulation of eosinophils in tissues in response s.c. eotaxin or IL-5 to a greater degree 
than that observed by treatment with i.v. IL-5 alone. These observations further 
demonstrate the cooperative nature of the interaction between eotaxin and EL-5 for 
eosinophil homing.
All of the chemoattractants tested (eotaxin, RANTES, M IP-la, LTB4 PAF and the 
ECF-a tetra peptide, VGSE) potently induced the accumulation of eosinophils in the skin. 
Interestingly, in these experiments, VGSE and PAF were equipotent. This observation is 
in contrast to previous reports by Wardlaw et a l,  (1986) which showed that PAF was 
more potent than VGSE at inducing human eosinophil chemotaxis in vitro. Species 
differences may account for the inconsistencies between in vitro studies and our in vivo 
experiments. As shown above, the cooperative action of IL-5 and eotaxin for the 
induction of eosinophilia was synergistic (figure II.7a). IL-5 also acted in synergy with
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M IP-la (figure II.7b) and RANTES (figure II.7c) to promote the accumulation of 
eosinophils in vivo and thus, this phenomena may be an effect of IL-5 on C-C-chemokine 
signalling. Interestingly, IL-5 did not act in synergy with VGSE or lipid mediators 
(LTB4 and PAF). Furthermore, eotaxin itself did not exhibit any synergistic activity with 
other eosinophil chemoattractants (other than IL-5), which further indicates that it is IL-5 
that contributes to this synergistic phenomenon.
IL-5 may selectively prime eosinophils to C-C chemokine signals. Eotaxin and RANTES 
are agonists for CCR3 which is expressed by eosinophils (Daugherty et al., 1996). 
Although the agonistic effect of M IP-la on the human eosinophil CCR3 is contraversial 
(Combadierie et a l, 1995a, Daughtery et al., 1996), M IP-la, RANTES and eotaxin may 
all signal through CCR3. It has recently been shown that the action of RANTES and 
eotaxin on the chemotaxis of human eosinophils is primarily (95%) mediated through this 
chemokine receptor (Heath etal., 1997). Collectively, these results and those of others 
strongly suggest that IL-5 may promote eosinophil trafficking in response to M IP-la, 
RANTES and eotaxin by potentiating CCR3-activated intracellular signalling pathways.
During the course of these experiments, Okada etal., (1997) demonstrated that IL-5 may 
act synergistically with eosinophil chemoattractants such as eotaxin and PAF to promote 
eosinophil transmigration in vitro and these effects were dependent on the VLA-4 and 
CD 18 adhesion pathways. Results in this Chapter showed that the i.v. administration of 
IL-5 amplified the accumulation of eosinophils in the skin in response to eotaxin.
Although peripheral blood eosinophil levels are elevated by i.v. IL-5 administration, this 
cytokine may also amplify the recruitment of eosinophils into tissues, in part, by 
promoting transmigration events. Interestingly, in these experiments, no synergy was 
observed between IL-5 and PAF on the accumulation of eosinophils. These results 
indicate that these two molecules did not act synergistically, to direct chemotaxis, unlike 
IL-5 and the C-C chemokines (eotaxin, M IP-la  and RANTES).
The synergistic action of IL-5 with the eosinophil active C-C chemokines allows these 
molecules to efficiently and potently promote the accumulation of eosinophils in tissues at 
concentrations which would normally be suboptimal for these molecules individually. 
Interestingly, this synergy appears to occur between molecules that selectively induce 
eosinophil migration (IL-5 and the eosinophil active C-C chemokines: eotaxin, M IP -la  
and RANTES), but not between IL-5 and lipid mediators (LTB4 and PAF) that also act on 
neutrophils. This suggests that this synergistic phenomenon is part of an eosinophil 
selective trafficking pathway which may provide a mechanism for the selective 
accumulation of eosinophil at sites of allergic inflammation. Eotaxin, M IP -la  and 
RANTES are expressed in tissues of sensitised mice following antigen challenge 
(Gonzalo et al., 1996a, 1996b; Alam et al., 1996). Thus, these chemokines may act in
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synergy with IL-5 to provide a potent and selective mechanism for the recruitment of 
eosinophils into inflamed tissues during allergic reactions.
It would be interesting to further elucidate the synergistic mechanism operating between 
IL-5 and the C-C-chemokines, RANTES, M IP-la  and eotaxin. Such studies could be 
directed at examining the action of EL-5 of the CCR3 signalling pathway since all of these 
chemokines may signal through this receptor. Monitoring parameters such as cell motility 
with transient changes in intracellular-signalling molecules and free calcium may further 
our understanding of the processes that underlie the selective trafficking of eosinophils 
into tissues and may identify targets for the treatment of allergic diseases.
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CHAPTER III
THE RELATIONSHIP BETWEEN 
INTERLEUKIN-5 AND EOTAXIN IN 
REGULATING PULMONARY EOSINOPHILIA 
AND THEIR ROLE IN AIRWAYS 
DYSFUNCTION IN MICE
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III.l INTRODUCTION.
Eosinophilic inflammation of the airways is a major characteristic of asthma and is 
believed to underlie the pathophysiological changes to the lung. Of the numerous 
inflammatory cytokines implicated in eosinophil trafficking during allergy it has become 
increasingly obvious that both IL-5 and eotaxin play central roles (Jose et a l, 1994a; 
Rothenberg et a l, 1995b; Baggiolini, 1996; Gonzalo et al., 1996b; Foster et a l, 1996).
Unlike guinea pigs, mice do not develop pulmonary eosinophilia following the instillation 
of recombinant eotaxin into the lungs (Rothenberg et a l, 1996). However, the instillation 
of this chemokine into the lungs of IL-5 transgenic mice that over express this cytokine, 
potently induces pulmonary eosinophilia in a dose dependent manner (Rothenberg et a l, 
1996). This indicates that IL-5 acts with eotaxin to regulate eosinophil trafficking in 
mice. The ability of IL-5 to enhance eotaxin-induced pulmonary eosinophilia may be due 
to the increased levels of circulating eosinophils in IL-5 transgenic mice (Rothenberg et 
a l,  1996). In Chapter II and other investigations (Collins et a l, 1995), it has been 
shown that IL-5 cooperatively enhances eosinophilic responses to eotaxin. The action of 
IL-5 in these processes may be two fold; IL-5, acting in synergism with eotaxin may 
promote eosinophil migration into tissues, in addition to elevating the circulating 
eosinophil pool.
In transgenic mice, where IL-5 was specifically over expressed in the airway epithelium, 
both pulmonary eosinophilia and airways hyperreactivity developed (Lee et a l, 1997). 
This suggests a central role for IL-5 in the pathogenesis of asthma. In contrast, although 
the instillation of recombinant IL-5 into airways of guinea pigs induced a pulmonary 
eosinophilia, it did not promote the development of airways hyperreactivity (Lilly et a l, 
1996). These apparently conflicting roles of IL-5 in the development of airway 
hyperreactivity may be due to species difference and/or the duration of IL-5 exposure in 
these two studies.
IL-5 has a multitude of actions on eosinophil function (eg. haempoiesis, priming, 
migration, degranulation and survival [refer to introduction]). Eotaxin, although 
primarily characterised as an eosinophil chemoattractant (Rothenberg e ta l,  1996), also 
potently induces respiratory bursts in this cell (Eisner et a l, 1996). The aims of the 
experiments in this Chapter were to determine the ability of, and the relationship between, 
IL-5 and eotaxin to regulate eosinophil recruitment to pulmonary tissues. Furthermore, 
since the role of eotaxin and IL-5 in eosinophil activation and the effect of these two 
molecules on pulmonary function is unknown, the effect of these two cytokines on 
airways structure and function in the presence and absence of antigen processing in the 
lung was also examined.
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Due the reputed poor induction of pulmonary eosinophilia by the instillation of eotaxin in 
the lungs of mice (Rothenberg et aL, 1996), recombinant vaccinia viruses encoding the 
eotaxin or IL-5 genes were constructed (Ramsay and Kohonen-Corish, 1993) to 
determine the effects of transient expression of these two cytokines on pulmonary 
eosinophilia and airways function.
In contrast to transgenic mice, the vaccinia virus system for the expression of cytokines 
provides a unique way of studying the effects of localised transient cytokine expression in 
the lung. Another advantage of the vaccinia virus system over the transgenic 
manipulation of animals is that it avoids exposing animals to abnormally high levels of 
molecules during development, which can adversely alter physiological responses. By 
using the recombinant eotaxin and IL-5 -encoding vaccinia viruses, the roles of each of 
these molecules in isolation and in combination, upon the induction of pulmonary 
eosinophilia was examined. Furthermore, this system allowed for the study of the effect 
of eosinophils on airways function in the absence of other inflammatory cells associated 
with Th2 responses.
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III.2 MATERIALS AND METHODS.
111.2.1 Cloning of YV-HA-eotaxin.
Refer to figure IE.1 for a graphic representation of this process.
111.2.1.1 Cloning of eotaxin cDNA from MR#310 into the vaccinia virus 
vector pPS 7.5A.
Murine eotaxin cDNA (21-328 bp of full length murine eotaxin which encodes the mature 
protein), cloned into plasmid PCRII (Invitrogen, Carlsbad, CA., USA.) with 5' Hind E l 
and 3' Eco R1 restriction enzyme sites, was a gift from Professor Mark Rothenberg 
(Childrens Hospital Medical Centre, Cincinnati, OH., USA.) and was denoted MR#310.
Due to the incompatibility of common restriction sites between MR#310 and the multiple 
cloning site of the vaccinia virus vector, pPS 7.5a (Coupar et a l,  1988), the eotaxin 
cDNA was excised (restriction enzyme digested) from MR#310 and blunt-end ligated into 
pPS 7.5a. Briefly, pPS 7.5a was digested with Hind El and Bam HI and the resultant 5' 
overhangs end-filled to form blunt-end termini using Klenow polymerase (Promega, 
Madison, WL, USA.). Five prime blunt-end termini were dephosphorylated using calf 
intestinal alkaline phosphatase to prevent self-ligation. Eotaxin cDNA was excised from 
MR#310 using Hind IE (5') and Eco R1 (3'). The resultant 5' overhangs were end filled 
to form blunt end termini using Klenow polymerase (Promega, Madison, WI., USA.). 
Eotaxin cDNA was ligated to the linearized pPS 7.5a using ligase (Sambrook et al., 1989) 
and the orientation of the inserted eotaxin cDNA was determined by restriction enzyme 
digest with Bgl E and Eco R l. The resultant plasmid containing eotaxin cDNA was 
named pA M #l.
111.2.1.2 Maintenance of HuTK~143B cells.
Human thymidine kinase negative 143B cells (143B cells) were grown in F I5 Complete 
[FI5 supplemented with 5% heat inactivated foetal calf serum (FCS), 2 mM L-glutamine 
and 10 mM HEPES buffer] at 37°C/5% CO2. Cells were passaged upon confluence by 
aspirating the media off, washing the monolayer with PBS and incubating the cells at 
37°C with enough 0.25% trypsin/0.02% EDTA in HBSS to cover the monolayer until the 
cells detached. Ten millilitres of FI 5 Complete was added to arrest trypsinization and 
new flasks seeded with cells at 4 x 104 cells/cm2/0.20-0.25 mis FI 5 Complete.
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Figure III.l Cloning of W-HA-eotaxin.
Eotaxin cDNA was excised from MR#310 and ligated into pPS7.5a (Coupar et al., 
1988). The resulting vaccinia virus vector containing eotaxin cDNA was called 
pAM#l and was transfected into 143B cells with VV-HA-PR8 (Coupar et al., 1988). 
Homologous recombination of the F regions of VV-HA-PR8 with pAM#l formed the 
recombinant VV-HA-eotaxin.
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III.2.1.3 Transfection and viral recombination.
VV-HA-eotaxin was constructed from VV-HA-PR8 (Coupar et al., 1988) which carries 
the hemagglutinin (HA) gene of the influenza virus A/PR/8/34 in the Hind III J region and 
the thymidine kinase (TK) gene of the herpes simplex virus (HSV) in the Hind ID F 
region. Recombinant virus was purified using marker rescue of the TK gene (Coupar et 
al., 1988) and methotrexate selection (Panicali and Paoletti, 1982). Briefly, near 
confluent 143B cells in a 25 cm2 tissue culture flask were infected with W -H A -PR 8 at a 
multiplicity of infection (M.O.I.) of 0.05. Sixty minutes after viral infection the cells 
were transfected with 20 fig pAM#l using DOTAP transfection reagent (Boehringer 
Mannheim, Castle Hill, NSW., Australia) according to the manufacturer's instructions. 
After overnight incubation at 37°C/5% CO2, fresh F15 Complete, supplemented with 
MTAGG solution (3 mM methotrexate, 15 mM thymidine, 50 mM adenosine, 50 mM 
guanosine and 100 mM glycine) was added and the cells incubated for a further two days.
Cells were harvested using a cell scraper and pelleted by centrifugation (400 x g for 5 
minutes at 4°C). The cell pellet was resuspended in 1 ml of gelatine saline/20 mM 
HEPES (GSH). Virus was freed from the cells by trypsinization (100 mg/ml trypsin,
37 °C for 30 minutes) and was amplified by infecting 143B cells in a 25 cm2 tissue culture 
flask seeded with 1.5 x 106 cells the previous day. After 2 days incubation at 
37°C/5%C02 under MTAGG selection, the virus infected cells were harvested using a cell 
scraper and resuspended in 1 ml of GSH.
III.2.1.4 Primary plaque purification using TK+Ve selection.
Logarithmic dilutions (100 pi) of trypsinised (see section IQ.2.1.3) viral stock (10_1 to 
10'6) were added drop-wise to drained 143B cells in a 6 well tissue culture plate that had 
been seeded with 8 x 105 cells/well the previous day. After incubation at 37°C/5% CO2 
for 60 minutes, 2.5 mis of F15 Complete/MTAGG selection media was added and the 
cells were incubated for a further 2 days. The media was then removed and 2.5 mis of 
neutral red (0.01% in PBS) added to each well and the virus plaques counted. Individual 
plaques were collected using a micro pipette and were added to semi drained 143B cells in 
a 24 well tissue culture plate that had been seeded the previous day at 1.67 x 105 
cells/well. Following 2 days of incubation at 37°C/5% CO2 under MTAGG selection, 
each well was scored for cytopathic effect and the drained cells lysed (using 20 pi of 
sterile ddH20) to liberate virus. The viral mix was then tested for the presence of the 
eotaxin cDNA using dot blot hybridisation (see section ÜI.2.1.5).
The 24 well tissue culture plate was freeze/thawed 3 times and 10 pi from each well was 
spotted onto a nitrocellulose membrane and air dried. pAM#l and VV-HA-PR8 DNA
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served as positive and negative controls respectively. The nitrocellulose membrane was 
soaked sequentially in 0.5 M NaOH, 1 M Tris (pH 7.5) and 0.5 M Tris/1.5 M NaCl (pH 
7.5) for 5 minutes each, then blotted dry, hot baked at 80°C for 2 hours under vacuum, 
sealed in plastic and stored at 4°C awaiting radio probing.
111.2.1.5 Checking primary plaque purifications for the presence of 
recombinant virus containing the eotaxin cDNA.
A radioactively labelled eotaxin probe was synthesised from 40 ng of purified eotaxin 
cDNA using the "Ready To Go" DNA labelling Kit (-dCTP) (Pharmacia Biotec, Uppsala, 
Sweden), according to the manufacturer's instructions. Unincorporated radio nucleotide 
was removed using a Sepharose G-50 fine DNA grade Nick column (Pharmacia Biotech, 
Uppsala, Sweden), according to the manufacturer's instructions.
Nitrocellulose membranes that were dotted with viral DNA were pretreated with a 
prehybridization mix containing 5 x SSPE [0.18 M NaCl/10 mM NaH2P04/l mM HPT A 
(pH 7.7)], 0.1% sodium dodoecyl sulphate (SDS), 0.2% Blotto [4% skim milk powder 
(w/v)/0.02% NaN3 (w/v)] and 200 pg/ml denatured salmon sperm DNA, at 68°C for 4 
hours with shaking. The membranes were then plac^into a clean plastic bag containing a 
hybridization mix [5 x SSPE, 0.1% SDS, 0.2% Blotto and 200 pg/ml salmon sperm 
DNA and 40 ng of (a-32p) dCTP labelled eotaxin probe (previously denatured at 100°C 
for 10 minutes)] and were incubated on a roller at 68°C overnight. After washing for 1 
minute with 2 x SSC (0.15 M NaCl/1.5 mM trisodium citrate)/0.1 % SDS, followed by 
30 minutes with 2 x SSC/0.1% SDS, 2 x 1 5  minutes with 0.5 x SSC /0.1% SDS, 2 x 1 5  
minutes with 0.1 x SSC/0.1% SDS and 2 x 1 5  minutes with 15 mM NaCl/1.5 mM 
trisodium citrate/0.1% SDS at 68°C, the membrane was heat sealed in plastic and exposed 
to Kodak XAR-5 X-ray film with intensifying screen overnight at -70°C. The film was 
developed using an automatic developer.
Virus underwent two more rounds of plaque purification using MTAGG for TK+ 
selection and after the final plaque purification round, virus was checked again for the 
presence of the eotaxin cDNA using dot blot hybridization as described above.
111.2.1.6 Checking for parent virus contamination after final round- 
plaque purification using polymerase chain reaction.
III.2.1.6.1 Preparation of viral DNA.
The cell particulate from each well (5 |il) of the 24 well plate from the final round of 
plaque purification was incubated with proteinase K (0.4 mg/ml) for 60 minutes at 56°C
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in 200 fil of 10 mM Tris-HCl (pH 7.6)/50 mM 2-mercaptoethanol/100 mM NaCl/20 mM 
EDTA/1% sarkosyl (w/v) and 26% sucrose (w/v). After phenol/chloroform extraction, 
the DNA was ethanol precipitated and resuspended in 30 fil TE buffer containing 20 
fig/ml RNase and then stored at 4°C.
III.2.1.6.2 Polymerase chain reaction amplification o f  recombination site.
Viral DNA (5 fil) was added to a 20 fil reaction mix containing 5 pmol of each of FA 
(forward primer) and FB (reverse primer), 1 x AmpliTaq buffer (Perkin Elmer, Roche 
Molecular Systems, Branchburg, NJ., USA.), 1 unit of AmpliTaq DNA polymerase 
(Perkin Elmer, Roche Molecular Systems, Branchburg, NJ., USA.) and 25 |iM  each of 
dGTP, dCTP, dATP and dTTP (Promega, Madison, WI., USA.). The PCR primers,
FA (5' GTTTAATATGACGCTCG 3') and FB (5’ GCGTCACAGAATCTACC 3') that 
were homologous to the 5' and 3' (of the opposite strand) of the Hind HI and Bam HI 
(insert recombination site) sites of the F region, respectively, were provided by Dr D. 
Boyle, CSIRO Animal Health Laboratory, Australia. The PCR was run using an FTS-1 
Thermal Sequencer (Corbett Research, Sydney, Australia) under the following 
conditions. Ninety four degrees Centigrade for 3 minutes followed by 40 cycles of 3 
seconds at 96°C (denaturation), 3 seconds at 50°C (annealing) and 2 minutes at 72°C 
(extension) followed by a further 7 minutes at 72°C. Ten microlitres of each PCR 
product was analysed by polyacrylamide gel electrophoresis (PAGE, see section 
m .2 .1.6.2.1). As calculated, the non-homologous recombinant viruses showed a single 
band approximately 55 bases in length, while homologous recombinants showed a band 
at approximately 2.4 kilo bases.
M.2.1.6.2.1 Analysis o f polymerase chain reaction products by non-denaturing 
polyacrylamide gel electrophoresis.
Electrophoresis was performed through 3.75% stacking/18% resolving non-denaturing 
polyacrylamide gels (Sambrook et al., 1989) using a Mini-Protean II cell (BioRad, 
Hercules, CA., USA.) at 200V for 35 minutes. Samples were diluted 1:1 with 2 x 
sample loading buffer [10 mM Tris HC1 (pH 8.0); 20 mM EDTA; 0.2% N- 
lauroylsarcosine; 1.5% (w/v) Ficoll 400 (Pharmacia Biotech, Uppsala, Sweden); 0.05% 
(w/v) bromophenol blue and 0.05% xylene cyanol] and were heated at 65°C for 3 minutes 
immediately prior to loading on the gel. The gels were stained with ethidium bromide 
(100 ng/ml) for 10 minutes and the DNA was visualised under UV light (Sambrook et al., 
1989).
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III.2.1.7 Preparation of virus stocks.
Seed stocks of VV-HA-eotaxin were prepared by 2 rounds of amplification in 143B cells 
in 25 cm2 and 175 cm2 tissue culture flasks under MTAGG (TK+) selection. 143B cells 
were infected with logarithmic dilutions of trypsinised virus (see section III.2.1.3) and 
were grown in F15 Complete for 2 days at 37°C/5% CO2. After draining the media, cells 
were stained with 0.1% crystal violet/20% EtOH and the viral plaques counted.
Roller stocks of VV-HA-eotaxin and VV-HA-TK (Andrew et al, 1986) were prepared in 
confluent monolayers of CV-1 cells that were grown in 850 cm2 roller bottles. CV-1 cell 
were infected with 2 x 106 plaque forming units (pfu) of virus (seed stock) and were 
grown for 3 days on a roller at 37°C. The cells were then harvested using a cell scraper, 
pelleted by centrifugation (1800 x g for 5 minutes at 4°C) and resuspended in 15 mis of 
GSH. Roller stocks were stored at -70°C.
Roller stocks of virus were titred (see section 111.2.1.8) using either F15 Complete 
medium, F I5 Complete medium supplemented with MTAGG or F15 Complete medium 
supplemented with 25 |ig/ml BrdU to determine total virus, TK+ or TK_ viral titres, 
respectively.
III.2.1.8 Viral titring using plaque assay.
Viral suspensions were sonicated [ 2 x 1 0  seconds in ice water at 50 watts in a Sonifyer 
B12 cup sonicator (Branson Sonic Power Company, Danbury, CT., USA.)] and 
logarithmically diluted in GSH. Each dilution (100 fil) was added drop wise to drained 
143B cells in a 6 well tissue culture plate that had been seeded at a density of 8 x 105 
cells/well the previous day. After incubation at 37°C/5% CO2 for 60 minutes, 2.5 mis of 
FI 5 Complete media was added to each well and then the plates were incubated for a 
further 2 days at 37°C/5% CO2. The media was then removed and enough crystal violet 
(0.1 % in 20% EtOH) was added to fully cover the well surface. Plates were air dried and 
viral plaques were counted. Viral titres were performed in duplicate and were determined 
from wells that contained 10-40 viral plaques.
III.2.2 Animals.
Male mice (C57BL/6, 6-8 wk of age) were used in all experiments.
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III.2.3 The analysis of viral growth in murine lung.
eotaxin) or days 1 to 7 and 9 (VV-HA-IL-5 + VV-HA-eotaxin or VV-HA-TK) after viral 
inoculation and their lungs aseptically removed and stored at -70°C. Lungs were 
homogenised in 1 ml of PBS using a teflon homogeniser and sonicated as describe for 
viral suspension (section 111.2.1.8). Viral titres were determined in monolayers of 143B 
cells in 6 well plates by logarithmic dilution (see section III.2.1.8).
111.2.4 The effect of VV-HA-eotaxin on the induction of pulmonary 
eosinophilia.
Mice were i.n. inoculated with 1 x 107 pfu of either VV-HA-eotaxin or VV-HA-TK. At 
peak viral growth (4 days post infection) the mice were sacrificed by cervical dislocation 
and the levels of leukocytes in the BALF determined (see section III.2.9) or histological 
examination of pulmonary tissues performed (see section m.2.12). Blood smears were 
taken daily post viral inoculations and the percentage of eosinophils in the total circulating 
leukocyte population determined by staining the slides with Giemsa-May-Grunwald. 
Routinely, 300-400 cells were counted per slide.
111.2.5 Effect of i.n. inoculation with VV-HA-eotaxin and/or VV-HA-IL- 
5 and i.v. injection of IL-5 on BALF eosinophilia.
Mice were given an i.n. inocula of 1 x 107 pfu of either VV-HA-eotaxin, VV-HA-IL-5 or 
VV-HA-TK or 0.5x 107 pfu each of VV-HA-eotaxin and VV-HA-IL-5 in combination. 
Four days later mice received an i.v. injection of either 200 pmol/kg of IL-5 or control 
vehicle (100 pi of 0 .1%BSA/PBS). Blood samples were taken prior to and at 30 minutes 
post i.v. injection to confirm the induction of blood eosinophilia by IL-5. Blood 
eosinophil levels were determined using Discombe's method (section II.2.2). Twenty- 
four hours after i.v. injections the levels of eosinophils in the airways were assessed by 
BAL (section EII.2.9).
111.2.6 Effect of i.n. inoculation with VV-HA-eotaxin and/or 
VV-HA-IL-5 and i.v. IL-5 on pulmonary function.
Mice were given an i.n. inocula of 0.5 x 107 pfu each of VV-HA-eotaxin and VV-HA-IL- 
5 or 1 x 107 pfu of VV-HA-TK (control virus). Four days later mice received an i.v. 
injection of 200 pmol/kg IL-5 in 100 pi of 0.1%BSA/PBS (pH 7.4). Seventy-two hours
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after i.v. injections the mice were analysed for leukocyte infiltration into the airways (see 
section EII.2.9), airways hyperreactivity to ß-methylcholine (see section 111.2.11) and 
changes to tissue structure (see section EH.2.12).
111.2.7 Determining the effect of i.n. co-inoculation with VV-HA-eotaxin 
and VV-HA-IL-5 on pulmonary dysfunction during antigen inhalation.
Mice were exposed to aerosolized Ova (10 mg/ml) in saline or saline alone, for 3 x 30 
minutes periods with 30 minutes rest between exposures, every second day for 8 days. 
Three days after the first exposure to Ova the mice were i.n inoculated with a combination 
of 0.5 x 107 pfu of VV-HA-eotaxin and VV-HA-IL-5 or 1 x 107 pfu of VV-HA-TK 
alone. Four days after viral inoculation the mice received an i.v. injection of 200 pmol/kg 
of IL-5 in 100 fil of PBS/0.1% BSA (pH 7.4). The infiltration of leukocytes into the 
airways was analysed 5 and 7 days after viral inoculations by BAL (section ID.2.9). The 
presence of extracellular MBP (as a marker of eosinophil activation) in BALF 
supernatants was also assessed (section III.2.13). A late-phase airways hyperreactivity 
was tested for 7 days after viral inoculation, 48 hours after the last exposure to Ova 
(section III.2.11). Ova-specific serum antibodies were determined 5 days after viral 
inoculations (see section in.2.10). Histological analysis of pulmonary tissues was 
performed 5 and 7 days after viral inoculations (section M.2.12).
111.2.8 Determining the role of CD4 in VV-HA-IL-5- and VV-HA-eotaxin- 
induced airways hyperreactivity following repeated exposure to Ova 
aerosol.
Mice were i.n. inoculated with W -H A -IL-5 and VV-HA-eotaxin at 0.5 x 107 pfu/virus 
and exposed to OVA aerosol as previously described (see section EH.2.7). Three days 
prior to viral inoculations and 3 days post viral inoculations the mice were i.p. injected 
with 1 mg of anti-CD4 mAb (GK1.5) or 1 mg of rat isotype control IgG mAb (GL113). 
Airways hyperreactivity (see section in .2 .11) and the leukocyte levels in the BALF (see 
section m.2.9) were determined 7 days after viral inoculation. The levels of Ova-specific 
serum IgGl and total Ova-specific serum IgG were also determined (see section III.2.10) 
7 days after viral inoculations.
111.2.9 The analysis and quantitation of leukocyte populations in the 
airway lumen by BAL.
Mice were killed by cervical dislocation and the trachea cannulated with a blunt 18 gauge 
needle. The lungs were then gently lavaged with 2 x 1 ml of HBSS and the lavage fluid 
placed on ice. The number of cells/ml of lavage fluid were determined using a
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haemocytometer and 2 x 105 cells were cytocentrifuged and stained with Giemsa-May- 
Grunwald for differential cell counting. Leukocyte populations were identified by 
morphological criteria. Routinely, 300-400 cells were counted per slide.
111.2.10 The analysis Ova-specific antibody titres in sera and BALF by 
ELISA.
R at bottom 96-well microtitre plates (Dynatech, Chantill, VA., USA.) were coated with 
either 100 pg/well Ova or 5 pg/well of either goat anti-mouse IgG], total IgG; IgA or IgE 
(Biosource International, Camarillo, CA., USA) in NaHC03 buffer (pH 9.6) and 
incubated at 4°C overnight. After washing 5 times with PBS/0.04% Tween-20 (SIGMA 
Chemical Co., St Louis, MO., USA.) the non-specific binding sites were blocked with 
3% skim milk powder/PBS/0.04% Tween-20 for 1 hour at 37°C. Plates were then 
washed in PBS/0.04% Tween-20 and incubated with serial dilutions of either BALF or 
serum samples or standard murine IgGi, total IgG, IgA or IgE (SIGMA Chemical Co.,
St Louis, MO., USA.). Following incubation at room temperature for 2 hours the plates 
were washed with PBS/0.04% Tween-20 and incubated with biotinylated goat anti-mouse 
IgGi, total IgG, IgA or IgE (Biosource International, Camarillo, CA., USA.) in 
PBS/0.04% Tween-20 at room temperature for 1 hour. The plates were then washed 
with PBS and incubated with streptavidin-conjugated alkaline phosphatase (Amersham 
International pic., Buchinghamshire, UK.) for 1 hour at room temperature. Alkaline- 
phosphatase substrate solution (SIGMA Chemical Co., St Louis, MO., USA.) was then 
added and left to develop for 30 minutes at room temperature. Colour reactions were 
stopped by the addition of 50 pi of 0.1 M citric acid and the plates were read at 405 nm 
using a Microplate reader (BIO-TECH Instruments Inc., Winooski, VT., USA.).
111.2.11 Analysis of airways hyperreactivity to ß-methylcholine.
Mice were anaesthetised by i.p. injection of 300 (il of a cocktail containing 60 mg/kg 
ketamine [Ketamil (Troy Laboratories Pty. Ltd., Smithfield, NSW., Australia)]/8 mg/kg 
xylazine [Rompun (Bayer Australia Ltd., Pymble, NSW., Australia)/?.2 mg/kg 
Acepromazine [Promex-2 (Apex Laboratories Pty. Ltd., St Mary's, NSW., Australia)] 
and the left or right lateral tail veil cannulated with a 25 gauge x 3/4 inch Winged Infusion 
set (Terumo Co-operation, Tokyo, Japan). The trachea was then exposed and cannulated 
with a blunt 18 gauge needle that was co-connected to a rodent ventilator (60 
strokes/minute with a stroke volume of 1 ml) and a bronchospasm transducer (Ugo Basil- 
7020, Varese, Italy). The bronchospasm transducer was linked (Foster et al, 1996) to a 
Lab Mac/8 analysis station (Adlnstruments, Sydney, Australia). The mice were 
maintained at 30°C and injected via the tail vein cannula with 50 pi of suxamethonium 
chloride [0.5 mg/kg (Astral Pharmaceuticals, Sydney, Australia)] to inhibit spontaneous
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respiration. After a stable baseline was achieved, airway constriction was measured by 
monitoring changes in respiratory overflow volume during cumulative i.v. administration 
of ß-methylcholine (12.5-1000 ftg/kg) (SIGMA Chemical Co., St Louis, MO., USA.). 
Following the final dose of ß-methylcholine, the tracheal cannula was totally occluded to 
determine the maximal occlusion.
111.2.12 Histological analysis of pulmonary tissues.
Transverse sections (approximately 4 mm wide) of lung were cut from the left lobe and 
fixed in 10% neutral buffered formalin for a minium of 24 hours. Samples were 
processed by the Histological Unit (John Curtin School of Medical Research ANU, 
Canberra, A.C.T., Australia). Briefly, fixed tissue was embedded in paraffin and 8 fim 
sections were cut onto glass slides. After heat affixing to the glass slide, the sections 
were deparaffinized in xylene, rehydrated using a gradient alcohol solutions and stained 
with Mayer's haematoxylin and eosin. Slides were mounted in DePeX mounting medium 
(BDH Laboratory Supplies, Poole, England) and coversliped. The sections were 
examined using light microscopy and were photographed using Ektachrome 64T tungsten 
colour film (Eastman Kodak Company, Rochester, NY., USA.).
111.2.13 The detection of free MBP in BALF using Western dotblot.
Polyvinylidene difluoride (PVDF) membranes were submerged in 100% methanol for 1
was
placed on the membrane. After drying at room temperature membranes were immersed in 
methanol and then TBS as described above. Membranes were then incubated with 1/2000 
dilution of a polyclonal rabbit anti-mouse MBP (a gift from Dr G. J. Gleich, Mayo Clinic, 
Rochester, MI., USA.) in TBS/0.04% Tween-20 [polyoxyethylene-sorbitan 
monolaurate] (SIGMA Chemical Co., St Louis, MO., USA.) for 1 hour at room 
temperature on a rocker. After washing with TBS for 3 x 5 minutes on a rocker at room 
temperature, 0.2 ftg/ml of goat anti-rabbit IgG alkaline-phosphatase conjugate was added 
and the membranes incubated for 1 hour at room temperature on a rocker. After washing 
the membranes with TBS for 3 x 5 minutes, Western Blue stabilised substrate for 
alkaline-phosphatase (Promega Corporation, Madison, WI., USA.) was added to cover 
the membrane and the reaction developed for 3 minutes at room temperature. Colour 
reactions were arrested by washing the membrane in PBS.
minute and then in TBS [20 mM Tris-HCl/150 mM NaCl (pH 8.0)] for^ m inutes. 
Membranes were placed on TBS soaked filter paper and 3 (il of eachi^BALF sample
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III.3 RESULTS.
111.3.1 The sustained expression of eotaxin induces pulmonary 
eosinophilia in mice.
The kinetics of W -HA-eotaxin growth and clearance in the lungs of mice that were 
inoculated with 1 x 107 pfu were similar to that observed for the control virus (VV-HA- 
TK) (figure III.2). The peak viral titres for both VV-HA-eotaxin and VV-HA-TK were 
observed 4 to 5 days after inoculation at the level of 106 pfu/lung. Viral titres 
subsequently declined to 103 pfu/lung by day 7. Neither virus was detected (level of 
detection < 102 pfu/lung) in the lungs 9 days after viral inoculation (figure III.2). Four 
days post viral inoculation (at peak viral burden), the mice that received W -HA-eotaxin 
displayed a significant BALF eosinophilia (4.01 x 103 ± 0.62 x 103 eosinophils/ml 
BALF), in contrast to mice inoculated with control virus (W -HA-TK) ( i f  0.2 x 103 
eosinophils/ml BALF). The level of eosinophils in the BALF of VV-HA-TK inoculated 
mice were the same as those of non-treated mice (figures III.3).
111.3.2 VV-HA-eotaxin and VV-HA-IL-5 co-inoculation induces a 
pronounced pulmonary eosinophilia in mice that is further amplified in the 
presence of i.v. IL-5.
Viral growth and viral clearance in the lungs of mice was similar for groups that received 
W -HA-eotaxin and W -HA-IL-5 each at half dose (0.5 x 107 pfu) to those that received 
a full dose (1 x 107 pfu) of the control virus (VV-HA-TK) (figure III.4). Viral growth 
and clearance of VV-HA-IL-5 in the lungs of mice that were given an i.n. inocula of 1 x 
107 pfu has previously been reported (Ramsay and Kohonen-Corish, 1993) and was not 
significantly different from that of the control virus (VV-HA-TK). Thus, neither eotaxin 
alone (figure III.2) or in combination with IL-5, significantly effects vaccinia viral growth 
or viral clearance mechanisms in the lungs of mice.
VV-HA-eotaxin (0.5 x 107 pfu) and VV-HA-IL-5 (0.5 x 107 pfu) together induced a 
significantly greater BALF eosinophilia when compared with groups that received either 
of the viruses alone at the same total viral load (1 x 107 pfu) (figure III.5). VV-HA-IL-5 
induced a BALF eosinophilia equivalent to VV-HA-eotaxin (figure III.5).
In Chapter II it was shown that the i.v. injection of IL-5 enhanced the cutaneous 
accumulation of eosinophils in mice in response to eotaxin or IL-5 (see section II.3.2). 
Similarly, i.v. administration of IL-5 also amplified eosinophil recruitment to pulmonary 
tissues in response to VV-HA-IL-5 and/or VV-HA-eotaxin infection (figure M.5).
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Figure III.2 Kinetics of viral growth and clearance in the lungs for 
VV-HA-eotaxin in comparison to VV-HA-TK.
Mice were inoculated with 1 x 107 pfu of VV-H A-eotaxin or VV-HA-TK. Data 
represents mean viral titre/lung ± SEM of groups of 4 mice in duplicate as 
determined by viral plaque assay. The kinetics of VV-HA-eotaxin growth and 
clearance in the lungs of mice were the same as that for the VV-HA-TK.
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Figure M.3 VV-HA-eotaxin induces BALF eosinophilia.
Mice were inoculated with 1 x 107 pfu of either VV-HA-eotaxin or VV-HA-TK 
(control virus) and the levels of eosinophils in the BALF analysed 4 days later.
Mice inoculated with VV-HA-eotaxin had significantly higher levels of eosinophils 
in the BALF compared with VV-HA-TK (control virus) inoculated mice. Data 
represents mean eosinophils/ml BALF ± SEM of groups of 5 mice. The 
significance of differences between experimental groups was analysed using 
Student's unpaired Ftest. Differences in means were considered significant if 
P < 0.05. *P < 0.001 when compared with VV-HA-TK.
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VV-HA-eotaxin (0.5 x 107 pfu) +
VV-HA-IL-5 (0.5 x 107 pfu) 
VV-HA-TK (1 x 107 pfu)
level of detection
day post i.n. inoculation
Figure III.4 Kinetics of VV-HA-eotaxin and VV-HA-IL-5 growth and 
clearance in the lungs.
Viral growth and clearance in the lungs of mice that received an i.n. co-inocula of 
VV-HA-eotaxin (0.5 x 107 pfu) and VV-HA-IL-5 (0.5 x 107 pfu) were simiarto
that for the VV-HA-TK (control virus) at the same total viral load (1 x 107 
pfu/lung). Data represents mean viral titre/lung ± SEM of groups of 4 mice in 
duplicate as determined by viral plaque assay.
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Figure in.5 W-HA-IL-5 and VV-HA-eotaxin together are potent inducers of 
BALF eosinophilia in mice.
Mice were given an i.n. co-inocula of both VV-HA-eotaxin (0.5 x 107 pfu) and
VV-HA-IL-5 (0.5 x 107 pfu), or a single inocula (1 x 107 pfu) of of VV-HA- 
eotaxin, VV-HA-IL-5, or VV-HA-TK (control virus). Four days later the mice 
received an i.v. injection of 200 pmol/kg IL-5 or control vehicle [100 |il of 10
mM PBS/0.1% BSA (pH 7.4)]. Mice were sacrificed 24 hours after i.v. 
injections and their airways lavaged (BAL) with 2 x 1 ml of HBSS. Data 
represents mean eosinophils/ml BALF ± SEM of groups of 5 mice. The 
significance of differences between experimental groups was analysed using 
Student's unpaired ?-test. Differences in means were considered significant if P 
< 0.05. *P < 0.05 and **P < 0.01 when compared with VV-HA-eotaxin or VV- 
HA-IL-5 alone with i.v. control vehicle.
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The BALF eosinophilia induced by VV-HA-eotaxin and/or VV-HA-IL-5 was further 
enhanced 5 days after inoculation when IL-5 (200 pmol/kg i.v.) was administered 24 
hours earlier (figure III.5). Interestingly, i.v. IL-5 also significantly increased the levels 
of eosinophils in the BALF in response to VV-HA-TK (control virus). Although the 
levels of each of the viruses in the lungs were similar 5 days after viral inoculations, 
VV-HA-eotaxin (0.5 x 107 pfu) and VV-HA-IL-5 (0.5 x 107 pfu) induced a BALF 
eosinophilia that was significantly higher than that induced by either virus in isolation (at 
the same total viral load) (figure III.5).
The histological examination of lung sections from all groups of vaccinia virus inoculated 
mice revealed a considerable cellular infiltrate in the perivascular and the peribronchiolar 
regions (figure 111.6). In contrast to VV-HA-TK (control virus), VV-HA-eotaxin and 
VV-HA-IL-5 induced tissue eosinophilia in perivascular (not shown) and peribronchiolar 
regions (figure III.7). Notably, eosinophils in the peribronchiflar regions were 
specifically localised to areas directly under the smooth muscle layer. In contrast, few 
eosinophils were found in the region between the airways smooth muscle and the 
bronchial epithelium.
Although W -HA-IL-5 and VV-HA-eotaxin selectively induced a significant BALF 
eosinophilia (P > 0.001 compared with VV-HA-TK) (figure III.8a) they did not induce 
airways hyperreactivity (figure III. 8b). Furthermore, no MBP was detected in the BALF 
following VV-HA-IL-5 and VV-HA-eotaxin or VV-HA-TK inoculation (table IIL1). 
None of the viruses causes significant damage (epithelial shedding) to the airways (figure 
III.7).
III.3.3 VV-HA-eotaxin and VV-HA-IL-5, but not VV-HA-TK, induces 
airways hyperreactivity to ß-methylcholine in mice following repeated 
exposure to aeroallergen.
a
Ova aerosol exposure did not$ffect the levels of eosinophils, lymphocytes or neutrophils 
in the BALF, either in the presence of VV-HA-IL-5 and VV-HA-eotaxin or VV-HA-TK 
(figure IH.9a). However, macrophage levels in the BALF were significantly higher (P < 
0.05) following Ova aerosol exposure when compared with saline aerosol exposed 
controls (figure III.9a).
Following multiple exposures to Ova aerosol, VV-HA-eotaxin and VV-HA-IL-5 induced 
airways hyperreactivity to i.v. ß-methylcholine (figure III.9b). In contrast, these viruses 
had no effect of airways reactivity following multiple exposures to saline aerosol (figure 
m.9b). VV-HA-TK (control virus) failed to induce airways hyperreactivity following 
multiple exposures to either Ova or saline aerosol (figure III.9b).
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MBP was only detected in the BALF of the VV-HA-IL-5 and YV-HA-eotaxin co­
inoculated group following repeated exposure to Ova aerosol. MBP was detected 5 days 
after viral inoculation (table III. 1) and airways hyperreactivity was detected two days later 
(figure III.9b). Interestingly, no MBP was detectable in the BALF when airways 
hyperreactivity developed.
Although the repeated exposure of mice to aerosolized Ova did not induce pulmonary 
eosinophilia to the same magnitude as that observed in mice during severe allergic airways 
inflammation (Foster et al., 1996), it did elicit a weak immune response 5 days after viral 
inoculation, as detected by the presence of Ova-specific serum IgG. The antibodies were 
predominantly of the IgGi isotype (figure HI. 10) and no Ova-specific BALF IgA or 
serum IgE were detectable in these mice.
Although VV-HA-IL-5 and W -HA-eotaxin induced airways hyperreactivity in the 
presence of repeated exposures to Ova aerosol, no visible damage to the structure of the 
airways was observed at 5 and 7 days after viral inoculation (not shown). Similar to the 
BALF, eosinophil levels in the lungs after VV-HA-IL-5 and VV-HA-eotaxin inoculation 
were not different between Ova and saline aerosol treatments (figure IH.9a).
Furthermore, the eosinophils that were present in the lungs of all of these groups were 
consistently and predominantly localised to regions under the airways smooth muscle as 
previously observed (figure III.7).
III.3.4 The development of airways hyperreactivity in VV-HA-IL-5 and 
VV-HA-eotaxin inoculated mice following exposure to Ova aerosol is CD4 
dependent.
To test the role of CD4 in the induction of airways hyperreactivity by VV-HA-IL-5 and 
VV-HA-eotaxin following repeated exposure to Ova aerosol, mice were treated i.p. with 
anti-CD4 mAb. Anti-CD4 mAb treatments abolished the production of Ova specific 
serum IgGi and total Ova-specific serum IgG (figure III.l la) and the development of 
airways h y p r r r n ?ivr'rinr (figure III.l lb). Furthermore this treatment did not 
affect individual leukocyte levels in the BALF (figure ID. 12).
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Figure III.6 Peribronchial and perivascular infiltration of leukocytes in 
vaccinia virus infected lungs.
(a) There was a substantial infiltration of leukocytes in the perivascular (PV) and 
peribronchial (PB) regions of lungs 5 days after viral (VV-HA-TK) inoculation when 
compared to (b) the lungs from untreated controls. Photographs (100 x magnification) 
are of 8 pM paraffin sections stained with Giemsa-May-Grunwald.
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Table III.l MBP levels in the BALF of vaccinia virus inoculated mice 
following multiple exposures to Ova or saline aerosol.
Saline aerosol Ova aerosol
Viral inocula Day 5 Day 7 Day 5 Day 7
VV-HA-TK(1.0 x 107 pfu)
X X X X
VV-HA-IL-5 (0.5 x 107 pfu)+ VV- 
HA-eotaxin (0.5 x 107 pfu) X X V X
The presence of free MBP in the BALF of mice inoculated with VV-HA-IL-5 (0.5 x 107 
pfu) and VV-HA-eotaxin (0.5 x 107 pfu) or VV-HA-TK (1.0 x 107 pfu) was analysed in 
sample taken from mice 5 and 7 days after viral inoculation and was determined by 
western dot blot. Ticks represent positive MBP staining on immuno dot blots and a cross 
denotes that MBP was not detected. MBP was only detected in the BALF of Ova aerosol 
exposed VV-HA-IL-5 and VV-HA-eotaxin inoculated mice 5 days after virus inoculation.
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Figure III.7 VV-HA-eotaxin and VV-HA-IL-5 induce pulmonary 
eosinophilia.
Mice were co-inoculated with VV-HA-IL-5 (0.5 x 107 pfu) and VV-HA-eotaxin (0.5 x 
107 pfu) or VV-HA-TK (1 x 107 pfu). Five days later the mice were sacrificed and the 
lungs examined. Photographs (400 x magnification) are of 8 fiM paraffin sections stained 
with Giemsa-May-Grunwald. (a) Eosinophils were present in peribronchial regions 
following W -HA-IL-5 and VV-HA-eotaxin inoculation and were specifically localised to 
areas adjacent to the airways smooth muscle layer (ASM), (b) In contrast, few 
eosinophils were found in this region following VV-HA-TK (control virus) inoculation.
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Figure III.8 Co-inoculation with VV-HA-eotaxin and VV-HA-IL-5 
induces a selective recruitment of eosinophils into the lungs but does not 
induce airways hyperreactivity.
Mice were inoculated with VV-HA-eotaxin (0.5 x 107 pfu) and W -H A -IL-5 (0.5 x 107 
pfu) or VV-HA-TK (1 x 107 pfu) and four days later were given an i.v. injection of 200 
pmol/kg IL-5. Airway hyperreactivity and leukocyte levels in the BALF were analysed 7 
days after viral inoculation, (a) Leukocyte levels in BALF. Data represents mean cells 
[eosinophils (eos), neutrophils (neuts), lymphocytes (lymphs) or macrophages 
(m/phages)] per ml of BALF ± SEM of groups of 5 mice, (b) Measurement of airways 
reactivity to ß-methylcholine. Airways reactivity was measured by monitoring i.v. ß- 
methylcholine-induced changes in respiratory overflow volume. Ova 
sensitised/challenged mice (Foster et a l, 1996) and non-treated mice were used as 
positive and negative controls, respectively. Data represents mean percentage airway 
occlusion ± SEM of groups of 6 mice. The significance of differences between 
experimental groups was analysed using the Student's unpaired r-test. Differences in 
means were considered significant if P < 0.05. (a) < 0.001 when compared with
eosinophils levels in W -H A -TK  infected mice, (b) No significant difference in means 
between VV-HA-eotaxin/VV-HA-IL-5 and VV-HA-TK or between either of these groups 
and a non-treated (negative control) group at the same doses of ß-methylcholine.
87
(a)
2.5 -I
□  VV-HA-TK
I VV-HA-IL-5 + VV-HA-eotaxin
2 . 0 -
(b)
VV-HA-eotaxin + VV-HA-IL-5
VV-HA-TK
positive control 
negative control
cumulative ß-methylcholine
88
Figure III.9 The repeated exposure of mice to Ova aerosol induces late- 
phase airways hyperreactivity in mice inoculated with VV-HA-eotaxin and 
VV-HA-IL-5 but not with VV-HA-TK, without changing BALF leukocyte 
populations.
(a) Leukocyte levels in BALF 7 days after W -HA-eotaxin and VV-HA-IL-5 or 
VV-HA-TK inoculation following multiple exposures to Ova or saline aerosol. Data 
represents mean eosinophils (eos), neutrophils (neuts), lymphocytes (lymphs) or 
macrophages (m/phages) per ml of BALF ± SEM of groups of 5 mice, (b) Airways 
reactivity was measured by monitoring i.v. ß-methylcholine-induced changes in 
respiratory overflow volume. Ova sensitised/challenged mice (Foster et al., 1996) were 
used as a positive control. Data represent the mean percentage airway occlusion ± SEM 
of groups of 6 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired r-test. Differences in means were considered 
significant if P  < 0.05. (a) *P < 0.05 when compared with groups that were exposed to 
saline aerosol, (b) *P < 0.05 and ** P < 0.01 when compared with VV-HA-TK + Ova 
aerosol and VV-HA-DL-5 + VV-HA-eotaxin + saline aerosol groups.
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Figure III.10 The level o f Ova-specific IgGj in comparison to total Ova- 
specific IgG in sera o f mice exposed to Ova aerosol.
Levels of Ova-specific serum IgG] and total Ova-specific serum IgG in
VV-HA-IL-5 and VV-HA-eotaxin or VV-HA-TK inoculated mice following 
repeated exposure to Ova or saline aerosol. Serum samples were analysed 5 days 
after viral inoculation by ELISA. Data represents mean ng/ml sera of (a) Ova- 
specific IgG and (b) Ova-specific IgG] ± SEM of groups of 5 mice. Each sample
was analysed in duplicate by serial dilution. No Ova-specific IgG was detectable 
in groups that were exposed to saline aerosol (not shown).
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Figure III .ll Treatment of mice with anti-CD4 mAb abolishes the 
production of Ova-specific IgG l and the development o f late-phase 
airways hyperreactivity induced by VV-HA-eotaxin and VV-HA-IL-5 
following repeated exposure to Ova aerosol.
(a) Anti-CD4 mAb (GK1.5), but not control mAb (GL113) treatment abolished the 
production of Ova-specific IgGi and total Ova-specific IgG in the sera of VV-HA-eotaxin 
and VV-HA-IL-5 inoculated mice that were repeatedly exposed to Ova aerosol. Data 
represent mean ng/ml of sera of (a) total Ova-specific serum IgG and Ova-specific serum 
IgGi ± SEM of groups of 5 mice. Each sample was analysed by ELISA in duplicate by 
serial dilution, (b) Late-phase airways reactivity was measured by monitoring i.v. ß- 
methylcholine-induced changes in respiratory overflow volume. Anti-CD4 mAb 
treatment abolished Ova aerosol-induced airways hyperreactivity in VV-HA-IL-5 and VV- 
HA-eotaxin inoculated mice. Data represent mean percentage airway occlusion ± SEM of 
groups of 6 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired r-test. Differences in means were considered 
significant if P < 0.05. (b) < 0.05 and **P < 0.02 when compared with GL113
treated mice.
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Figure IIL12 Leukocyte levels in BALF 7 days after VV-HA-eotaxin and VV- 
HA-IL-5 inoculation in the presence of Ova aerosol and following treatment 
with anti-CD4 mAb.
Mice were inoculated with VV-HA-EL-5 and VV-HA-eotaxin, repeatedly exposed 
to Ova aerosol and i.p. injected with anti-CD4 mAb (GK1.5) or isotype control 
mAb (GL113). Data represents mean eosinophils (eos), neutrophils (neuts), 
lymphocytes (lymphs) or macrophages (m/phages) per ml of BALF 7 days after 
viral inoculation ± SEM of groups of 5 mice. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. No significant 
differences were detected between the means of any leucocyte population 
following GK1.5 treatment when compared with groups treated with GL113.
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III.4 DISCUSSION.
Although a single exposure of mice to recombinant eotaxin did not elicit a B ALF 
eosinophilia (Rothenberg et al, 1996), the sustained in vivo expression of this cytokine 
by recombinant vaccinia virus induced a significant BALF eosinophilia. IL-5, expressed 
by recombinant vaccinia virus also potently induced the accumulation of eosinophils in 
pulmonary tissues. Furthermore, the co-expression of these two cytokines significantly 
amplified pulmonary eosinophilia. The recent characterisation of mice where IL-5 was 
specifically expressed by the airway epithelium (under the control of the CC10 promoter), 
has indicated a role for this cytokine in the trafficking of eosinophils in the airways (Lee et 
al., 1997). Both IL-5 and eotaxin have been shown to have important roles in eosinophil 
trafficking during allergic pulmonary inflammation in mice (Foster et al, 1996; 
Rothenberg et al, 1997). Results presented in this Chapter suggest that these two 
cytokines act co-operatively to regulate pulmonary eosinophilia and such interactions may 
also operate in the allergic lung. Furthermore, IL-5 and eotaxin appeared to operate 
synergistically at equivalent levels of virus.
Th2 type responses to N. brasiliensis (Nb) infection are impaired in IL-4 deficient mice 
(Kopf et al, 1993). Although elevated levels of eotaxin expression are still induced in the 
absence of IL-4 in these animals in response to Nb infection, both the accumulation of 
eosinophils and IL-5 production are greatly reduced (Gonzalo et a l, 1996b; Hogan et al., 
1997). These investigations support observations in this Chapter that IL-5 plays an 
important role in the mechanism of eotaxin-induced eosinophil trafficking during TI12 type 
immune responses.
Similar to experiments in the skin (Chapter II), the i.v. administration of IL-5 enhanced 
the accumulation of eosinophils in the lungs in response to the localised production of 
IL-5 and eotaxin by the recombinant vaccinia viruses. The enhanced eosinophilic 
response in the airways in the presence of i.v. IL-5 may be due to the elevated circulating 
eosinophil pool. IL-5 may also prime the circulating eosinophils leading to the enhanced 
migration in response to chemotactic stimuli (IL-5 and eotaxin) in the lungs and promote 
the activation of adhesion systems in the vascular endothelium (Walsh et a l, 1990; 
Ebisawa et a l, 1994). Interestingly, the i.v. administration of IL-5 also enhanced the 
accumulation of eosinophils in the BALF in the presence of control virus. Viral infection 
may induce the production of RANTES by bronchial epithelial cells (Matsukura et al, 
1996; Becker et al, 1997), which could then promote the accumulation of eosinophils in 
the airways.
Eosinophils are thought to be a primary effector cell in the induction of tissue damage and 
airways hyperreactivity in asthma and in animal models of allergic airway inflammation
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(refer to introduction, section 1.2). However, the presence of eosinophils alone may not 
be enough to induce airways dysfunction and tissue damage. In guinea pigs, IL-5 
induced pulmonary eosinophilia and inflammation, but not airways hyperreactivity (Lilly 
et al, 1996). Upon activation, eosinophils have the ability to synthesise lipid mediators 
and oxygen radicals and may also release numerous cytotoxic cationic proteins. All of 
these inflammatory molecules have the potential to cause tissue damage and airways 
hyperreactivity (refer to introduction, section 1.3). One of the cytotoxic cationic proteins 
in particular, MBP, has been implicated in the development airways hyperreactivity to ß- 
methylcholine in both primates and rodents (Gundel et al, 1991; Uchida et al., 1993). 
Although W -H A -IL-5 and VV-HA-eotaxin induced pronounced airways eosinophilia, no 
MBP was detected in the BALF, furthermore, these two cytokines did not promote 
airways hyperreactivity. These results demonstrate that the presence of IL-5 and eotaxin 
are not sufficient to induce eosinophil degranulation in vivo and airways hyperreactivity.
In contrast to these experiments, mice that were genetically altered for the over expression 
of IL-5 by airway epithelial cells, exhibited both pulmonary eosinophilia and airways 
hyperresponsiveness to ß-methylcholine (Lee et al., 1997). IL-5 over long periods of 
time induces the degranulation of eosinophils in vitro (Kita et al., 1992) and this process 
may underlie this phenomena. Interestingly, airways hyperreactivity was induced in the 
presence of VV-HA-IL-5 and VV-HA-eotaxin following multiple exposures to 
aeroallergen. In contrast, VV-HA-TK (control virus) inoculation and aeroallergen 
exposure has no effect on airways reactivity. Antigen inhalation also resulted in the 
release of MBP from eosinophils in the presence of VV-HA-IL-5 and W -HA-eotaxin. 
These results suggest that other factors are produced during antigen processing that are 
required for eosinophil degranulation and the induction of airways hyperreactivity.
MBP has been shown to mediate the induction of airways hyperreactivity in allergic 
airways inflammation in guinea pigs (Lefort et al., 1996). Our results also show a 
correlation between the presence of MBP in the BALF and the induction of airways 
hyperreactivity; suggesting that the changes in airways reactivity that were seen in the 
presence of inhaled antigen were directly attributable to the action of eosinophil derived 
MBP. Moreover, it appears that the release of MBP by eosinophils is regulated by 
signals elicited during antigen processing.
Eosinophils express receptors for numerous classes of immunoglobulins, including IgG, 
IgA and IgE and each of these immunoglobulin types have been implicated in eosinophil 
degranulation (Looney et al., 1986; Abu-Ghalez et al., 1989; Hartnell et al., 1992; 
Gounni et a l, 1994a, 1994b; Kaneko et al., 1995). Thus, Ova-induced changes in 
airways reactivity following W -HA-eotaxin and VV-HA-IL-5 inoculation may involve
96
the immunoglobulin dependent activation of eosinophils as Ova-specific IgGi was 
elevated in these mice.
Damage to pulmonary structure, including epithelial cell shedding occurs during allergic 
airways inflammation in mice (Foster et al., 1996) and it appears likely that eosinophils 
mediate this process (Motojima et a l,  1989; Foster et al, 1996). However, this 
particular action of the eosinophil may be secondary to the induction of airways 
hyperreactivity during allergy, since the induction of airways hyperreactivity by W -H A -  
IL-5 and VV-HA-eotaxin following multiple exposures to aeroallergen did not induce 
gross morphological changes in pulmonary structure. These observations also suggest! 
airways damage is not obligatory for the development of airways hyperreactivity.
The preferential localisation of eosinophils in regions that are directly below airways
smooth muscle, but not between the bronchial epithelium and the basement membrane,
suggests that eosinophils (or their products) may effect changes in airways reactivity by 
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acting upoirsmooth muscle. Recently, it was demonstrated that MBP induces airways
hyperreactivity by antagonising inhibitory M2 muscarinic receptor during allergic airways
inflammation in guinea pigs (Evans et al., 1997). Thus, MBP may primarily induce
airways hyperreactivity through this process; rather than as an effect of its cytotoxic
properties upon the respiratory epithelium.
The recruitment of CD4+ lymphocytes is a prominent feature associated with allergic 
eosinophilic inflammation (Bradley et al., 1991; Bochner et al., 1994). The accumulation 
of eosinophils and the induction of airways hyperreactivity during allergic airways 
inflammation has been shown to be dependent on the presence of mature CD4+ T- 
lymphocytes (Gavette et al., 1994; Gonzalo et al., 1996). Furthermore, the development 
of late-phase eosinophilic response in murine model of cutaneous late-phase reaction 
(CLPR) is also inhibited by pretreatment with anti-CD4 mAb, but not by anti-CD8 mAb 
(Iwamoto et al,  1992). However, previous studies could not define whether CD4+ 
lymphocytes are required for eosinophil activation during allergic airways inflammation or 
for the recruitment of this cell.
Experiments in this Chapter demonstrate a direct dependence upon CD4 for the induction 
of eosinophil degranulation and airways hyperreactivity in the presence of IL-5, eotaxin 
and antigen processing. This process may involve the direct stimulation of eosinophil 
activation through CD4+ lymphocyte-eosinophil interactions, possibly involving ICAM-1 
(Hoire et a l ,  1997) or MHC-II (Weller et a l,  1993). Eosinophil degranulation may also 
be stimulated by allergen specific immunoglobulins (IgG) whose production also appears 
to be dependent on the presence of CD4 in this model.
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Further characterisation of mechanisms of eosinophil activation in the presence of IL-5, 
eotaxin and antigen may elucidate the role of the eosinophil in airways hyperreactivity in 
this system. The role of allergen specific immunoglobulins in this CD4-dependent 
phenomenon is unclear. Because the treatment of mice with anti-CD4 mAh abolishes the 
production of allergen specific IgGl it is difficult to determine if the development of 
airways hyperreactivity is dependent on this molecule. It would be interesting to see if 
VV-HA-IL-5 and VV-HA-eotaxin can induce airways hyperreactivity in CD40 deficient 
mice [which do not develop Ova specific immunoglobulin IgG, IgA or IgE in a murine 
model of asthma, (Hogan et al., 1996)] following multiple exposures to Ova aerosol.
In summary, the delivery of IL-5 and eotaxin together by recombinant vaccinia virus 
provides a useful tool for inducing pulmonary eosinophilia in mice in the absence of 
allergen or parasitic stimuli. Although IL-5 and eotaxin co-operatively induce pulmonary 
eosinophilia, these cytokines alone are not sufficient to cause airways hyperreactivity. 
However, these cytokines do promote airways hyperreactivity and eosinophil 
degranulation in the presence of antigen and this process is dependent on CD4. 
Furthermore, the localisation of eosinophils near airways smooth muscle and the 
correlation between the presence of MBP and the development of airways hyperreactivity 
suggests that eosinophils promote airways hyperreactivity by affecting airways smooth 
muscle function.
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CHAPTER IV
DISSECTING THE REQUIREMENT OF IL-5 
FOR EOSINOPHILIA
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IV.l INTRODUCTION.
In Chapters II and III it was demonstrated that IL-5 potently induced the accumulation of 
eosinophils in tissues and acted in synergy with the C-C-chemokines, eotaxin, M IP -la  
and RANTES. Furthermore, the i.v. administration of IL-5 was shown to potentiate the 
tissue eosinophilia in response to these chemokines. The i.v. administration of IL-5 has 
also been shown to enhance the effectiveness of other eosinophil chemoattractants such as 
LTB4 (Collins et al, 1995) at sites of administration. IL-5 may promote eosinophil 
trafficking in response to chemoattractants by increasing the number of circulating 
eosinophils that are available to migrate into tissues and by priming eosinophils in the 
circulation leading to enhanced chemotactic responses. From studies in Chapter II it 
appears that eotaxin may also regulate the level of eosinophils in the circulation, although 
whether or not this is dependent on EL-5 has yet to be determined.
IL-5, in addition to acting as an eosinophil chemoattractant (Chapters II and III; 
Hakansson and Venge, 1994) and a regulator of eosinophil levels in the circulation (Kopf 
et al, 1996), may also promote the adhesion of eosinophils to the vascular endothelium 
(Walsh et a l, 1990; Ebisawa et al, 1994). Although it has been demonstrated that the 
responsiveness of eosinophils to chemoattractants are enhanced in the presence of IL-5 
(chapters II and III, Coeffier et a l, 1994; Hakansson and Venge, 1994; Collins et al, 
1996), the role of basal production of this cytokine for eosinophil trafficking into tissues 
remains unclear.
In this chapter, IL-5 deficient mice [IL-5'/_ (Kopf et al, 1996)] were employed to dissect 
the requirement of IL-5 for blood and tissue eosinophilia at base line levels and in 
response to the eosinophil specific chemokine, eotaxin and in response to itself.
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IV.2 MATERIALS AND METHODS.
IV.2.1 The role of IL-5 in eotaxin-induced eosinophil trafficking in vivo.
IV.2.1.1 The effect of IL-5 or eotaxin on levels of circulating eosinophils 
in IL-5m,~ mice.
IL-5 (100-500 pmol/kg i.v.) and eotaxin (2.4 nmol/kg i.v.) were tested for their ability to 
induce blood eosinophilia in IL-5'/_ mice (see section II.2.2). The effects of IL-5 (500 
pmol/kg i.v.) or eotaxin (2.4 nmol/kg i.v.) on the bone marrow eosinophil levels of 
IL-5"/_ mice were also determined (see section II.2.3), at the peak of the blood 
eosinophilia, induced by IL-5 (3 hours) or eotaxin (30 minutes). The effects of eotaxin 
and IL-5 on circulating and bone marrow levels of eosinophils in IL-5+/+ mice were 
previously determined (see Chapter II).
IV.2.1.2 Bioassay of the chemoattractant activity of IL-5 and eotaxin in 
IL-5'/m mice.
IL-5 (10 pmol/skin site) and eotaxin (5 pmol/skin site) were analysed for their ability to 
induce the accumulation of eosinophils in the skin of IL-5'/_ mice (see section II.2.4). 
IL-5"/_ mice were injected i.v. with 500 pmol/kg of IL-5 (in place of 100 pmol/kg used in 
IL-5+/+ mice as this concentration of IL-5 was required to elicit a pronounced elevation in 
circulating eosinophil levels). Similar experiments on IL-5+/+ mice were previously 
performed (see Chapter II).
IV.2.1.3 The production and purification of donor eosinophils.
Donor eosinophils for homing experiments were obtained by sensitising mice (C57BL/6, 
8-10 weeks old) by i.p. injection with 50 fig Ova and 1 mg Alhydrogel (CSL Ltd., 
Parkville, Australia) in 0.9% sterile saline on days 0 and 12. From day 24, sensitised 
mice received an i.p. injection of 50 fig OVA in 0.2 mis of 0.9% sterile saline, every 
second day for 8 days. Eosinophils were then washed from the peritoneal cavity with 3 x 
5 mis of RPMI-1640 medium. In some experiments mice were injected with supernatants 
(0.5 mg protein/100 p.1) obtained from cultured SF9 insect cells, instead of Ova, as this 
was found to induce a stronger i.p. eosinophilia. Eosinophils were purified by FACS 
using forward Vs side scatter and polarisation of light. The purity of the enriched 
population of eosinophils was > 98% as determined by differential staining with Giemsa- 
May-Grunwald. Purified eosinophils were diluted as required into RPMI-1640 and 100 
fil injected into the tail vein of recipient mice. Greater than 97% of injected cells were 
determined as viable by trypan blue exclusion.
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IV .2.1.4 The role of basal production of IL-5 in the chemoattractant 
signal elicited by IL-5 and eotaxin for the recruitment of eosinophils into 
the skin.
IL-5_/_ and IL-5+/+ mice were injected i.v. with 1 x 106 or 4 x 106 donor eosinophils (see 
section IV.2.1.3) and 10 minutes later peripheral blood samples were taken from the tail 
vein and analysed for eosinophil numbers using Discombe's method (see section II.2.2). 
The mice were then injected s.c. (see section II.2.4) with eotaxin [5.0 pmol/site (ECioo)L 
IL-5 [10 pmol/site (ECioo)] or control vehicle [100 pi HBSS/0.01% BSA (pH 7.4)]. 
After 2 hours the mice were sacrificed by CO2 asphyxiation and the dorsal skin 
membranes excised onto a glass slide and prepared for differential cell counting (see 
section II.2.4).
IV .2 .1 .5  The restoration of eosinophil homing in IL-5~,m mice by mini- 
asmotic pumps.
IL-5_/* mice were anaesthetised by i.p. injection of 300 pi of a cocktail containing 60 
mg/kg ketamine [Ketamil (Troy Laboratories Pty. Ltd., Smithfield, NSW., Australia)] 
and 8 mg/kg xylazine [Rompun (Bayer Australia Ltd., Pymble, NSW., Australia) and 
their ventral skin shaved and washed with hibitane. Mini-osmotic-pumps [M.O.P.
(model 2001, Alzet Corporation, Palo Alto, USA)] containing IL-5 or control vehicle [10 
mM PBS/0.1% BSA (pH 7.4)] were implanted i.p. under sterile conditions and the 
wound sealed. M.O.P. were calibrated to deliver control vehicle or 100 pmol/kg of IL-5 
per hour for 7 days. After 72 hours mice were injected i.v. with IL-5 (500 pmol/kg) or 
control vehicle [100 \i\ of 10 mM PBS/0.1% BSA (pH 7.4)] at 0 and 30 minutes.
Eotaxin (5.0 pmol/site), IL-5 (10 pmol/site) or control vehicle [100 pi of HBSS/0.01%  
BSA (pH 7.4)] was injected s.c. 30 minutes later. After 2 hours, the mice were sacrificed 
and the dorsal skin membrane excised for differential cell counts (see section II.2.4). 
Blood samples were taken before i.v. injection of IL-5 and at intervals of 30 minutes 
thereafter and eosinophils/ml of blood determined using Discombe's method (see section 
II.2.2).
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IV.3 RESULTS.
IV.3.1 Eotaxin, but not IL-5, induces a rapid peripheral blood 
eosinophilia in IL-5‘/_ mice.
In IL-5+/+ mice, the i.v. administration of 100 pmol/kg of IL-5 induced a rapid increase 
in the number of circulating eosinophils that peaked 30 minutes after administration 
(figure II. la). In contrast, the i.v. administration of up to 5 times this concentration of 
IL-5 failed to induce a pronounced and rapid blood eosinophilia in IL-5^" mice (figure 
IV. la, results for < 500 pmol/kg i.v. IL-5 in IL-5'/_ mice not shown, data included from 
figure n.l for IL-5+/+ mice that received 100 pmol/kg i.v. IL-5). Blood eosinophil levels 
peaked in IL-5_/' mice 3 hours post i.v. administration of 500 pmol/kg IL-5.
Similar to previous studies in IL-5+/+ mice (Chapter II), the i.v. administration of IL-5 
was associated with a reduction in the level of eosinophils in bone marrow (figure IV.2), 
when measured at the peak of the blood eosinophilia (30 minutes post administration of 
IL-5 in IL-5+/+ mice and 3 hours in IL-5'/_ mice). In contrast to IL-5, the i.v. 
administration of eotaxin (2.4 nmol/kg) induced a rapid and pronounced peripheral blood 
eosinophilia in IL-5-/* mice (figure IV. lb). The kinetics of the induction of peripheral 
blood eosinophilia by i.v. administration of eotaxin were similar between IL-5+/+ and 
IL-5_/* mice (figure IV. la). However, the peak of eosinophilia was diminished by 
approximately 50% in the IL-5'/_ mice in comparison to that observed in IL-5+/+ mice, at 
the same dose of eotaxin. As previously observed in IL-5+/+ mice (section II.3.1), the 
increase in the number of eosinophils in the blood of IL-5"/_ mice in response to eotaxin 
did not correlate with a significant reduction in the level of this cell in the bone marrow 
(figure IV.2).
IV.3.2 In contrast to IL-5+/+ mice, the subcutaneous administration of 
eotaxin and/or IL-5 to IL-5'/_ mice fails to induce the accumulation of 
eosinophils in the skin.
In IL-5'/_ mice, eotaxin (5.0 pmol/site), IL-5 (10 pmol/site) or a combination of both of 
these cytokines at the same site did not induce tissue eosinophilia at subcutaneous sites of 
administration, in contrast to DL-5+/+ mice (figure IV.3, data for IL-5+/+ mice included 
from figure II.4).
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Figure IV. 1 The effect of i.v. administration of IL-5 or eotaxin on 
circulating eosinophil numbers in IL-5m/‘ mice.
Mice were injected i.v. with IL-5 (500 pmol/kg), eotaxin (2.4 nmol/kg) or control vehicle 
[(100 |il of 10 mM PBS/0.1% BSA (pH 7.4)]. Blood samples were taken before, at 30 
minutes and hourly after i.v. injection of the cytokines or control vehicle for quantitation 
of circulating eosinophils, (a) IL-5 (500 pmol/kg) induced a transient increase in 
circulating eosinophil levels in IL-5_/* mice with slower kinetics and reduced potency in 
comparison to the response obtained in IL-5+/+ mice at 100 pmol/kg i.v. (data included 
from figure ELI a), (b) Eotaxin (2.4 nmol/kg) induced a rapid increase in circulating 
eosinophil numbers in EL-5_y,‘ mice, although levels were reduced by 50% in comparison 
to IL-5+/+ mice (data included from figure II.lb). Results represent mean eosinophils/ml 
of blood ± SEM of groups of 5-6 mice. The significance of differences between 
experimental groups was analysed using the Student's unpaired Mest. Differences in 
means were considered significant if P < 0.05. (a) * P < 0.05 and **jP < 0.01 compared 
with control vehicle at the same time point. ***P < 0.001 when compared with IL-5-/' 
mice at the same time point, (b) * P < 0.001 compared with control vehicle and ** P < 
0.01 when compared with EL-5_/' mice injected i.v. with eotaxin, at 30 minutes.
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Figure IV.2 Eosinophil numbers in the bone marrow of IL-5-/- mice in the 
presence of i.v. IL-5 or eotaxin.
IL-5 (100 pmol/kg and 500 pmol/kg, for IL-5+/+ and IL-5‘/_ mice, respectively), 
eotaxin (2.4 nmol/kg) or control vehicle [100 pi of 10 mM PBS/0.1% BSA (pH 
7.4)] were injected i.v. into mice. Femurs were removed at the peak of the blood
eosinophilic response [30 minutes in IL-5+/+ mice (data included from figure II.2) 
and 3 hours in IL-5'/_ mice with i.v. IL-5 and 30 minutes for all mice with i.v.
eotaxin (data included for IL-5+/+ mice from figure II.2)] and the bone marrow 
cavity lavaged with 2 mis of HBSS. The number of cells/ml of lavage fluid was 
determined and 2 x 105 cells were cytocentrifuged and stained with Giemsa-May- 
Grunwald for differential cell counting. Results represent mean bone marrow 
eosinophils ± SEM of groups of 4 mice. The significance of differences between 
experimental groups was analysed using the Student's unpaired r-test. Differences 
in means were considered significant if P < 0.05. *P < 0.05 compared, with i.v. 
control vehicle.
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10 pmol IL-5
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control vehicle
Figure IV.3 Eotaxin and/or IL-5 do not induce the accumulation of eosinophils 
into the skin when administered s.c. to IL-5m/‘ mice.
IL-5*/_ mice were injected i.v. with 500 pmol/kg of IL-5 and 1 hour later were given 
a s.c. injection of eotaxin (5 pmol/skin site), IL-5 (10 pmol/skin site), a 
combination of both cytokines or control vehicle [100 pi of 10 mM PBS/0.1% BSA 
(pH 7.4)]. Eosinophil accumulation in skin membranes was assessed at 2 hours 
post s.c. injection. Results represent mean eosinophils/mm2 ± SEM of groups of 6 
mice. One dorsal membrane preparation was excised from each animal and 
prepared for differential cell counting. Ten fields per preparation were counted for 
eosinophil infiltration and the mean obtained. For comparative purposes, data from
previous experiments in IL-5+/f+ mice under similar conditions (figure II.4a) has
also been included. IL-5+/+ mice were treated similar to IL-5_/_ mice except they 
received an i.v. injection of 100 pmol/kg (see section H2.4) in place of 500 
pmol/kg of IL-5 i.v. The significance of differences between experimental groups 
was analysed using the Student's unpaired r-test. Differences in means were 
considered significant if P < 0.05. No significant levels of eosinophils were
detected in the skin of IL-5"/_ mice under any treatment.
107
IV.3.3 The adoptive transfer of eosinophils enhances the accumulation of 
eosinophils at skin sites of eotaxin or IL-5 administration in IL-5+/+, but 
not IL-5_/", mice.
To determine whether eotaxin-induced tissue eosinophilia was solely dependent on IL-5 
or on the available pool of circulating eosinophils and to ascertain the role of these 
cytokines in eosinophil homing, donor eosinophils were injected i.v. into IL-5+/+ and 
IL-5_/_ mice (figure IV.4). The i.v. adoptive transfer of 4 x 106 donor eosinophils into 
IL-5+/+ and IL-5'/_ mice (figure IV.4a) established blood eosinophil levels in these 
animals equivalent to those which were induced by i.v. IL-5 (100 pmol/kg) in IL-5+/+ 
mice [figure IV. la, ie. at levels that promoted enhanced the accumulation of eosinophils 
in tissues in response to eotaxin (figure II.3a) or IL-5 (figure II.3c)]. Eosinophil levels in 
the blood following the adoptive transfer of 4 x 106 eosinophils were also similar to that 
observed during allergic responses in mice (Foster et al, 1996). The adoptive transfer of 
eosinophils (1 x 106 donor cells) to IL-5+/+ mice significantly enhanced the accumulation 
of eosinophils in the skin in response to eotaxin (5.0 pmol/site) (figure IV.4b) or IL-5 (10 
pmol/site) (figure IV.4c). Responses to eotaxin were significantly amplified by 
transferring 4 x 106 donor cells to IL-5+/+ mice (figure IV.4b). In contrast, injection of 
up to 4 x 106 donor eosinophils into IL-5_/' mice did not promote eosinophil recruitment 
to sites of eotaxin (5.0 pmol/site) (figure IV.4b). The injection of 1 x 106 donor 
eosinophils into IL-5'/_ mice also failed to promote the accumulation of eosinophils at sites 
of IL-5 (10 pmol/site) (figure IV.4c) administration.
IV.3.4 Restoration of eotaxin- and IL-5- induced tissue eosinophilia and 
eosinophil homing in IL-5'/_ mice.
The central role of IL-5 in eotaxin- or IL-5- induced eosinophil recruitment was confirmed 
in IL-5"/_ mice pretreated with IL-5 i.p. for 72 hours using M.O.P. The continuous i.p. 
administration of IL-5 by M.O.P. in the pretreatment did not induce blood eosinophilia 
(figure IV.5a). However, subsequent administrations of IL-5 (500 pmol/kg i.v.) induced 
a rapid blood eosinophilia (figure IV.5a) equivalent to that induced by IL-5 (100 pmol/kg 
i.v.) in IL-5+/+ mice (figure II.la). Moreover, this level of eosinophils in the circulation 
of IL-5+/+ mice promoted enhanced eosinophilic responses to eotaxin (figure II.3a) or IL- 
5 (figure II.3c) in tissues. The ability of eotaxin (5.0 pmol/site) and IL-5 (10 pmol/site) 
to induce the recruitment of eosinophils into tissues was also restored (figure IV.5b).
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Figure IV.4 The role of IL-5 in eosinophil homing to the skin.
(a) Eosinophil levels in the blood after adoptive transfer of eosinophils to IL-5+/+ and 
IL-5'/* mice. Mice were injected i.v. with donor eosinophils (1 x 106 or 4 x 106 cells into 
mice receiving s.c. eotaxin or 1 x 106 cells into mice receiving s.c. IL-5) or control 
vehicle [100 fil of 10 mM PBS (pH 7.4)] and 10 minutes later peripheral blood samples 
were taken from the tail vein. Circulating eosinophil numbers in IL-5+/+ mice given 
4 x 106 donor eosinophils i.v. and in IL-5"/_ mice given 1 x 106 or 4 x 106 donor 
eosinophils, were significantly elevated relative to circulating eosinophil levels in mice 
that did not receive i.v. donor eosinophils, (b) Mice injected s.c. with eotaxin (5.0 
pmol/site) or control vehicle [100 fil HBSS/0.01% BSA (pH 7.4)] immediately following 
the i.v adoptive transfer of eosinophils. After 2 hours the mice were sacrificed and the 
dorsal skin membrane excised and prepared for differential cell counting. Donor 
eosinophils significantly enhanced the accumulation of eosinophils into the skin in 
response to eotaxin (5.0 pmol/site) in IL-5+/+ mice. In contrast, the adoptive transfer of 
eosinophils to IL-5'/_ mice did not promote eosinophil recruitment to sites of eotaxin (5.0 
pmol/site) exposure, (c) Mice were treated as for (b) above with the following 
exceptions. IL-5+/+ were injected i.v. with 1 x 106 donor eosinophils or control vehicle 
[100 fil of 10 mM PBS (pH 7.4)] and IL-5 (10 pmol/site) was injected s.c. This level of 
donor eosinophils was used since it promoted enhanced the accumulation of eosinophils 
at skin sites of eotaxin or IL-5 administration in IL-5+/+ mice. Results represent (a) mean 
eosinophils/ml of blood ± SEM and (b and c) mean eosinophils/mm2 ± SEM. Ten fields 
(200 x magnification) were counted from each membrane preparation. Data for all 
experiments was obtained from groups of 5-6 mice. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. (a) * P < 0.01 and **P < 
0.001 when compared to i.v. control vehicle, (b ) * P < 0.01 and ** P < 0.001 when 
compared with 5.0 pmol eotaxin/skin site with i.v. control vehicle, (c) * P < 0.01 when 
compared with 10 pmol IL-5/skin site with i.v. control vehicle.
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Figure IV.5 Restoration of eotaxin- and IL-5- induced tissue eosinophilia 
and eosinophil homing in IL-5m/m mice using mini-osmotic pumps.
(a) IL-5'/_ mice were pretreated for 72 hours with i.p. IL-5 using mini-osmotic-pumps 
(M.O.P.). Blood eosinophilia was induced in these mice by two i.v. injections of IL-5 
(500 pmol/kg) at 0 and 30 minutes. Intravenous injection of IL-5 in mice which were not 
pretreated for 72 hours with i.p. IL-5 failed to induce a pronounced blood eosinophilia. 
Blood eosinophilia was not induced by i.v. injection of control vehicle [100 gil of 10 mM 
PBS/0.1% BSA (pH 7.4)] in IL-5 (M.O.P.) pretreated mice. Blood samples were taken 
before i.v. injection of IL-5 and at intervals of 30 minutes thereafter. The resulting 
eosinophilia at 30 minutes after the second i.v. injection of IL-5 in IL-5 (MOP) pretreated 
mice was equivalent to that induced by this cytokine (figure IV.la) at the time of 
subcutaneous administration of eotaxin (figure II.3a) or IL-5 (figure II.3c) in IL-5+/+ 
mice, (b) Eotaxin (5.0 pmol/site), IL-5 (10 pmol/site) or control vehicle [HBSS/0.01% 
BSA (pH 7.4)] were injected subcutaneously 30 minutes after the second i.v. injection of 
IL-5 or control vehicle and 2 hours later the mice were sacrificed and the dorsal skin 
membrane excised for differential cell counts. Eotaxin- and IL-5- induced recruitment of 
eosinophils to sites of exposure was only restored in IL-5_/_ mice that were pretreated i.p. 
with IL-5 for 72 hours. Results represent (a) mean eosinophils/ml of blood ± SEM of 
groups of four mice and (b) mean eosinophils/mm2 ± SEM of groups of four mice. Ten 
fields were counted from each membrane preparation. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. (a) * P < 0.001 when 
compared with i.v. IL-5 in the absence of IL-5 pretreatment by M.O.P. and (b) * P < 
0.001 when compared with i.v. IL-5 in the absence of IL-5 pretreatment by M.O.P.
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IV.3 DISCUSSION.
IL-5 regulates basal circulating eosinophil levels (Kopf, et al., 1996) and this cytokine 
promotes blood eosinophilia (Dent, et al., 1990). The i.v. administration of IL-5 (100 
pmol/kg) induced a rapid and pronounced blood eosinophilia in IL-5+/+ mice (Chapter 
II). In contrast, IL-5 at doses up to 5 times this concentration failed to induce a rapid and 
pronounced blood eosinophilia in IL-5_/' mice. Data in IL-5'/_ mice suggests that the 
mechanism involved in the rapid induction of blood eosinophilia and the maintenance of 
basal circulating eosinophil levels requires the presence of this cytokine. Interestingly, 
IL-5'/_ mice developed a delayed blood eosinophilia following the i.v. administration of 
IL-5 and this response correlated with a reduction in bone marrow levels of this cell. - 
Thus, the ability of IL-5 to induce peripheral blood eosinophilia in EL-5'/_ mice, although 
delayed when compared to its action in IL-5+/+ mice, appears to involve at least partially 
the mobilisation of eosinophils from the bone marrow. The inability of i.v. IL-5 to 
induce a rapid blood eosinophilia in IL-5'/_ mice may not soley reflect the reduced 
capacity of this cytokine to mobilise bone marrow eosinophils into the circulation. IL-5'/_ 
mice have reduced basal levels of eosinophils in the blood which may affect the number 
of eosinophils migrating through tissues (Kopf et al, 1996) and thus, eosinophils 
migrating from the bone marrow compartment may be rapidly sequestered from the 
circulation into tissues.
The ability of eotaxin to induce a rapid increase in eosinophil levels in the blood of IL-5‘/_ 
mice and the demonstration that eotaxin does not mobilise eosinophils from the bone 
marrow suggests that this cytokine regulates eosinophilia via different mechanisms to that 
of IL-5. Furthermore, eotaxin induces blood eosinophilia independently of IL-5 and may 
recruit tissue eosinophils into the circulation. Although eotaxin-induced blood 
eosinophilia was significantly reduced in IL-5'/_ mice, in comparison to IL-5+/+ mice, this 
does not necessarily indicate a direct role for IL-5 in this process. The reduced 
eosinophilic response to eotaxin may also reflect the number of eosinophils available to be 
recruited from tissues into the blood of IL-5'/_ mice. Collectively, these experiments 
demonstrate a novel mechanism for the induction of blood eosinophilia that is regulated 
independendy of IL-5. Eotaxin expression is upregulated in endothelial cells by IFNy 
(Rothenberg et al., 1995a), providing a mechanism for its release into the blood. Eotaxin 
is expressed in tissues quickly following antigen provocation and elevated levels of this 
cytokine in the blood may assist a rapid eosinophilic response in inflamed tissues by 
amplifying the circulating eosinophil pool. This eotaxin regulation would provide a 
mechanism to rapidly elevate the available pool of blood eosinophils to be recruited to 
sites of allergen provocation. During later stages of the allergic reaction, IL-5, produced 
by infiltrating Th2 lymphocytes may then promote the eosinophilic response by inducing 
and maintaining blood eosinophilia (Dent et a l, 1990; Foster, et al., 1996).
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Although numerous molecules induce eosinophil chemotaxis and/or the accumulation of 
eosinophils in tissues at sites of instillation, only eotaxin and IL-5 appear to specifi^y 
control the migration of this leukocyte (Wardlaw etal., 1994; Rothenberg et al., 1996; 
Chapter II). Furthermore, IL-5 potently amplifies the eotaxin signal (and that of other C- 
C chemokines) (Collins et al., 1995; Rothenberg et al., 1996; Chapter II). However, the 
requirement for IL-5 in the trafficking of eosinophils in tissues in response to this 
chemoattractant is unknown.
Neither s.c. eotaxin » IL-5 induced the accumulation of eosinophils in the skin of IL-5'/_ 
mice (figure IV.3). This was in contrast to the action of these two cytokines in IL-5+/+ 
mice, where they are potent eosinophil chemoattractants. In these experiments, all 
animals received an i.v. injection of IL-5 (500 pmol/kg for IL-5_/" and 100 pmol/kg for 
IL-5+/+ mice) as this enhanced the circulating eosinophil pool and was previously shown 
to enhance the eosinophilic response to chemoattractants in tissues in wild type mice (see 
section n.3.2). The inability of IL-5"/' mice to recruit eosinophils into tissues at sites of 
eotaxin and/or IL-5 instillation did not reflect the reduced circulating level of eosinophils 
in these animals since intravenous administration of IL-5 restored circulating eosinophil 
numbers to levels that are sufficient for basal eosinophilic responses in the tissues of 
IL-5+/+ mice. Furthermore, at times of peak eosinophil accumulation in the skin (3 hours 
post i.v. administration of IL-5), circulating eosinophil levels were the same in 
IL-5_/' and IL-5+/+ mice. This indicates that equivalent amounts of this leukocyte were 
available for trafficking into tissues in both groups at this time. The adoptive transfer of 
eosinophils also enhanced the accumulation of eosinophils into the skin in response to 
eotaxin and IL-5 in IL-5+/+ mice, but not in IL-5"/_ mice. These results further 
demonstrate that increased levels of circulating eosinophils alone are not sufficient to 
promote the enhanced recruitment of eosinophils to sites of eotaxin or IL-5 administration 
in IL-5‘/_ mice. Furthermore, the adoptive transfer experiments suggest that the failure of 
IL-5"/_ mice to recruit eosinophils into tissues is due to impaired eosinophil homing 
mechanisms at the tissue level.
The i.p. pretreatment of IL-5-/'  mice with IL-5 by M.O.P. restored the ability of these 
mice to accumulate eosinophils at subcutaneous sites of eotaxin and IL-5 administration 
and thus, establishes an essential role for IL-5 in the chemoattractant signal elicited by 
these cytokines. This result also suggests that basal levels of IL-5 may play a critical role 
in regulating eosinophil homing by other molecules. IL-5 may promote/regulate basal 
eosinophil migration in tissues by activating adhesion systems on the vascular 
endothelium (Walsh et al., 1990; Ebisawa etal., 1994). Future studies, specifically 
looking at the local expression and/or activation of different adhesion systems at sites of 
s.c eotaxin administration in IL-5+/+ mice, IL-5'/_ mice and IL-5"/_ mice pretreated i.p. 
with IL-5 by M.O.P. may elucidate the mechanism behind the requirement for IL-5 in
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eosinophils trafficking in response to chemoattractants. Collectively these results 
demonstrate an essential role for IL-5 in eosinophil homing and migration into tissues in 
response to specific chemoattractant stimuli.
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CHAPTER V
THE ROLE OF INTERLEUKIN-5 IN 
EOSINOPHIL TRAFFICKING AND FUNCTION
DURING ALLERGY
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V .l IN TRO D U CTIO N .
Numerous studies in animal models of allergic inflammation have shown a key role for 
IL-5 in regulating eosinophil trafficking and in the development of disease (Iwamoto et 
a l, 1992; Nakajima et a l, 1992; Bozza et al, 1994; Foster et a l, 1996; Lee et a l, 1997). 
However, the action of IL-5 in these experimental systems remains unclear.
Iwamoto et al., (1992) have reported that anti-IL-5 mAb inhibits the second phase (but 
not the first phase) of the accumulation of eosinophils at sites of allergen-induced 
cutaneous late-phase reactions in mice. These studies suggested that IL-5 may act as an 
eosinophil chemoattractant, however, the action of IL-5 in these experiments was not 
defined. IL-5 has a multitude of effects on eosinophils. This cytokine not only acts as a 
chemoattractant for eosinophils but also primes eosinophils for function, regulates the 
level of eosinophils levels in the circulation and can activate adhesion mechanisms utilised 
by the cell (Walsh et a l, 1990; Ebisawa et a l, 1994; Hakansson and Venge, 1994; Kopf 
et a l, 1996). Thus, anti-IL-5 mAb could inhibit any one or more of these processes.
IL-5"/_ mice do not develop a pronounced pulmonary eosinophilia during allergic airways 
inflammation, in contrast to wild types.jj n  addition, IL 5~l~ mice do not exhibit gross» 
airways-damage or pronounced -airways hyperreactivity that normally follows exposure to 
aeroallergen^ Foster et a l, 1996). In comparison to the wild type, IL-5"/' mice also have 
lower circulating levels of eosinophils and their ability to mount a blood eosinophilia in 
response to antigen provocation is markedly impaired (Foster et a l, 1996). Although 
these data indicate an important role for IL-5 in regulating eosinophilia they do not dissect 
the role of this cytokine in individual steps regulating eosinophil migration. The failure of 
IL-5‘/_ mice to develop tissue eosinophilia in response to antigen-stimulation may reflect 
the lower circulating pool rather than a direct involvement of IL-5 in regulating eosinophil 
homing, adhesion or chemotaxis.
The role of IL-5 in the induction of airways hyperreactivity during allergic airways 
inflammation is also unclear. Sensitised IL-5'/_ mice do not develop airways damage or 
hyperreactivity following exposure to aeroallergen (Foster et al, 1996). In addition, 
these mice do not develop a pronounced pulmonary eosinophilia and thus, It remains 
unclear whether or not it is the eosinophil or IL-5 (or both) that are required for disease. 
Of all inflammatory cytokines, IL-5 is the most intimately associated with eosinophil 
function and therefore, it has been difficult to separate the roles of IL-5 and eosinophils in 
the pathogenesis of allergic airways disease.
Mice that were genetically altered for the specific over production of IL-5 in the airway 
epithelial clara cell (Lee et al, 1997) displayed airways hyperreactivity to inhaled
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methacholine. These mice also exhibited a pulmonary eosinophilia and morphological 
changes gnomonic of asthma. Therefore, similar to studies in IL-5_/_ mice, it was difficult 
to separate the role of IL-5 from that of the eosinophil in the induction of airways 
hyperreactivity in these mice.
In this Chapter, by using IL-5'/_ mice, we have studied the individual roles of this 
cytokine in eosinophil recruitment during allergy in the lung and skin. Furthermore, by 
selectively amplifying the eosinophilic response in absence of IL-5 using recombinant 
eotaxin, the role of this cell and IL-5 in the development of airways hyperreactivity in 
mice, following aeroallergen provocation, was examined.
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V.2 M A TER IA L AND M ETHODS.
V.2.1 The role of IL-5 in eosinophil trafficking during allergy. 
V.2.1.1 The induction of cutaneous late-phase reaction in mice.
Cutaneous late-phase reaction (CLPR) was induced in mice using methods similar to 
those previously described (Iwamoto et al., 1992). Briefly, male C57BL6 mice, 6-8 
weeks of age were immunised by i.p. injection of 50 |Ltg Ova and 1 mg Alhydrogel (CSL 
Ltd., Parkville, Australia) in 0.2 mis of sterile 0.9% saline on days 0 and 12. Non- 
sensitised mice received 1 mg Alhydrogel in sterile saline only. On day 24 the mice 
received a s.c. co-injection of 50 pg Ova in 100 pi of sterile 0.9% saline plus 900 pi of 
air into the upper dorsal flank. Control animals received saline and air only. At 0, 3, 6, 
9, 12, 24, 48 and 72 hours after subcutaneous injections a blood sample was taken from 
the tail vein and the animals sacrificed by CO2 asphyxiation. The dorsal skin membrane 
was then excised and prepared for differential cell counting (see section II.2.4). 
Eosinophils/ml of blood were determined using Discombe's methods (see section II.2.2).
V.2.1.2 Determining the role of IL-5 in eosinophils accumulation during 
cutaneous late-phase reaction.
CLPR was induced in IL-5+/+ and IL-5"/' mice (male, 6-8 weeks of age) (see section 
V.2.1.1). At 6 and 24 hours post s.c. injection the mice were sacrificed and the dorsal 
skin membrane excised and prepared for differential cell counting (see section 11.2.^  
Blood samples were taken at 0, 6 and 24 hours post s.c. injection andrasm api 
qm  tA  blood were quantified using Discombe’s method (see section II.2.2).
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V.2.1.3 Determining the role of IL-5 in eosinophils homing during 
cutaneous late-phase reaction.
Donor eosinophils were produced in IL-5+/+ mice by twice weekly i.p. injections of 100 
pg Polymyxin B sulphate (SIGMA Chemical Co., St Louis, MO., USA.) in 0.2 mis of 
sterile 0.9% saline for a period of 6-8 weeks (Pincus, 1978). Eosinophils were collected 
from the peritoneal cavity and purified by FACS (see section IV.2.1.3). Purified 
eosinophils were labelled with the non-toxic fluorescent nuclear stain, H33342 (SIGMA 
Chemical Co., St Louis, MO., USA.) using the methods of Lyons and Parish (1994). 
Briefly, FACS-purified eosinophils (see section IV.2.1.3) were pelleted by centrifugation 
(400 x g for 5 minutes, 4°C) and resuspended at 1 x 107 cells/ml in RPMI-1640. One 
microlitre of H33342 (5 mM in DMSO) was then added to give a final concentration of 5 
pM H33342 and the eosinophils incubated at 37°C for 10 minutes in the absence of light.
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After washing twice in ice cold serum free RPMI-1640 medium, eosinophil viability was 
assessed by trypan blue exclusion (> 95% viable).
CLPR was induced in IL-5+/+ and IL-5_/' mice (see section V.2.1.1). At 4 or 22 hours 
post s.c. injection the mice were given an i.v. injection of 1 x 106 H33342-labelled 
eosinophils in 100 [il of RPMI-1640. The adoptive transfers were confirmed by taking a 
blood sample 10 minutes after i.v. injection, via the tail vein and fluorescent cells/ml of 
blood quantified. Briefly, following red cell lysis, fluorescent cells/ml blood were 
quantified using fluorescence microscopy (Ex 355 nm, Em 460 nm) and a 
haemocytometer. The mice were sacrificed 2 hours after adoptive transfer (at 6 or 24 
hours after induction of CLPR) and the dorsal skin membrane of each animal was excised 
onto a glass slide. Membrane sections were viewed immediately by fluorescence 
microscopy (Ex 355 nm, Em 460 nm) and fluorescent cells/mm2 were determined by 
counting 10 fields (200 x magnification). Representative sections were photographed 
using Tri-X pan-100 black and white film (Eastman Kodak Company, Rochester, NY., 
USA.).
V.2.1.4 Induction of allergic airways inflammation.
IL-5+/+ and IL-5'/_ mice (male, 8-10 weeks of age) were sensitised to Ova by i.p. 
injection on days 0 and 12 (see section V.2.1.1). Non-sensitised mice received 1 mg of 
Alhydrogel in sahne only. On day 24, the sensitised mice were exposed to an aerosol of 
Ova (10 mg/ml) in 0.9% saline for 1 hour and the controls were exposed to saline 
aerosol. The blood and BALF levels of eosinophils were analysed at 0, 3, 6, 9,12, 15, 
18, 21, 24, 36 and 48 hours following the aerosol exposure (see sections II.2.2 and 
m.2.9). In other experiments, some mice were exposed to an aerosol of Ova (10 mg/ml 
in saline) on day 24 for 3 x 30 minutes instead of 1 hour, with 30 minutes rest between 
the exposures. These mice were further exposed to Ova aerosol every second day 
thereafter for a total of 6 days. Airways hyperreactivity to i.v. ß-methylcholine was 
analysed (see section 131.2.11) on days 23, 25, 27, 29 and 31. Immediately following the 
analysis of airways hyperreactivity the mice were sacrificed by cervical dislocation and the 
eosinophils/ml of BALF were then quantified (see section 111.2.9). Blood smears were 
prepared on glass slides from blood samples taken prior to the analysis of airways 
hyperreactivity and the levels of the different types of circulating leukocytes were 
quantified after staining with May-Grunwald-Giemsa solution. Two to three hundred 
leukocytes were routinely counted on each slide and cell types were identified by 
morphological criteria.
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V.2.1.5 Determining the role of IL-5 in eosinophils homing to the 
allergic lungs of mice.
Eosinophils were produced, purified and then labelled with the non-toxic fluorescent 
nuclear stain H33342 (see section V.2.1.3). IL-5+/+ and IL-5'/" mice were sensitised to 
Ova by i.p. injection on days 0 and 12 (see section V.2.1.1) and on day 24 the mice were 
exposed to an aerosol of Ova (10 mg/ml) in 0.9% saline for 1 hour. Non-sensitised 
control groups were exposed to an aerosol of saline instead of Ova. Six hours later all 
groups of mice received an i.v. adoptive transfer of 5 x 106 H33342-labelled eosinophils. 
Adoptive transfers were confirmed by taking a blood sample 10 minutes after transfer and 
the fluorescent cells/ml of blood quantified (see section V.2.1.2). The levels of H33342- 
labelled eosinophils in the airways were determined 24 hours after aerosol exposure by 
lavaging the lungs with 2 x 1 ml of HBSS and counting fluorescent eosinophil/ml BALF 
using a haemocytometer and fluorescence microscopy (Ex 355 nm, Em 460 nm).
These homing experiments were performed during a mild allergen-induced pulmonary 
inflammation (after 1 aerosol) to keep the total and individual leukocyte populations in the 
lungs of IL-5+/+ and IL-5'/* mice as similar as possible. Chronic allergic airways 
inflammation in mice, induced by the repeated exposures of sensitised mice to aerosolized 
Ova, leads to a more pronounced elevation in leukocyte populations, specifically 
lymphocytes and eosinophils in the BALF of IL-5+/+ mice compared with the BALF of 
IL-5'/' mice (Foster et al., 1996) and this would have complicated the interpretation of 
experimental results.
V.2.1.6 The enhancement o f pulmonary eosinophilia and airways 
hyperreactivity in IL-5'1' mice during allergic airways inflammation by 
i.v. adoptive transfer of eosinophils or i.v. eotaxin.
IL-5'/' mice (male, 8-10 weeks of age) were sensitised to Ova by i.p. injection on days 0 
and 12 (see section V.2.1.1). On days 24, 26, 27 and 28, the mice were exposed to an 
aerosol of Ova (10 mg/ml) in 0.9% sahne for 3 x 30 minutes with 30 minutes rest 
between exposures. On day 27, immediately after the first Ova aerosol exposure, the 
mice were given an adoptive transfer of 5 x 106 eosinophils i.v. from one of three 
sources; (a) the blood of IL-5"/' mice that were infected with W -HA-IL-5, (b) the allergic 
lungs of IL-5+/+ mice or (c) the allergic lungs of IL-5'/' mice that were infected with 
VV-HA-IL-5 (see section V.2.1.6.1.1). Control mice received 100 pi of control vehicle 
(PBS) only. In other experiments some mice were given an i.v. injection of 2.4 nmol/kg 
eotaxin (see section V.2.2 for production and purification) or 100 pi of control vehicle 
[10 mM PBS/0.1% BSA (pH 7.4)], instead of an i.v. adoptive transfer of eosinophils. 
Blood samples were taken via the tail vein immediately prior to, and at 10 minutes (donor
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eosinophil recipients) or at 30 minutes (eotaxin recipients) after injection. Eosinophils/ml 
of blood in these samples were determined using Discombe's method (see section II.2.2). 
On day 29, some mice were analysed for airways hyperreactivity (see section III.2.11) 
and the levels of leukocytes in the BALF quantified (see section III.2.9). Other mice, that 
had not been tested for airways hyperreactivity or undergone BAL, were sacrificed by 
cervical dislocation and their lungs processed for histological examination (see section 
III.2.12). The lungs of an additional group of non-sensitised IL-5'/_ mice (given 1 mg of 
Alhydrogel in 0.2 mis of sterile 0.9% saline on days 0 and 12), that were exposed an 
aerosol of saline instead of Ova on days 24, 26, 27 and 28, also underwent histological 
examination and were used for comparative purposes.
V.2.1.6.1 Production of donor eosinophils from the lungs and the blood.
V.2.1.6.1.1 Production o f donor eosinophils from the lungs.
IL-5+/+ and I L - 5 m i c e  (male, 8-10 weeks of age) were sensitised to Ova by i.p. 
injection on days 0 and 12 (see section V.2.1.1). On day 23, the IL-5'/_ mice received an 
i.n. inoculum of 1 x 107 pfu of VV-HA-IL-5. On days 24, 26, 28 and 30, the IL-5+/+ 
and IL -5 /_ mice were exposed to an aerosol of Ova (10 mg/ml) in 0.9% saline for 30 
minutes, 3 times with 30 minutes rest between exposures. Mice were sacrificed on day 
31 and the cells in the airways collected by BAL (see section III.2.9). The BALF cells 
were sequentially incubated with rat anti-mouse CD45R (B220, Pharmingen, San Diego, 
CA., USA.), rat anti-mouse CD2 mAb (LFA-2, Pharmingen, San Diego, CA., USA.) 
and goat anti-rat IgG, conjugated to MACS colloidal super-paramagnetic microbeads 
(Miltenyi Biotec Inc, Sunnyvale, CA., USA.). The eosinophils were separated from the 
CD45R-positive and CD2-positive cells by negative selection using the MiniMACS 
system (Miltenyi Biotec Inc., Sunnyvale, CA., USA.). The purity of the enriched 
population of eosinophils was > 90% as determined by differential staining with Giemsa- 
May-Grunwald, with neutrophils being the major contaminating cell type. Cell viability 
was > 98% as assessed by trypan blue exclusion.
V.2.1.6.1.2 Production o f donor eosinophils from blood.
IL-5-/' mice were inoculated i.v. with 0.5 x 107 pfu of VV-HA-IL-5. Eight days later the 
mice were anaesthetised with ketamine (60 mg/kg) and rompun (8 mg/kg) by i.p. 
injection and their blood collected by cardiac puncture. After red cell lysis, eosinophils 
were purified from the blood using the MiniMACS system (see section V.2.1.6.1.1). 
Eosinophil purity was > 90% (see section IV.2.1.3), with neutrophils being the major 
contaminating cell type. Eosinophil viability was > 98% as assessed by trypan blue 
exclusion.
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V.2.2 The production of recombinant murine eotaxin using the 
baculovirus expression system.
See figure V. 1 for a schematic representation of the cloning of the eotaxin producing 
baculovirus (BV-eotaxin).
V.2.2.1 Cloning of murine eotaxin cDNA into the baculovirus transfer 
vector pBacPAK8.
Murine eotaxin cDNA (21-328 bp of full length murine eotaxin which encodes functional 
eotaxin) was a gift from Professor Mark Rothenberg (Childrens Hospital Medical Centre, 
Cincinnati, OH., USA.) and was supplied cloned in the PCRII plasmid (Invitrogen, 
Carlsbad, CA., USA.), with added 5' HindUI and 3' EcoRl restriction enzyme sites.
This plasmid was called MR#310. pBacPAK8 (1 pg) (CLONTECH Laboratories, Inc. 
Palo Alto, CA., USA.) was digested with Sma I (Boehringer Mannheim, Castle Hill, 
NSW., Australia) and the 5' blunt end termini were dephosphorylated using calf intestinal 
alkaline phosphatase (CLAP) (Boehringer Mannheim, Castle Hill, NSW., Australia) 
according to the manufacturer's instructions to prevent self-ligation. The CLAP was 
removed by treatment with proteinase K (Boehringer Mannheim, Castle Hill, NSW., 
Australia) according to methods described by Sambrook et al., (1989). The plasmid 
DNA was then phenol/chloroform extracted, ethanol/acetate precipitated (Sambrook et al., 
1989) and resuspended in TE buffer.
MR#310 was electro-transformed into competent DH5a E. coli cells. Following 
amplification in Luria-broth (LB) supplemented with 50 fig/ml ampicillin, the transformed 
cells were plated onto 2% bactoagar/LB plates containing 100 qg/ml ampicillin. Five 
individual colonies were further amplified in LB containing 50 ftg/ml ampicillin. The 
MR#310 plasmid was purified from these 5 broths using Wizard mini-preps (Promega, 
Madison, WI., USA.) according to the manufacturer's instructions and after restriction 
enzyme digest with EcoRl and HindUI, the plasmid DNA was analysed on a 1% 
agarose/TAE gel to check for transformants. Transformed cells exhibited a band of DNA 
of approximately 310 base pairs in length, which corresponded to the size of the eotaxin 
cDNA sequence. Two positive transformants were then amplified in LB containing 50 
p.g/ml ampicillin and the MR#310 plasmid was purified using the Wizard maxi-preps 
system (Promega, Madison, WL, USA.) according to the manufacturer's instructions.
Eotaxin cDNA was excised from MR#310 using HindUI (5') and EcoRl (3') and the 
resulting 5' overhangs were end filled to form blunt end termini using the Klenow
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Figure V.l Cloning of BV-eotaxin.
Eotaxin cDNA was excised from MR#310 using Hind III and Eco Rl and 
blunt end ligated into the multiple cloning site of the baculovirus compatible 
vector pBacPAK8. The resulting plasmid pEOBAC8 was cotransfected with 
linearized (Bsu 361 digest) wildtype baculovirus (BacPAK6) into Sf9 cells. 
After homologous recombination of the polyhedron open reading frame (ORF 
692-1629 of AcMPV) BV-eotaxin was generated.
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fragment of E. coli polymerase I (Promega, Madison, WL, USA) according to the 
manufacturer's instructions. Using a molar ratio of 20:1, 108 ng of eotaxin cDNA was 
ligated with 100 ng of linearized pBacPAK8 by incubation with 1 Weiss unit of T4 DNA 
Ligase in ligase buffer (Promega, Madison, WI., USA.) according to the manufacturer's 
instructions. The ligation mix was electro-transformed into competent D H 5a E. coli and 
the transformed cells were plated onto 2% bactoagar/LB plates containing 100 pg/ml 
ampicillin. Individual colonies were amplified in LB containing 50 |!g/ml ampicillin and 
the plasmid DNA was purified using Wizard mini-preps (Promega, Madison, WL,
USA.) according to the manufacturer's instructions. pBacPAK8/eotaxin positive 
ligations were identified by PCR using primers designed homologous to 5' and 3' regions 
of the ligation site (see section V.2.2.1.1).
V.2.2.1.1 Determination of positive ligation using PCR.
Plasmid DNA (5 pi) was added to a 20 pi reaction mix containing 5 pmol of each of 
forward primer (BAC-1) and reverse primer (BAC-2)(CLONTECH Laboratories, Inc., 
Palo Alto, CA., USA.), 1 unit of AmpliTaq DNA polymerase (Perkin Elmer, Roche 
Molecular Systems, Inc., Branchburg, NL, USA.) and 250 pM each of dGTP, dCTP, 
dATP and dTTP (Promega, Madison, WL, USA.) in AmpliTaq buffer (Perkin Elmer, 
Roche Molecular Systems, Inc., Branchburg, NL, USA.). The PCR primers, BAC 1 
(5’ ACCATCTCGCAAATAAATAAG 3') and BAC 2 (5' ACAACGCACAGAATCTA 
3'), were designed homologous to the 5' and 3' regions (of the opposite strand) of the 
multiple cloning site, respectively. The PCR was performed using a FTS-1 Thermal 
Sequencer (Corbett Research, Sydney, Australia) using the following conditions. 
Denaturation at 94°C for 5 minutes, followed by 5 cycles of denaturation at 94°C for 15 
seconds, annealing for at 55°C 20 seconds and extension at 72°C for 1 minute. This was 
followed by another 31 cycles of denaturation for 5 seconds at 94°C, annealing at 55°C 
for 20 seconds and extension at 72°C for 1 minute and finished with 1 cycle of 
denaturation at 94°C for 5 seconds, annealing at 55°C for 20 seconds and extension at 
72°C for 15 minutes.
PCR products (3 pi) were analysed by polyacrylamide gel electrophoresis (PAGE, see 
section III.2.1.5.2.1) and were identified by size by reference to a 50-2000 base pair 
DNA size standard ladder (BioRad, Hercules, CA., USA.).
V.2.2.1.2 Confirmation of ligations and determination of the insert's orientation.
Plasmid DNA was purified from 8 ligation positive colonies amplified in LB under 
ampicillin selection using the Wizard plasmid miniprep system (Promega, Madison, WL, 
USA.). The orientation of the eotaxin cDNA in pBacPAK8 was determined by digestion
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of each plasmid with BglII (Boehringer Mannheim, Castle Hill, NSW., Australia) and 
analysing the digestion products by PAGE (see section 111.2.1.5.2.1). BglII digestion of 
a plasmid containing the eotaxin gene in the correct orientation was calculated to liberate 2 
fragments of DNA of 5595 and 251 base pairs in length while an incorrect orientation was 
calculated to liberate 2 fragments of DNA 5665 and 181 in length. A plasmid showing 
correct orientation eotaxin cDNA was chosen and named pEoBAK8.
V.2.2.2 Transfection and viral purification.
V.2.2.2.1 Maintenance of Spodoptera frugiperda insect cells.
Spodopterafrugiperda (Sf9) cells were a gift from Professor Ian Young (John Curtin 
School of Medical Research, ANU., ACT., Australia). The cells were grown at 27°C in 
TNM-FH medium [Graces' insect cell culture medium (Gibco BRL, Life Technologies, 
Gaithersburg, MD., USA.) supplemented with 40 mM NaHCC>3, 0.4% yeastolate 
ultrafiltrate (Gibco BRL, Life Technologies, Gaithersburg, MD., USA) and 0.33% 
lactalbumin hydrolysate (Gibco BRL, Life Technologies, Gaithersburg, MD., USA.)] 
supplemented with 10% heat inactivated FCS. The cells were grown either as 
monolayers in plastic tissue culture flasks (Gibco BRL, Life Technologies, Gaithersburg, 
MD., USA.) or as spinner cultures in BELCO spinner flasks (BELCO Biotechnology, 
NJ., USA.). Monolayers of cells were passaged upon confluence by removing the media 
and gently washing adherent cells off the bottom of the tissue culture flask with fresh 
medium. Cells were diluted 1 in 5 in fresh media and reseeded into new culture flasks. 
Spinner cultures of cells were seeded at a density of 5 x 105 cells/ml into BELCO spinner 
flasks and were grown at 27°C on a magnetic stirrer plate set at 75 rpm. Cells in 
suspension cultures were passaged when their density reached 2 x 106 of cells/ml.
V.2.2.2.2 Transfection of Spodoptera frugiperda cells with pEoBAK8 and BacPAK6.
Two 25 cm2 tissue culture flasks were seeded with 1.5 x 106 exponentially growing Sf9 
cells in 5 mis of TNM-FH/10% FCS and were incubated overnight at 27°C. The cells 
were then gently washed twice (1 x 20 seconds and 1 x 1 5  minutes) with fresh TNM-FH, 
followed by the addition of 1.5 mis of fresh TNM-FH. One hundred microlitres of 
transfection solution [5 pi of BacPAK6 viral DNA (Bsu36 I digest (CLONTECH 
Laboratories, Inc. Palo Alto, CA., USA.), 500 ng of pEoBAK8 (see section V.2.2.1) 
and 50 pg Lipofectin (GIBCO BRL, Life Technologies, Gaithersburg, MD., USA.)], 
that had been previously incubated at room temperature in a polystyrene tube for 15 
minutes, was added drop wise to one flask of cells. To the other flask of cells, only 
plasmid DNA was added and served as a control. After 5 hours incubation at 27°C, 1.5 
mis of TNM-FH/10% FCS was added to the cells. The flasks were then incubated for a
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further 3 days at 27°C. The media was collected and the cellular debris pelleted by 
centrifugation (400 x g, for 10 minutes at room temperature). The supernatants, 
containing virus, were stored at 4°C in the dark.
V .2.2.3. Viral purification.
V.2.2.3.1 Isolation and amplification of individual viruses by plaque assay.
Individual viruses were cloned from culture supernatants (see section V.2.2.2.2) as 
follows. Tissue culture dishes (35 mm, Gibco BRL, Life Technologies, Gaithersburg, 
MD., USA.) were seeded with 1.5 x 106 exponentially growing Sf9 cells in 3 mis TNM- 
FH/10% FCS and were incubated at 27°C for 5 hours. The media was removed and the 
cells were infected with logarithmic dilutions of virus containing culture supernatants in 1 
ml of TNM-FH for 1 hour at room temperature on a rocking platform. The media was 
then removed and the cells were overlayed with 4 mis of agarose solution [0.5% SeaKem 
agarose (FMC BioProducts, Rockland, ME., USA.) in TNM-FH/10% FCS at 37°C]. 
The cells were incubated for 6 days at 27°C and the viral plaques were visualised under 
low power light microscopy (10 x magnification) with incident light From a plate with 
well-separated plaques, individual viral plaques were harvested by cutting out an agar 
plug directly above the viral plaque using a sterile pasteur pipette. Individual agar plugs 
were placed in 1 ml TNM-FH and the virus allowed to diffuse into the medium over 24 
hours at 4°C in the dark.
Viruses from each of the 8 individual agar plugs were amplified as follows. Viral 
solution (from agar plug in 1 ml of TNM-FH) was diluted 1 in 2 in TNM-FH and was 
added to a 25 cm2 tissue culture flask of media-drained Sf9 cells, that was seeded the 
previous day with 1 x 106 exponentially growing cells. The virus was left to infect the 
cells for 1 hour at room temperature on a rocking platform. TNM-FH/10% FCS (4 mis) 
was then added to the tissue culture flask and the flask incubated for a further 3 days at 
27°C. The virus was then harvested (see section V.2.2.2.2) and was stored at 4°C in the 
dark.
V.2.2.3.2 Checking for presence of eotaxin gene in recombinant baculoviruses.
Each of the 8 individual baculoviral stocks (section V.2.2.3.1) was checked for the 
presence of the eotaxin gene using PCR. Samples were prepared for PCR by 
centrifuging 50 |il of each viral stock at 1000 x g for 10 minutes at room temperature to 
remove cellular debris. The supernatants were then boiled for 10 minutes and debris 
pelleted by centrifugation (1000 x g for 5 minutes). The DNA in the supernatant was
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precipitated using ethanol/acetate (Sambrook et al., 1989) and was resuspended in 30 pi 
of TE buffer.
Viral DNA (5 pi) was added to a 20 pi PCR reaction mix containing 5 pmol each of 
forward primer (EOBACF1) and reverse primer (EOBACR1), 1 unit of AmpliTaq DNA 
polymerase (Perkin Elmer, Roche Molecular Systems, Inc., Branchburg, NJ., USA.) 
and 250 pM each of dGTP, dCTP, dATP and dTTP (Promega) in AmpliTaq buffer 
(Perkin Elmer, Roche Molecular Systems, Inc., Branchburg, NJ., USA.). To control 
for contamination, a water control was also run and consisted of 5 pi of PCR-grade water 
added to 20 pi of reaction mix. The PCR primers, EOBACF1 (51 TAGTTGCTGATATC 
ATGGAG AT 3’) and EOBACR1 (5' ACAACGCACAGAATCTAGCG 3’) were 
designed homologous to 5' and 3'(of the opposite strand) regions respectively of the 
eotaxin cDNA in pEoBAK8. The primers were designed to amplify a 564 bp section of 
cDNA and were synthesised at the Biomolecular Resource Facility of the John Curtin 
School of Medical Research School (Canberra, Australia).
The PCR was performed using a FTS-1 Thermal Sequencer (Corbett Research, Sydney, 
Australia) under the following conditions. Denaturation at 94°C for 3 minutes followed 
by 39 cycles of denaturation at 94°C for 3 seconds, annealing at 55°C for 3 seconds and 
extension at 72°C for 2 minute. The PCR was concluded by 1 cycle of denaturation at 
94°C for 3 seconds, annealing at 55°C for 3 seconds and extension at 72°C for 9 minutes. 
The PCR products (3 pi) were analysed using PAGE (see section III.2.1.6.2.1). All 
virus clones were positive for the presence of the eotaxin gene.
V.2.2.3.3 Virus selection bv analysis of eotaxin production using Western dot blot.
Each viral stock was titred in duplicate by plaque assay (see section IV.2.1.3). Flasks 
(25 cm2) of SF9 cells that had been seeded the previous day with 1 x 106 cells, were 
infected with virus at a M.O.I. of 2 at room temperature for 1 hour on a rocking platform. 
An additional 4 mis of TNM-FH/10% FCS was then added and the culture flasks were 
incubated at 27°C for 3 days. The media was then harvested and centrifuged (1000 x g 
for 5 minutes at 4°C) to pellet the cellular debris. Supernatants containing virus were 
stored at 4°C in the dark.
The level of eotaxin expression by each virus clone was analysed by Western dot blot (see 
section III.2.13) with one adaptation; Polyclonal rabbit anti-mouse eotaxin (0.2 pg/ml) 
was substituted for polyclonal rabbit anti-mouse MBP as the primary antibody. Each 
virus was graded on its ability to express eotaxin according to the intensity of the dot blot 
reaction. The virus with the highest eotaxin production was chosen and denoted BV- 
eotaxin.
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V.2.2.4 Large scale viral stock production.
Suspension cultures of exponentially growing Sf9 cells (500 mis of 5 x 105 cells/ml in 
TNM-FH/10% FCS, in a Belco spinner flask) were inoculated with BV-eotaxin at a 
M.O.I. of 0.2. The cultures were incubated at 27°C until 80% cells were dead 
(approximately 6-7 days) as assessed by trypan blue exclusion. Culture media (viral 
stock) were then harvested and the cellular debris pelleted by centrifugation (1000 x g for 
5 minutes, 4°C). Viral stocks (supernatant) were stored at 4°C in the absence of light and 
the viral titre determined by plaque assay (V.2.2.3.1). The viral titres were usually 
approximately 108 pfu/ml.
V.2.2.5 Production of recombinant murine eotaxin.
Recombinant murine eotaxin was produced in suspension cultures of Sf9 cells. Briefly, 
spinner cultures of exponentially growing SF9 cells (2 x 106 cells/ml in TNM-FH/10% 
FCS) were infected with BV-eotaxin at a M.O.I of 2. After 3 days of incubation at 27°C, 
the cultures were centrifuged (1000 x g for 5 minutes) to remove cellular debris and the 
supernatant collected and stored at 4°C.
V.2.2.6 Purification of recombinant murine eotaxin from BV-eotaxin 
culture supernatants.
Recombinant murine eotaxin was purified from BV-eotaxin conditioned culture medium 
(see section V.2.2.5) to > 90% homogeneity using methods described by Kitaura et al., 
(1996). Briefly, culture supernatants were dialysed against 3 changes of 10 mM sodium 
phosphate/150 mM NaCl (pH 7.4) over 24 hours. The dialysed culture supernatant (25 
mis) was then loaded at a rate of 1 ml/minute onto a 1 ml HiTrap Heparin column 
(Pharmacia Biotech, Uppsala, Sweden) that was pre-equilibrated with 10 mM sodium 
phosphate buffer/150 mM NaCl (pH 7.4). After washing the column with 10 volumes of 
10 mM sodium phosphate buffer/400 mM NaCl (pH 7.4), the bound protein was eluted 
with 10 volumes of 10 mM sodium phosphate buffer/600 mM NaCl (pH 7.4). The 
Elutant was diluted with 1 volume of 10 mM sodium phosphate buffer (pH 7.4) and was 
loaded at a rate of 1 ml/minute onto a 1 ml HiTrap SP ion exchange column (Pharmacia 
Biotech, Uppsala, Sweden) that was pre-equilibrated with 10 mM sodium phosphate/300 
mM NaCl (pH 7.4). After washing the column with 10 volumes of 10 mM sodium 
phosphate/300 mM NaCl (pH 7.4), the bound protein was eluted at a rate of 1 ml/minute 
with a 10 ml NaCl gradient (300 mM to 1 M) in 10 mM sodium phosphate buffer. 
Fractions (1 ml) were collected and analysed for eotaxin content by dot blot (see section 
V.2.2.3.3). The fractions that contained eotaxin were pooled, dialysed against 3 changes 
of 10 mM sodium phosphate/150 mM NaCl (pH 7.4), over 24 hours and filter sterilised
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through a 0.22 pm filter. An aliquot of purified eotaxin was stored at 4°C and the 
remainder was snap frozen in liquid N2 and stored at -70°C.
Eotaxin was quantified by the BCA protein assay kit (Pierce, Rockford, II., USA.) using 
BSA as the protein standard. Eotaxin homogeneity was checked by analysing samples on 
a 3.75% stacking/18% separating reducing polyacrylamide gel (Sambrook et a l, 1989). 
Samples were diluted 1:1 with 2 x sample loading buffer [10 mM Tris HC1 (pH 8.0); 20 
mM EDTA; 0.2% N-lauryloarcosine; 1.5% (w/v) Ficoll 400 (Pharmacia Biotech,
Uppsala, Sweden); 0.05% (w/v) bromophenol blue; 0.05% xylene cyanol] and were 
denatured at 65°C for 3 minutes immediately prior to loading on the gel. The gels were 
run using a Mini-Protean II cell (BioRad, Hercules, CA., USA.) at 200 V for 35 minutes. 
The eotaxin that was produced by the baculovirus expression system was approximately 
equipotent as a commercially available E. coli -produced eotaxin when tested using the 
i.v. bioassay system (see section II.2.2).
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V.3 RESULTS.
V.3.1 The role of IL-5 in eosinophil trafficking during cutaneous late- 
phase reaction in mice.
V.3.1.1 The accumulation of eosinophils during cutaneous late-phase 
reaction is significantly reduced in the absence of IL-5.
Similar to previous observations (Iwamoto et al., 1992), the recruitment of eosinophils at 
sites of Ova-induced CLPR in mice was biphasic (figure V.2a). The first phase of 
eosinophil accumulation at cutaneous sites of Ova administration was transient 
Eosinophils were first detected in the skin 3 hours after Ova administration, peaked at 6 
hours and fell again by 12 hours. The second phase of eosinophil accumulation at sites of 
CLPR began at approximately 18 hours after Ova administration and peaked 6 hours later. 
Although peak eosinophil accumulation was observed at 24 hours, high levels of 
eosinophils were present at skin sites up to 48 hours post Ova administration. 
Furthermore, more eosinophils accumulated at sites of CLPR during the second phase 
than the first phase. Interestingly, the s.c. administration of saline to the non-sensitised 
control group also induced the accumulation of eosinophils in the skin (figure V.2a), 
however, the levels of this cell at these sites were significantly lower than those at the 
sites of CLPR. Furthermore, the accumulation of eosinophils at sites of saline 
administration was monophasic, unlike that seen at sites of CLPR.
The levels of eosinophils in the circulation of the sensitised IL-5+/+ mice were 
significantly (P < 0.05) higher than those of the non-sensitised controls (figure V.2b).
The levels of eosinophils in the circulation of the sensitised mice fell dramatically at 3 
hours after the s.c. injection of Ova and remained at low levels up to 24 hours. This 
reduction correlated with the accumulation of eosinophils at sites of CLPR. In contrast, 
no change in the levels of eosinophils in the circulation of the non-sensitised mice were 
observed after they received a s.c. injection of saline (figure V.2b). This was despite the 
minor level of eosinophil accumulation at the s.c. injection site (figure V.2a).
The accumulation of eosinophils, at the times of peak eosinophil infiltration (6 and 24 
hours, as determined in IL-5+/+ mice), at sites of Ova-induced CLPR in the IL-5"/" mice 
was reduced in comparison to the IL-5+/+ mice (figure V.3a). In contrast to sensitised 
IL-5+/+ mice, sensitised IL-5-/_ mice did not exhibit significantly higher levels of 
eosinophils in the circulation compared with the non-sensitised controls (figure V.3b). 
However, similar to IL-5+/+ mice, a dramatic reduction in the levels of eosinophils in the 
circulation of the IL-5'/_ mice was observed at the times of peak accumulation of 
eosinophils (6 and 24 hours) at sites of CLPR (figure V.3b). To determine if the
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Figure V.2 Eosinophils trafficking during cutaneous late-phase reaction 
in wild type mice.
IL-5+/+ mice were sensitised to Ova by i.p injection on days 0 and 12 and on day 24 were 
given s.c. injection of 50 p.g of Ova in 100 fil of saline. Non-sensitised mice were 
injected s.c. with saline only, (a) The accumulation of eosinophils at sites of CLPR was 
biphasic. Peak eosinophil accumulation was seen at 6 and 24 hours and was significantly 
greater than the accumulation of eosinophils at sites of saline administration in the non- 
sensitised controls. Results represent mean eosinophils/mm2 ± SEM of groups of 6 
animals, (b) Levels of eosinophils in the blood of mice during CLPR. Sensitised mice 
had significantly higher levels of eosinophils in the blood compared with the non- 
sensitised controls at the time of s.c. injection. Eosinophil levels in the blood of the 
sensitised mice fell 3 hours after s.c. Ova administration and remained low for the 
duration of the experiment (24 hours). In contrast, the eosinophil levels in the blood of 
non-sensitised control after the s.c. administration of saline were not significantly 
reduced. Results represent mean eosinophils/ml of blood ± SEM of groups of 6 animals. 
The significance of differences between experimental groups was analysed using the 
Student's unpaired r-test. Differences in means were considered significant if p < 0.05. 
(a) *P < 0.05 when compared with saline controls at 3 hours, **P < 0.05 when 
compared to eosinophil level at 6 hours and ***P < 0.001 when compared with saline 
controls at the same time point, (b) < 0.05 when compared with the saline controls at
the same time point and **P < 0.001 when compared with the saline controls at 6 and 24 
hours.
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Figure V.3 The role of IL-5 in eosinophil trafficking during cutaneous 
late-phase reaction in mice.
IL-5+/+ mice and IL-5_/" mice were sensitised to Ova by i.p injection on day 0 and 12 and 
on day 24 were challenged with 50 fig of Ova by s.c. injection in 100 fil saline. Non- 
sensitised mice received s.c. saline only, (a) The accumulation of eosinophils at sites of 
CLPR at 6 and 24 hours [peak infiltration times in wild type mice (figures IV.7 and V.2)] 
was significantly reduced in the IL-5"^- mice when compared to IL-5+/+ mice. Saline- 
induced accumulation of eosinophils in the skin of the non-sensitised control animals was 
also reduced in the IL-5'/_ mice when compared with the IL-5+/+ mice. Results represent 
mean eosinophils/mm2 ± SEM for groups of 6 animals, (b) Circulating eosinophil levels 
in DL-5_/' mice during CLPR. Resting levels of eosinophil in the blood of sensitised and 
non-sensitised mice were significantly lower than those in the IL-5+/+ mice. Circulating 
eosinophils levels in the sensitised IL-5+/+ and IL -5 /_ mice at 6 and 24 hours post s.c. 
administration of Ova were significantly lower that the levels in these mice prior to Ova 
administration. In contrast, the levels of eosinophils in the blood of the non-sensitised 
controls were unaffected following s.c. saline administration. Results represent mean 
eosinophils/ml blood ± SEM of groups of 5 animals each. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. (a) *P < 0.05 when 
compared with Ova challenged IL-5+/+ mice at the same time point, (b) *P < 0.01 when 
compared to levels at 0 hours or when compared with the non-sensitised saline controls at 
the same time point and **P < 0.001 when compared with resting levels of eosinophils in 
the blood of the sensitised mice. No significant difference was detected between the mean 
resting eosinophil levels in the blood of the non-sensitised and sensitised IL-5_/' mice 
groups.
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reductions in the accumulation of eosinophils at sites of CLPR in the IL-5'/' mice were 
due to the lower circulating eosinophil levels in these animals or a decreased homing 
response, the trafficking of fluorescently-labelled donor eosinophils in IL-5+/+ and IL-5"/_ 
mice was analysed. The adoptive transfer of H33342-labelled donor eosinophils was 
confirmed in each animal by taking a blood sample 10 minutes after i.v. administration 
and counting the number of fluorescent cells/ml of blood. The levels of H33342-labelled 
eosinophils in the blood of all groups of mice (IL-5+/+ Ova, IL-5+/+ saline, IL-5_/' Ova 
and IL-5'/' saline) were equivalent at this time (figure V.4a).
Significantly greater numbers of H33342-labelled eosinophils accumulated at sites of 
CLPR than at skin sites of saline administration in non-sensitised mice, at 6 and 24 hours 
(figure V.4b). Furthermore, the accumulation of H33342-labelled eosinophils at sites of 
CLPR at 6 and 24 hours, or at s.c. sites of saline administration were not affected in the 
absence of IL-5 (figure V.4b).
V.3.2 The role of IL-5 in eosinophil trafficking and activation during 
allergic airways inflammation in mice.
The single exposure of sensitised mice to an aerosol of Ova caused a time dependent 
increase in the level of eosinophils in the B ALF of IL-5+/+ mice, but not IL-5"/' mice 
(figure V.5a). No eosinophils were detected in the BALF of the non-sensitised control 
groups following their exposure to sahne aerosol. A significant elevation in the level of 
eosinophils in the circulation of the sensitised IL-5+/+ mice was detected between 3 and 
12 hours and after 24 hours, following Ova aerosol exposure (figure V.5b). In contrast, 
no peripheral blood eosinophilia was detected in the sensitised IL-5'/' mice following Ova 
aerosol exposure or in the non-sensitised IL-5+/+ and IL-5'/' control groups following 
saline aerosol exposure (figure V.5b) at any time.
The i.v. adoptive transfer of 5 x 106 H33342-labelled donor eosinophils to sensitised 
mice groups following their exposure to Ova aerosol induced the accumulation of 
H33342-labelled cells in the BALF 24 hours later (figure V.6a). Equivalent levels of 
H33342-labelled eosinophils accumulated in the lungs of IL-5'/" mice and IL-5+/+ mice.
In contrast, no H33342-labelled eosinophils accumulated in the BALF of the non- 
sensitised control groups following exposure to saline aerosol (figure V.6). The adoptive 
transfer of eosinophils was confirmed in each animal by taking a peripheral blood sample 
at 10 minutes post transfer and measuring the levels of fluorescent cell/ml of blood. The 
levels of H33342-labelled eosinophils in the blood of all groups of mice were equivalent 
at this time (figure V.6b).
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Figure V.4 The role of IL-5 in eosinophil homing during cutaneous late- 
phase reaction in mice.
IL-5+/+ mice and IL-5'/_ mice were sensitised to Ova by i.p injection on days 0 and 12 
and on day 24 the mice were challenged with 50 fig Ova by s.c. injection in 100 fil saline. 
Non-sensitised mice received s.c. saline only. At 4 or 22 hours post s.c. injection, mice 
received an adoptive transfer of 1 x 106 H33342 labelled eosinophils. The mice were 
sacrificed 2 hours later and the accumulation of fluorescent eosinophils/mm2 on dorsal 
skin membrane sections determined, (a) Fluorescent cells in the blood 10 minutes post 
i.v. adoptive transfer of 1 x 106 H33342-labelled eosinophils. Equivalent levels of 
fluorescent cells in the blood were present in all groups of mice at 10 minutes post 
adoptive transfer. Results represent mean fluorescent cells/ml blood ± SEM of groups of 
5 mice each, (b) Adoptively transferred H33342-labelled eosinophils home to sites of 
CLPR at 6 and 24 hours and this response is not affected in IL-5"/_ mice. Significantly 
greater levels of H33342-labelled eosinophil accumulation was seen at sites of CLPR than 
at sites of saline administration in the non-sensitised controls. Equal levels of 
accumulation of H33342-labelled eosinophils were seen in the IL-5~/_ mice compared with 
the IL-5+/+ mice. Results represent mean fluorescent cells/mm2 ± SEM of groups of 5 
animals. The significance of differences between experimental groups was analysed 
using the Student's unpaired r-test. Differences in means were considered significant if P 
< 0.05. (a) No significant difference between the means of any group of mice receiving 
an adoptive transfer of eosinophils was detected, (b) < 0.005 when compared with
saline controls at the same time point. No significant difference was detected between the 
means of IL-5+/+ and IL-5'/_ groups when compared within the same treatment.
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Figure Y.5 The induction of BALF and blood eosinophilia in sensitised 
mice following a single exposure to aeroallergen, is attenuated in the 
absence of IL-5.
IL-5+/+ and EL-5"/' mice were sensitised to Ova by i.p. injection. On day 24 mice were 
exposed to an aerosol of Ova (10 mg/ml in saline) for a period of 1 hour. Non-sensitised 
mice were exposed to saline only. Circulating and BALF eosinophil levels were 
determined immediately prior to and every 3 hours after aerosol exposure at 24 hours and 
at 36 and 48 hours, (a) The exposure of sensitised mice to an Ova aerosol induced a 
delayed BALF eosinophilia in the IL-5+/+ mice which (began at 18 hours and peaked by 
24 hours post aerosol exposure) but not in the IL-5'/' mice. No significant increases in 
the levels of eosinophils in the BALF of the non-sensitised controls were detected 
following exposure to saline aerosol. Data represents mean eosinophil/ml BALF ± SEM 
of groups of 5 animals, (b) Antigen challenge of sensitised mice via the airways leads to 
the development of a rapid transient increase in circulating eosinophil levels in IL-5+/+ 
mice which is abolished in the absence of IL-5. The significance of differences between 
experimental groups was analysed using the Student's unpaired Ftest. Differences in 
means were considered significant if P < 0.05. *P < 0.05, **P < 0.01 and ***P < 0.001 
when compared with IL-5+/+ saline or IL-5'/' Ova groups. No significant change in 
eosinophil levels were detected throughout the duration of the experiment in the non- 
sensitised controls that were exposed to sahne aerosol.
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Figure V.6 The role of IL-5 in eosinophil homing to the allergic lungs of 
mice.
IL-5+'/+ mice and IL-5'/' mice were sensitised to Ova by i.p injection on day 0 and 12 and 
on day 24 exposed to an aerosol of Ova (10 mg/ml in saline) for 1 hour. Non-sensitised 
mice were exposed to saline aerosol only. Six hours post aerosol exposure the mice were 
given an i.v. adoptive transfer of 5 x 106 H33342-labelled eosinophils. The levels of 
fluorescent cells in the BALF of mice were determined 18 hours later, (a) Fluorescent 
cells in BALF at 24 hours post aerosol exposure. Significantly greater levels of cells 
were present in the BALF of the sensitised mice when compared with the saline controls. 
Equivalent levels of H33342-labelled eosinophils were present in the BALF of the IL-5_/' 
mice compared with the IL-5+/+ mice, (b) The levels of fluorescent cells in the blood at 
10 minutes after transfer of H33342 labelled eosinophils. The levels of fluorescent cells 
in the blood of all groups of mice were equal when measured at 10 minutes post adoptive 
transfer. Results represent (a) mean fluorescent cells/ml BALF ± SEM of groups of 5 
animals and (b) mean fluorescent cells/ml blood ± SEM of groups of 5 animals. The 
significance of differences between experimental groups was analysed using the Student's 
unpaired Mest. Differences in means were considered significant if P < 0.05. (a) <
0.005 when compared with the saline control groups at the same time point. No 
significant differences were detected between the means of IL-5+/+ and IL-5‘/_ groups 
within same treatment, (b) No significant difference between the means of any group of 
mice receiving the transfer of eosinophils were detected.
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V.3.2.1 Eosinophil and lymphocyte levels in BALF correlate with the 
degree o f  airways hyperreactivity in 7L-5+/+ and IL-5'1' mice.
As previously demonstrated in this laboratory (Foster eta l, 1996), aeroallergen (Ova) 
exposure of sensitised IL-5+/+ mice induced BALF eosinophilia (figure V.7a). Elevated 
levels of lymphocytes were also observed in the BALF of these mice (figure V.7b). The 
level of eosinophils and lymphocytes in the BALF correlated with the amount of 
aeroallergen exposures, furthermore, the BALF levels of both of these leukocytes 
correlated with the degree of airways hyperreactivity (figure V.7c). Following the first 
Ova aerosol exposure both neutrophil and macrophage levels in the BALF were elevated, 
however, subsequent exposures of mice to Ova aerosol failed to further increase the levels 
of these cells in the BALF (figure V.7b).
The induction of airways hyperreactivity occurred only in the sensitised mice and only 
following exposure to Ova aerosol. Non-sensitised mice that were exposed to saline 
aerosol did not develop airways hyperreactivity. Earlier studies in chapter 3 showed that 
the exposure of naive mice to an aerosol of Ova every second day for up to 10 days does 
not alter airways reactivity and thus, this group was not included in this study. Free MBP 
was exclusively detected in the BALF of the Ova sensitised mice, but only following 
exposure to Ova aerosol. Furthermore, the BALF levels of this cationic protein in these 
animals appeared to increase with subsequent exposures to aeroallergen. No Free MBP 
was detected in the BALF of the non-sensitised mice groups at any time.
As previously observed (Foster et al.} 1996), the induction of airways eosinophilia in 
EL-5"/' mice during allergic airways inflammation was significantly inhibited. In contrast 
to the IL-5+/+ mice, few eosinophils were detected in the BALF of sensitised IL-5'/' mice 
when measured at 24 hours after a single exposure to Ova aerosol. However, subsequent 
exposures of these animals to Ova aerosol induced a slight, but significant (P < 0.05) 
increase in the levels of eosinophils in the BALF (figure V.8a). These levels were 
approximately 100 fold less than those observed in IL-5+/+ mice under the same 
conditions (V.7a). As observed in the IL-5+/+ mice, increases in the level of eosinophils 
in the BALF of the IL-5'/_ mice also correlated with the number of Ova aerosol exposures. 
Free MBP was also detected in the BALF of the sensitised IL-5'/_ mice, but only after the 
3 day of exposure to Ova aerosol (table V.l).
Interestingly, although it has previously been reported to be totally abolished in IL-5-/" 
mice, airways hyperreactivity to i.v. ß-methylcholine was detected in the sensitised 
IL-5'/‘ mice following exposure to Ova aerosol (figure V.8b), albeit at a significantly
lower level than the IL-5+/+ mice (figure V.7b) under the same conditions. A significant 
6A)*\ei\ c o v e t e d  on t> a ^ 2 q  a\-
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Table V .l Free MBP levels in the BALF of IL-5+/+ and IL-5m/m m ice  
during allergic airways inflammation.
Days of aerosol exposure
Group 0 (day 23) 1 (day 25) 2 (day 27) 3 (day 29) 4 (day 31)
IL-5+/+, saline X X X X X
IL-5+/+, Ova X v vv vvv ww
IL-5“/", saline X X X X X
IL-5_/', Ova X X V V vv
The relative levels of free MBP in the BALF of IL-5+/+ and IL-5 '^ mice following 
aeroallergen or saline aerosol exposure were determined using immuno dot blot. Ticks 
indicated the intensity of the MBP staining on immuno dot blots and a cross denotes that 
MBP was not detected. Increasing levels of MBP were detectable in cell free BALF of 
sensitised IL-5+/+ mice (IL-5+/+, Ova) following aeroallergen (Ova) exposure. MBP 
levels in these mice correlated with the amount of aerosol exposure. Free MBP was also 
detected in the cell free BALF of the sensitised rL-5'/_ mice, but only following 2 days of 
aerosol exposure. Similar to the IL-5+/+ mice, MBP levels in the BALF of the sensitised 
IL-5_/‘ mice correlated with the amount of aerosol exposures. No MBP was detected in 
the cell-free BALF of the non-sensitised IL-5+/+ (IL-5+/+, saline) and IL-5_/- (IL-5"/_, 
saline) groups prior to or post saline aerosol exposures.
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Figure V.7 The induction o f airways hyperreactivity correlates with the 
levels of eosinophils in the BALF following aeroallergen provocation.
IL-5+/+ mice were sensitised to Ova by i.p. injection on days 0 and 12. On day 24, 26,
28 and 30 the mice were exposed to an aerosol of Ova in saline. For comparative 
purposes another group of non-sensitised IL-5+/+ mice were exposed to and aerosol of 
saline. Airways hyperreactivity to i.v. b-methylcholine and the levels of leukocytes in the 
BALF were determined on days 23, 25, 27 and 29 and 31. (a) Eosinophil levels in the 
BALF of sensitised IL-5+/+ mice correlated with the levels of Ova aerosol exposure. No 
eosinophils were present in the BALF of non-sensitised controls following saline aerosol 
exposure, (b) Lymphocyte (but not neutrophils or macrophages) levels in the BALF of 
sensitised IL-5+/+ mice correlated with the levels of Ova aerosol exposure, (c) Airways 
hyperreactivity was first detected in mice on day 27 and further increases in reactivity 
correlated with the level of Ova aerosol exposure. No differences were detected between 
the saline aerosol exposed group or the Ova sensitised mice prior to and 24 hours after the 
first exposure to Ova aerosol (data not shown). Data represents (a and b) mean cells/ml 
of BALF ± SEM of groups of 5 mice and (c) mean percentage airways occlusion ± SEM 
of groups of 5 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired f-test. Differences in means were considered 
significant if P < 0.05. (a) *P < 0.01 compared with non-sensitised saline exposed mice 
and **P < 0.005 when with levels in the same group 48 hours earlier, (b) < 0.05
when compared with the levels of lymphocytes in these mice prior to Ova aerosol 
exposure (day 23). (c) *P < 0.05 and **P < 0.01 compared with non-aerosol exposed 
sensitised mice (day 23) at the same dose of ß-methylcholine.
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Figure V.8 BALF eosinophilia and the development of airways 
hyperreactivity is significantly inhibited in IL-5~/m mice following 
aeroallergen provocation and levels of BALF eosinophils correlates with 
the degree of airways hyperreactivity.
IL-5_/" mice were sensitised to Ova by i.p. injection on day 0 and 12. On day 24, 26, 28 
and 30, mice were exposed to an aerosol of Ova in saline. For comparative purposes 
another group of non-sensitised IL-5'/_ mice were exposed to an aerosol of saline, instead 
of Ova. Mice were analysed for airways hyperreactivity to i.v. ß-methylcholine and 
BALF eosinophil levels determined on days 23, 25, 27, 29 and 30. (a) Increases in the 
levels of eosinophils in the BALF correlated with the amount of exposure to Ova aerosol. 
Few eosinophils were present in the BALF of the non-sensitised, saline aerosol exposed 
mice. Data represents the mean number of eosinophil/ml BALF ± SEM of groups of 5 
mice, (b) Airways hyperreactivity was first detected in sensitised the IL-5_/" mice on day 
29 and reactivity was further increased on day 31. No differences were detected between 
saline aerosol exposed mice or Ova sensitised mice prior to and 24 hours after the first or 
second exposures to Ova aerosol (data not shown for 24 hours after the first aerosol). 
Data represent the mean percentage airways occlusion ± SEM of groups of 5 mice. The 
significance of differences between experimental groups was analysed using the Student's 
unpaired r-test. Differences in means were considered significant if P < 0.05. (a) <
0.05 compared with non-sensitised saline exposed mice and **P < 0.05 when compared 
with the sensitised mice on day 27. (b) *P < 0.05 and **P < 0.01 when compared with 
the non-aerosol exposed sensitised mice (day 23) at the same dose of ß-methylcholine and 
compared with saline controls.
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elevation in airways reactivity of the sensitised IL-5'/_ mice was first detected on day 29 
(figure V.8b, following the third day of exposure to Ova aerosol). This was in contrast to 
the sensitised IL-5+/+ mice that displayed airways hyperreactivity as earlier as day 27 
(figure V.7b, 24 hours after the second exposure to Ova aerosol). It is of particular 
interest to note that the onset of airways hyperreactivity in the sensitised IL-5_/' mice 
occurred at the same time as free MBP was first detectable in the BALF of these animals 
(see table V.l).
Similar to the sensitised IL-5+/+ mice, there was a correlation between the level of 
eosinophils and the presence of free MBP in the BALF, and the degree of airways 
hyperreactivity in the sensitised IL -5 /_ mice on day 29. Interestingly, the levels of 
eosinophils in the BALF of the sensitised IL-5"/_ mice at times when airways 
hyperreactivity was first detected (day 29, after 3 Ova aerosol exposures), were 
significantly lower than the levels of this cell in the BALF of the sensitised IL-5+/+ mice 
at the onset of airways hyperreactivity (see table V.l). No airways hyperreactivity was 
seen in IL-5+/+ mice 24 hours after the first exposure to Ova aerosol, even though these 
mice had MBP in the BALF (see table V .l) and had levels of eosinophils in the BALF 
(V.7a) that were equivalent to the sensitised IL-5_/" mice on day 31 (figure V.8a).
V.3.3 A role for IL-5 in the enhancement of eosinophil-mediated airways 
hyperreactivity in IL-5'/_ mice during allergic airways inflammation.
In an attempt to further elucidate the role of eosinophils in the induction of airway 
hyperreactivity and to determine the contribution of IL-5 to this processes, IL-5'/_ mice 
were manipulated by the i.v. administration of eotaxin or the i.v. adoptive transfer of 
eosinophils to amplify the eosinophilic response in the lungs in response to aeroallergen 
provocation. In contrast to the sensitised IL-5+/+ mice (figure V.7a), the sensitised 
IL-5"/_ mice only developed a very mild airways eosinophilia following exposure to 
aeroallergen (figure V.8a). The reduced accumulation of eosinophils in the BALF of 
sensitised IL-5_/" mice may reflect the lower circulating levels of eosinophils in these 
animals. It was thus hypothesised that by increasing the circulating eosinophil pool it 
would be possible to enhance the accumulation of eosinophils in BALF of IL-5‘/_ mice 
during allergic airways inflammation and thereby to determine the effect of the selective 
increase in eosinophil levels in the BALF on the development of airways hyperreactivity.
Two methods were employed to amplify the circulating eosinophil levels in the IL-5"/_ 
mice during allergic airways inflammation. The first involved the i.v. administration of 
eotaxin (2.4 nmol/kg, see section IV.3.1) which allowed for the study of the role of 
eosinophils in the induction of airways hyperreactivity during allergic airways 
inflammation in the absence of IL-5. The second method involved supplementing the
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circulating eosinophil pool by i.v. adoptive transfer of donor eosinophils. For adoptive 
transfer experiments, eosinophils were isolated from three sources; (a) the BALF of 
allergic IL-5+/+ mice, (b) the BALF of allergic IL-5'/_ mice inoculated with VV-HA-IL-5 
(to induce a blood eosinophilia) and (c) the blood of non-sensitised IL-5"/_ mice inoculated 
with VV-HA-IL-5. This provided three different populations of eosinophils that were (a) 
exposed to allergic mediators (including IL-5) and able to produce IL-5, (b) exposed to 
allergic mediators and IL-5, but unable to produce IL-5 and (c) exposed to IL-5, but 
unable to produce IL-5. The use of these three different populations of eosinophils 
allowed for the study of the effect of the activation of eosinophils by allergic mediators, 
the effect of IL-5 priming on eosinophils and the production of IL-5 by the eosinophils, 
on the development of airways hyperreactivity during allergic airways inflammation.
The i.v. administration of eotaxin to IL-5'/_ mice during an allergic airways inflammatory 
reaction caused a significant elevation in the peripheral eosinophil levels when measured 
30 minutes after administration. However, the effect of i.v. eotaxin on the circulating 
eosinophil pool in the allergic IL -5 /_ mice was diminished in comparison with the effect 
of this chemokine on naive IL-5'/" mice when administered i.v. at the same concentration 
(figure V.9a).
The adoptive transfer of 5 x 106 donor eosinophils from the 3 donor sources induced 
significant elevations in the levels of eosinophils in the blood of the sensitised IL-5"/' mice 
when measure# 10 minutes after the adoptive transfer (figure V.9b). Thus, both of these 
methods were effective in elevating the circulating eosinophil pool. The elevation of the 
circulating eosinophil pool by i.v. eotaxin or by adoptive transfer eosinophils (irrespective 
of their source) were equivalent in their effect on the amplification of BALF eosinophilia. 
Furthermore, all of these treatments selectively increased eosinophils levels in the BALF 
(figure V.10 a). No significant increase in the numbers of neutrophils, lymphocytes or 
macrophages in the BALF were observed in any of the treatment groups (figure V.lOb). 
Interestingly, the peak circulating eosinophilia induced by i.v. eotaxin (30 minutes post 
i.v. administration) was significantly lower than that induce by the i.v. adoptive transfer 
of 5 x 106 eosinophils (when measured at 10 minutes post adoptive transfer).
The histological analysis of the lung sections from the sensitised IL-5'/_ mice revealed low 
level of eosinophils in tissues. The accumulation of eosinophils in pulmonary tissues was 
enhanced in sensitised IL-5"/_ mice that were given i.v. eotaxin or an i.v. adoptive transfer 
of 5 x 106 eosinophils 48 hours earlier (figure V .l 1). The eosinophils in all groups of 
sensitised IL-5“/ '  mice were specifically localised to the region beneath the airways 
smooth muscle, but not in the surrounding tissues (the parenchyma or between the 
airways smooth muscle and the bronchial epithelium) (figure V.12).
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Figure V.9 The adoptive transfer of 5 x 106 donor eosinophils or an i.v. 
administration of eotaxin, significantly amplifies circulating eosinophil 
levels during allergic airways inflammation in IL-5’/m mice.
IL-5'/_ mice were sensitised to Ova by i.p injection on days 0 and 12 and exposed to 
aerosolized Ova on days 24, 26, 27 and 28. On day 27 some mice received an adoptive 
transfer of 5 x 106 donor eosinophil isolated either from the BALF of allergic IL-5+/+ 
mice, the BALF of allergic IL-5'/_ mice inoculated with W -HA-IL-5 or the blood of 
IL-5-/' mice inoculated with VV-HA-IL-5. Mice were also injected i.v. with eotaxin (2.4 
nmol/kg) or control vehicle [100 |il of 10 mM PBS/0.1% BSA (pH 7.4)] instead of an 
adoptive transfer of eosinophils. (%) The adoptive transfer of 5 x 106 donor eosinophils 
or ($) the i.v. administration of 2.4 nmol/kg eotaxin, significantly amplified circulating 
eosinophils in IL-5_/" during allergic pulmonary inflammation. Elevations in blood 
eosinophil levels induced by i.v. eotaxin (2.4 nmol/kg) in IL-5'/_ mice during allergy were 
significantly lower than those induced by i.v. eotaxin, at the same concentration, in naive 
IL-5'/_ mice (refer to figure IV.2b). Blood samples were analysed prior to (resting level) 
and (a) 10 minutes post i.v. injection of donor eosinophil recipients or control vehicle 
(PBS) or (b) 30 minutes post i.v. eotaxin or control vehicle (PBS/0.1% BSA). Data 
represents mean eosinophils/ml of blood +/- SEM of groups of 5 mice. The significance 
of differences between experimental groups was analysed using the Student's unpaired t- 
test. Differences in means were considered significant if P < 0.05. (*) *P < 0.001 
compared with resting levels of control vehicle i.v. (%) < 0.05 when compared with
resting levels or control vehicle i.v. and **P < 0.002 when compared with i.v. eotaxin 
(2.4 nmol/kg).
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Figure V.IO The adoptive transfer of 5 x 106 donor eosinophils or the 
i.v. administration of eotaxin, significantly amplifies BALF eosinophil 
levels during allergic airways inflammation in IL-5~/m mice.
The adoptive transfer of 5 x 106 donor eosinophils or the i.v. administration of 2.4 
nmol/kg eotaxin significantly amplified (a) BALF eosinophil levels but not (b) BALF 
neutrophil, lymphocyte or macrophage levels in IL-5'/_ mice during allergic airways 
inflammation. IL-5_/‘ mice were sensitised to Ova by i.p injection on days 0 and 12 and 
exposed to Ova aerosol on days 24, 26, 27 and 28. On day 27 some mice received an 
adoptive transfer of 5 x 106 donor eosinophil isolated either from the BALF of allergic 
IL-5+/+ mice, the BALF of allergic IL-5"/_ mice inoculated with VV-HA-IL-5 or the blood 
of LL-5_/" mice inoculated with W -HA-IL-5 or control vehicle (PBS). Another group of 
mice was injected i.v. with eotaxin (2.4 nmol/kg) or control vehicle [10 mM PBS/0.1% 
BSA (pH 7.4)] instead of an adoptive transfer of eosinophils. BALF leukocyte 
populations were quantified on day 30 and data represents mean eosinophils/ml of BALF 
± SEM of groups of 5 mice. The significance of differences between experimental groups 
was analysed using the Student's unpaired t-test. Differences in means were considered 
significant if P < 0.05. (a) *P < 0.05 compared with control vehicle i.v. [PBS for 
eosinophil i.v. recipients or PBS/0.1% BSA for eotaxin i.v. injected mice], (b) No 
significant differences were found between the means of groups receiving an i.v. adoptive 
transfer of eosinophil or an i.v. administration of eotaxin and their respective i.v. vehicle 
alone controls when compared within BALF leukocyte populations.
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Associated with the increase in the accumulation of eosinophils in the lungs of sensitised 
IL-5_/‘ mice by i.v. eotaxin or an adoptive transfer of eosinophils was an increase in 
airways reactivity to i.v. ß-methylcholine. Interestingly, airways hyperreactivity of mice 
that received i.v. eotaxin (figure V.13a) was not as pronounced as those that received the 
i.v. adoptive transfer of eosinophils (figure V.13b and c), even though the BALF (figure 
V.lOa) and tissue levels (figure V.l 1) of eosinophils in all of these treatment groups were 
equal.
MBP was detected in the BALF of all groups of sensitised IL-5'/_ mice following 
aeroallergen provocation (data not shown). Although the BALF eosinophil levels and 
airways reactivity were significantly greater in the groups that received i.v. eotaxin or an 
adoptive transfer of eosinophils when compared to groups that received control vehicle 
i.v., there were no obvious increases in the level of MBP in BALF of any of these groups 
(data not shown). However, the inability to detect changes in MBP levels between 
treatment groups and their controls may reflect the low levels of eosinophils in the BALF.
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Figure V .ll The adoptive transfer of 5 x 106 donor eosinophils or the i.v. 
administration of eotaxin, significantly amplifies eosinophil levels in 
pulmonary tissues during allergic airways inflammation in IL-5'/m mice.
IL-5_/_ mice were sensitised to Ova by i.p injection on days 0 and 12 and 
exposed to Ova aerosol on days 24, 26, 27 and 28. On day 27 some mice 
received an adoptive transfer of 5 x 106 donor eosinophils that were isolated 
from either the BALF of allergic IL-5+/+ mice, the BALF of allergic IL-5'/_ mice
inoculated with VV-HA-IL-5 or the blood of IL-5_/' mice inoculated with VV- 
HA-IL-5. Mice were injected i.v. with eotaxin (2.4 nmol/kg) or control vehicle 
[10 mM PBS/0.1% BSA (pH 7.4)] instead of an adoptive transfer of eosinophils.
Eosinophil/mm2 of lung sections (formalin fixed, paraffin embedded and stained 
with Haematoxylin and Eosin) were quantified on day 30. Data represents mean 
eosinophils/mm2 in peribronchialar regions near airways smooth muscle ± SEM 
of groups of 3 mice. At least 10 fields of view were counted/lung section. The 
significance of differences between experimental groups was analysed using the 
Student's unpaired Mest. Difference in means were considered significant if P <
0.05. < 0.001 compared with non-sensitised IL-5"/_ mice exposed to saline
aerosol (saline) and **P < 0.05 when compare with control vehicle i.v. (PBS for 
eosinophil recipients and PBS/0.1% BSA for i.v. eotaxin injected control 
groups).
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Figure Y.12 Eosinophils specifically localise to regions near airways 
smooth muscles during allergic airways inflammation.
Eosinophils that infiltrated the lungs of IL-5~/_ mice during allergic airways inflammation 
on day 29 were specifically localised in peribronchiolar regions near the airways smooth 
muscle, (a) Significant levels of eosinophils were found in regions near the airways 
smooth muscle following aeroallergen provocation and (b) these levels were significantly 
increased in groups that received an i.v. adoptive transfer of eosinophils or an i.v 
administration of eotaxin (not shown), (c) No eosinophils were found in this region in 
the non-sensitised control groups. Photos are of 8 p.M formalin-fixed paraffin sections 
stained with Haematoxylin and Eosin (400 x magnification).
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Figure V.13 The adoptive transfer of 5 x 106 donor eosinophils or the 
i.v. administration of eotaxin, significantly amplifies airways 
hyperreactivity during allergic airways inflammation in IL-5m/~ mice.
IL-5_/‘ mice were sensitised to Ova by i.p injection on days 0 and 12 and exposed to Ova 
aerosol on days 24, 26, 27 and 28. On day 27 some mice received an adoptive transfer of 
5 x 106 donor eosinophils that were isolated from either the BALF of allergic IL-5+/+ 
mice, the BALF of allergic fL-5_/' mice inoculated with VV-HA-IL-5 or the blood of IL-5" 
mice inoculated with VV-HA-IL-5. Another group of mice were injected i.v. with 
eotaxin (2.4 nmol/kg) or control vehicle 110 mM PBS/0.1% BSA (pH 7.4)] instead of an 
adoptive transfer of eosinophils. Airways hyperreactivity to i.v. ß-methylcholine was 
measured on day 29, 24 hours after the final exposure to Ova aerosol. The lungs of the 
sensitised IL-5_/* mice that received an i.v. adoptive transfer of 5 x 106 eosinophils 
isolated from either (a) the blood of IL-5_/'  mice inoculated with VV-HA-IL-5 or (b) the 
allergic BALF of IL-5+/+ mice or the allergic BALF of IL-5_/' mice inoculated with VV- 
HA-IL-5 displayed airways reactivity to i.v. ß-methylcholine compared with groups that 
received i.v. PBS only, (c) The groups that received i.v. eotaxin (2.4 nmol/kg) on day 
27 also displayed airways hyperreactivity to i.v. ß-methylcholine on day 29 when 
compared with a group that received i.v. control vehicle (PBS/0.1% BSA) only, although 
the elevations in airways reactivity were observed at a higher dose of ß-methylcholine and 
were not as significant as that induced by the adoptive transfer of eosinophils. Airways 
reactivity was measured by monitoring i.v. ß-methylcholine-induced changes in 
respiratory overflow volume. Data represents mean percentage airway occlusion ± SEM 
of groups of 5 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired r-test. Differences in means were considered 
significant if P < 0.05. (a) < 0.05 and **P < 0.02 when compared with PBS i.v at
the same dose of ß-methylcholine. (b) *P < 0.05 and **P < 0.002 when compared with 
PBS i.v at the same dose of ß-methylcholine and (c) *P < 0.05 when compared with 
PBS/0.1% BSA i.v. at the same dose of ß-methylcholine.
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(a)
PBS i.v.
5 x 106 IL-5'/_ blood eos i.v.
cummulative ß-methylcholine (|Hg/kg i.v.) 
(b)
PBS i.v.
5x10^  IL-5'^' BALF eos i.v.
5 x 106 IL-5+/+ BALF eos i.v.
cummulative ß-methylcholine (^lg/kg i.v.)
(c)
0.1% BSA/PBS i.v.
2.4 nmol/kg eotaxin i.v.
cummulative ß-methylcholine (|ig/kg i.v.)
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V.4 DISCUSSION.
It is clear from studies in IL-5 deficient mice that this cytokine has an important role in the 
maintenance of basal circulating eosinophil levels (Kopf et al, 1996). Phenotypic 
observations of mice genetically altered for the over production of IL-5 also support a role 
for this cytokine in promoting eosinophil differentiation and the release of eosinophils 
from bone marrow stores into the circulation (Dent et al., 1990; Tominaga et al., 1991).
In studies presented in Chapter n, an essential requirement for IL-5 in eosinophil 
trafficking in response to eotaxin was demonstrated. Collectively, these observations 
[and many others (Foster et al., 1996; Mould et al., 1997; Lee et al., 1997)] suggests an 
important role for IL-5 in mechanisms that regulate eosinophil trafficking.
V.4.1 Role of IL-5 in the homing of eosinophils to sites of allergy in the 
skin and iung.
Despite the indication that IL-5 may play a significant role in regulating the accumulation 
of eosinophils in inflamed tissues during allergy, the role for this cytokine in the homing 
mechanisms of eosinophils to the skin or lung during allergic inflammation remains 
unknown. Similar to the studies by Iwamoto et al., (1994) (which involved the use of 
anti-IL-5 mAb), a reduction in the accumulation of eosinophils was observed at sites of 
CLPR at 6 and 24 hours in IL-5'/' mice relative to wild types. Notably, sensitised 
IL-5'/" mice had significantly lower levels of eosinophils in the circulation than sensitised 
wild types (figure V.3b). Eosinophilic responses to s.c. control vehicle were also 
reduced in the IL-5'/' mice when compared with the IL-5+/+ mice (figure V.3a). Thus, 
the impaired eosinophilic responses in the skin of IL-5"/" mice may have been attributable 
to a reduced recruitable eosinophil pool in the blood. Notably, adoptively transferred 
eosinophils homed to sites of CLPR in the IL-5'/' and IL-5+/+ mice groups with the same 
efficiency, demonstrating that IL-5 was not directly required for eosinophil homing 
during the first or second phase of eosinophil accumulation at sites of CLPR. In contrast, 
studies by Iwamoto et al., (1992) suggests that the second phase of eosinophil 
accumulation at sites of CLPR, but not the first phase are dependent on IL-5. IL-5 may 
act to prime the eosinophils in the circulation for enhanced chemotactic responses and/or 
may amplify the circulating eosinophil pool by promoting the release of eosinophils from 
bone marrow (see Chapter II). The pretreatment of mice with anti-IL-5 mAb may decrease 
the second phase of eosinophil recruitment at sites of CLPR by inhibiting these processes.
It is interesting to note that IL-5+/+ mice, but not IL-5'/' mice, have significandy higher 
levels of eosinophils in the circulation following i.p. sensitisation to Ova. The induction 
of peripheral eosinophilia in wild type mice may be due to the higher levels of IL-5 in sera
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(Ohkawara et al, 1997), which stimulates eosinophil differentiation in the bone marrow 
and mobilisation into the blood.
Similar to studies in the skin, no obligatory role for IL-5 in eosinophil homing to the 
allergic lung was demonstrated. Adoptively transferred eosinophils migrated to the 
allergic airways of both IL-5'/_ and IL-5+/+ mice. Interestingly, IL-5'/_ mice poorly 
developed airways eosinophilia during allergic airways inflammation in contrast to wild 
types, even though homing responses are not reduced. Thus, similar to the observations 
in mice during CLPR, the reduced accumulation of eosinophils in the airways of IL-5_/" 
mice during allergic airways inflammation may reflect the reduced circulating eosinophil 
levels in these mice as well as the inability of these mice to develop blood eosinophilia. 
Collectively, these data suggest that the primary role of IL-5 may be to regulate the 
development of blood eosinophilia during allergic inflammation (Foster et a l, 1996).
V.4.2 Role of IL-5 in the development of airways hyperreactivity.
Mice that are genetically altered for the specific over production of IL-5 in airway 
epithelial cells display pulmonary eosinophilia and airways hyperreactivity (Lee et al., 
1997). This indicates that IL-5 is not only involved in the activation of eosinophil 
recruitment pathways, but also in the development of airways hyperreactivity, possibly 
though die activation of eosinophils. Although previous reports (Foster et al., 1996) 
have indicated that sensitised IL-5_yL mice fail to develop airways hyperreactivity 
following exposure to aeroallergen, in this study sensitised and Ova challenged IL-5_/" 
mice developed airways hyperreactivity (albeit markedly reduced) to i.v. ß-methylcholine 
during allergic airways inflammation. Sensitised IL-5"/_ mice also exhibited an elevation 
in the level of eosinophils in the airways following aeroallergen exposure, however, this 
response was also markedly reduced in comparison to wild type mice. The degree of 
airways hyperreactivity in IL-5+/+ and LL-5'/_ mice also correlated with the level of 
eosinophils, and the presence of free MBP in the BALF. Collectively, these observations 
suggest a role for eosinophils and MBP in the induction of airways hyperreactivity 
independently of IL-5 during allergic airways inflammation.
Further evidence that eosinophils are responsible for the induction of airways 
hyperreactivity was shown in the temporal development of enhanced reactivity during 
allergic airways inflammation. Airways hyperreactivity developed more rapidly in 
IL-5+/+ mice than in IL-5'/_ mice and directly correlated with the degree of pulmonary 
eosinophilia. Interestingly, there also appears to be a delay between the accumulation 
(and activation) of eosinophils in BALF and the development of airways hyperreactivity 
in mice. Sensitised IL-5+/+ mice did not exhibit airways hyperreactivity 24 hours after 
the initial aeroallergen exposure, even though these mice had levels of eosinophils in the 
BALF that were equivalent to that observed in IL-5'/_ mice following multiple exposures
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of aeroallergen and when IL-5_/" mice exhibited airways hyperreactivity. Furthermore, 
MBP was detectable in the BALF of the sensitised IL-5+/+ mice 24 hours after the first 
aeroallergen challenge. Thus, other factors associated with the development of allergic 
inflammation (perhaps T-cell factors) are required to regulate eosinophil-induced airways 
hyperreactivity.
The i.v. administration of eotaxin and the i.v. adoptive transfer of eosinophils to IL-5'/_ 
mice selectively enhanced airways eosinophilia during allergic airways inflammation.
This response may have involved the ability of both of these treatments to enhance the 
circulating eosinophil pool. Interestingly, the i.v. administration of eotaxin to sensitised 
mice during an allergic reaction in the lungs was not as effective at inducing blood 
eosinophilia as this factor was in naive mice (chapter IV). The apparent decreased ability 
of i.v eotaxin to mount a blood eosinophilia in sensitised IL-5'/_ mice may reflect a 
competitive sequestration of eosinophils from the circulation into inflamed tissues. 
Although i.v. eotaxin was not as effective at inducing a rapid blood eosinophilia in 
sensitised IL-5_/" mice compared to the i.v. adoptive transfer of 5 x 106 eosinophils, it 
still effectively amplified pulmonary eosinophilia in these animals. Moreover, both 
treatments resulted in the recruitment of approximately the same number of eosinophils 
into the airways.
Eosinophils isolated from sites of inflammation reportedly have a different phenotype 
from those isolated from blood (Hansel et al., 1991). Pulmonary eosinophils express 
high levels of ICAM-1 and may have different activational states compared with this cell 
in the blood. However, the eosinophils that were isolated from the BALF and the 
peripheral blood homed with equal efficiency to the inflamed lungs of IL-5_/' mice. This 
indicates that if there are any phenotypic differences between these two eosinophil 
populations it does not effect the ability of these cells to home to sites of inflammation. 
Moreover, these results demonstrate that eosinophils that have already homed to sites of 
allergic inflammation remain mobile and are able to migrate to other sites of inflammation 
from the circulation. Thus, the accumulation of eosinophils at sites of inflammation may 
not be terminal and these cells may have the potential to migrate to other tissues following 
the resolution of inflammation.
Similar to previous observations in Chapter III, the specific localisation of eosinophils in 
regions proximal to the airways smooth muscle, rather than the airways epithelium, 
suggests that these cells (or their products) mediate the induction of airways 
hyperreactivity by acting on the airways smooth muscle. As previously stated, this
process may involve the release of MBP and the antagonism of inhibitory M2 muscarinic
6 0  « • w t l  &»»»©b,TV\ _
receptors (Gleich et al., 1995, Evans et al., 1997).
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Interestingly, the source of the donor cells used for adoptive^ transfer studies had no 
effect on the ability of eosinophils to home to pulmonary sites of allergic inflammation or 
to exacerbate airways hyperreactivity in sensitised IL-5~/_ mice. In contrast, although i.v. 
eotaxin was as effective at amplifying airways eosinophilia in sensitised IL-5_/' mice as 
the adoptive transfer of eosinophils, it did not induce the same degree of airways 
hyperreactivity. This may reflect priming of donor eosinophils with IL-5 for enhanced 
degranulation as opposed to the i.v. eotaxin treatment where IL-5 was absent. Although 
the ability of eosinophils to induce airways hyperreactivity during allergy was not solely 
dependent on IL-5 priming, it was markedly enhanced by it. Interestingly, the ability of 
the adoptively transferred eosinophils to produce their own IL-5 (IL-5+/+ cells) had no 
observable effect on the ability of these cells to home to the inflamed lungs of sensitised 
IL-5'/_ mice or to induce airways hyperreactivity.
These experiments demonstrate that eosinophils can home to the allergic lungs of mice in 
the absence of IL-5. Furthermore, they have shown for the first time that eosinophils can 
regulate airways hyperreactivity independently of IL-5. However, IL-5 plays a central 
role in enhancing eosinophil function or eosinophil-induced airways hyperreactivity. In 
tight of the observation that eosinophils specifically localise to regions proximal to the 
airways smooth muscle it is hypothesised that this cell effects changes in airways function 
via interaction with this cell.
These experiments implicate the eosinophil as a central mediator of airways 
hyperreactivity associated with allergic airways inflammation. Airways hyperreactivity is 
a hallmark of asthma and our results endorse the eosinophil as a primary target for the 
design of novel therapeutics. Furthermore, since IL-5 plays a key role in the 
amplification of eosinophil-mediated disease pathology, the inhibition of this cytokine 
may also be useful for the treatment for allergic diseases.
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CHAPTER VI
THE ROLE OF EOTAXIN IN EOSINOPHIL 
TRAFFICKING AND FUNCTION IN VIVO
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VI.1 INTRODUCTION.
The increased expression of eotaxin at sites of allergic inflammation and its selective role 
in regulating eosinophil chemotaxis suggests that this chemokine may promote 
eosinophil recruitment into inflamed allergic tissues. Furthermore, a role for eotaxin in 
eosinophil trafficking during allergy has previously been demonstrated. The 
pretreatment of sensitised mice with anti-eotaxin mAh reduced aeroallergen-induced 
pulmonary eosinophilia by 50% (Gonzalo et al., 1996). Similarly, mice rendered 
deficient in eotaxin by targeted disruption of the gene have impaired eosinophilic 
responses during early, but not the late phases of allergic airways inflammation 
(Rothenberg et al., 1996). Earlier studies (Chapter II) showed that eotaxin potently 
induced a blood eosinophilia when administered i.v. to mice suggesting a role for this 
chemokine in regulating the circulating eosinophil pool. Recent reports also support a 
role for eotaxin in the regulation of blood eosinophil levels (Rothenberg et a l,  1996). 
Basal circulating levels of eosinophils in eotaxin deficient mice (eotaxin"/_) were 
significantly reduced compared to wild types. Furthermore, the reduced accumulation of 
eosinophils at sites of inflammation in eotaxin‘/_ mice during the early phases of allergy 
may reflect these lower circulating eosinophil levels. The in vitro chemotactic activity of 
B ALF from naive and allergic guinea pigs are also inhibited in the presence of anti- 
eotaxin mAb (Humbles et al., 1997). Collectively, these studies suggest that eotaxin 
may regulate eosinophil trafficking at the basal state and during allergic responses.
There is an increase in the levels of eosinophils in the circulation of sensitised mice 
between 3 and 12 hours following aeroallergen provocation (Chapter V). Eotaxin 
mRNA is expressed at sites of allergic inflammation during this period indicating that 
eotaxin may play a role in inducing blood eosinophilia. It is likely that IL-5 plays a co­
operative role with eotaxin in regulating blood eosinophilia in allergic mice. In contrast 
to naive IL-5_/~ mice (Chapter II), i.v. administration of eotaxin after aeroallergen 
challenge does not induce as pronounced a blood eosinophilia (Chapter V). However, 
i.v. eotaxin did amplify the accumulation of eosinophils into the allergic lungs of IL-5'/_ 
(Chapter V). Since eosinophils are actively sequestered by the allergic lung, the blood 
eosinophilic response normally induced by eotaxin is probably masked in sensitised 
IL-5_/* mice.
Eotaxin is constitutively expressed in numerous tissues that are commonly associated 
with eosinophils including the lungs, skin and intestines (Rothenberg et al., 1995a, 
1995b). Interestingly, mRNA for eotaxin is also expressed in a number of tissues that 
are not associated with eosinophils such as the thymus and lymph nodes. The 
expression of eotaxin in these two tissues suggested that it may signal to lymphocytes 
(Rothenberg et al., 1995b). Recently, eotaxin was shown to induce intracellular calcium
166
signalling and the chemotaxis of a subclass of TI12 lymphocytes. Furthermore, these TI12 
cells were shown to express CCR3 (Sallusto et al., 1997). These observations are 
particularly interesting considering that eosinophil recruitment at sites of allergic 
inflammation is CD4+ dependent (Iwamoto et al., 1992; Gavett et al., 1994). Thus, 
eotaxin may have a range of actions on specific leukocyte subsets.
Th2-type immune responses, particularly those involving CD4+ T-cells are thought to 
underlie the pathogenesis of allergic airways disease (Robinson et al., 1992; Bochner et 
al., 1994). Interestingly, the expression of eotaxin at sites of allergic airways 
inflammation in mice is not affected in the absence of CD4 (Gonzalo et al., 1996), 
although it is dependent on the presence of CD3+ lymphocytes (Maclean et al., 1996). 
This suggests that CD4+ cells do not primarily regulate eotaxin expression during 
allergy. CD3+ lymphocytes may regulate eotaxin expression through the secretion of 
cytokines, however, the modulatory mechanism is currently unknown.
Eosinophil activation and the induction of airways hyperreactivity in the presence of 
eotaxin, IL-5 and antigen presentation is CD4-dependent (Chapter HI). Furthermore, 
there was a correlation between the levels of lymphocytes and eosinophils in B ALF and 
the induction of airways hyperreactivity during allergic airways inflammation in mice 
(Chapter V). In light of the demonstration that both eosinophils and Th2-lymphocytes 
express the eotaxin receptor (CCR3) (Heath et al., 1997; Sallusto et al., 1997), eotaxin 
may have an important role in the activation of these cell types at sites of allergic 
inflammation.
Although numerous studies have investigated the role of eotaxin in eosinophil 
recruitment at sites of allergic inflammation, the role of this chemokine in the aetiology of 
airways damage and hyperreactivity has not been determined. Eotaxin was recently 
shown to potently induce respiratory bursts in human eosinophils and in this capacity 
was comparable to the complement peptide, C5a (Eisner et al., 1996). Other C-C- 
chemokines, including RANTES and MCP-3 also induce respiratory bursts in 
eosinophils, although eotaxin appears to be the most potent.
In this Chapter the role of eotaxin in the trafficking of eosinophils was investigated in 
eotaxin deficient mice (eotaxin^-). The role of eotaxin in regulating blood eosinophilia in 
naive mice and in the mechanisms of eosinophil recruitment and activation at sites of 
allergic inflammation was investigated. In addition, the expression of eotaxin mRNA in 
the lungs and skin of sensitised IL-5, IL-4 and IFN-y deficient mice following antigen 
provocation was measured.
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V I.2 M ATERIALS AND M ETHODS.
VI.2.1 Analysis of the effect of eotaxin deficiency on eosinophil 
trafficking in the blood and eosinophil mobilisation in bone marrow.
Eotaxin deficient mice (eotaxin'/') were a gift from Professor Mark Rothenberg 
(Childrens Hospital Medical Centre, Cincinnati, OH., USA.). To determine the 
requirement of eotaxin for the regulation of eosinophil levels in the circulation and the 
bone marrow eotaxin"/' and eotaxin+/+ mice (129Svev, a gift from Dr Alistair Ramsay, 
John Curtin School of Medical Research, Australian National University) were injected 
i.v. with IL-5 (100 pmol/kg) and/or eotaxin (1.2 nmol/kg) or control vehicle [100 fil 
0.1%BSA/PBS (pH 7.4)] and the levels of eosinophil in these two compartments 
monitored. Blood samples were taken immediately prior to and at 30 minutes post i.v. 
injection and eosinophils/ml of blood were determined using Discombe's method (see 
section n.2.2). The mice were sacrificed by cervical dislocation 30 minutes after i.v. 
injections and the levels of eosinophils in the bone marrow of the femurs (right and left) 
were quantified (see section II.2.3).
Eotaxin-/' and eotaxin+/+ mice were also injected i.v. with eotaxin (1.2 nmol/kg) or IL-5 
(100 pmol/kg) and the levels of eosinophils in the circulation determined every 30 
minutes for a period of 3 hours. Blood samples taken via the tail vein and eosinophils/ml 
of blood were determined using Discombe's method (see section II.2.2).
VI.2.2 The effect of IL-5 on primary cultures of bone marrow cells from 
eotaxin'/' mice.
Bone marrow cells were obtained from two eotaxin'/' and two eotaxin+/+ mice by lavage 
with 2 mis of HBSS (see section II.2.3). Nucleated cells were pelleted by centrifugation 
(400 x g for 5 mins at 4°C) and resuspended to 1 x 106 cells/ml in mixed lymphocyte 
culture medium (MLC)/10% heat inactivated FCS. MLC consisted of DMEM 
supplemented with 4 mg/ml folic acid, 66 [ig/ml L-asparagine, 116 fig/ml L-arginine- 
HC1, 2 mg/ml NaHCC^ 2 mM L-glutamine, 1 mM sodium pyruvate and 10 mM 
HEPES. Cell viability was > 95% as determined by trypan blue exclusion. The cells 
were dispensed into 96 well tissue culture plates at 2 x 105 cells/well and IL-5 (in 
MLC/10% FCS) was added to half of the wells to give a final concentration of 30 nM. 
Control cultures received MLC/10% FCS only. The cultures were then incubated at 
37°C/5% CO2. Eosinophils as a percentage of total cells in culture were determined at 0, 
0.5, 1, 2 and 3 hours after IL-5 administration. Briefly, the cells were gently removed 
from triplicate wells using a 1 ml pipette to avoid cell damage. This process recovered > 
80% of the cells and the recovered cell viability (trypan blue exclusion) was > 92% after
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3 hours of culture, irrespective of the treatment. The cell samples (1 x 105 cells) were 
cytocentrifuged onto glass slides and stained with Giemsa/May-Grunwald. Eosinophils 
(identified by morphological criteria), as a percentage of total leukocytes were quantified 
by routinely counting 200-300 total nucleated cells.
VI.2.3 Analysis of eotaxin expression at skin and lung sites of allergic 
inflammation by semi-quantitative reverse transcription-polymerase chain 
reaction.
VI.2.3.1 Determination of peak eotaxin expression in the skin and lungs 
following allergen provocation using reverse transcription-polymerase 
chain reaction.
VI.2.3.1.1 Preparation of samples and isolation of total RNA.
Mice (male C57BL6, 6-8 weeks of age) were sensitised to Ova by i.p injection on days 0 
and 12 (see section Y.2.1.1). Control non-sensitised animals received 1 mg Alhydrogel 
(CSL, Parkville, Melbourne, Australia) in saline only. On day 24, some of the 
sensitised mice were exposed to an aerosol of Ova (10 mg/ml) in 0.9% saline for 1 hour 
while others received a s.c. injection of 50 qg of Ova in 0.1 mis of saline (see section
V. 2.1.1). The non-sensitised control groups were exposed to an aerosol of saline or 
received a s.c. injection of 0.1 mis of saline. At 0, 0.5, 1, 2, 3, 6, 12 and 24 hours post 
Ova or sahne exposure the mice were sacrificed by CO2 asphyxiation and the lungs (mice 
exposed to aerosolized Ova or saline) or the s.c. membrane (mice given s.c. injections) 
removed and immediately placed into 10 volumes of RNAzol B (BIOTEX Laboratories, 
Houston, Texas, USA.) on ice. The samples were homogenised and the RNA extracted 
using RNAzol B according to the manufacturer's instructions. RNA samples were 
stored in RNase-free water at -70°C.
VI. 2.3.1.2 Reverse transcription-polymerase chain reaction for eotaxin and 
hvpoxanthine ribovsltransferase.
RNA (1 |ig) was transcribed to first strand cDNA using M-MLV Reverse Transcriptase 
(Promega, Madison, WI., USA.) according to manufactures instructions. Reaction 
mixture (20 fil) contained 1 qg of RNA, 25 mM Tris-HCl (pH 8.3), 37.5 mM KC1, 1.5 
mM MgCl2, 5 mM dithiothrietol, 25 pg/ml oligo dTis and 10 mM each of dATP, dCTP, 
dGTP and dTTP.
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VI.2.3.1.2.1 Eotaxin polymerase chain reaction.
cDNA (5 pi of 1/30 dilution of lung samples or 1/20 dilution of membrane samples all in 
PCR-grade water) was added to a 20 pi reaction mix containing 5 pmol of each of the 
forward primer (eotax FI) and reverse primer (eotax R l), 1 x AmpliTaq buffer (Perkin 
Elmer, Roche Molecular Systems, Inc., Branchburg, NJ., USA.), 1 unit of AmpliTaq 
DNA polymerase (Perkin Elmer, Roche Molecular Systems, Inc., Branchburg, NJ., 
USA.) and 250 (iM each of dGTP, dCTP, dATP and dTTP (Promega, Madison, WI., 
USA,). To control for contamination, a water control was also included and consisted of 
5 pi of PCR-grade water instead of 5 pi of sample.
The PCR primers, eotax FI (5' TCCACCATGCAGAGCTCCACAG 3') and eotax R l 
(5' CCCACATCTCCTTTCATGCCCC 3') were homologous to the 5' (42-63 bases) 
and 3' (complementary to 551-572 bases) regions of the murine eotaxin cDNA. The 
eotax FI primer was synthesised with a 6-FAM fluorescent tag attached to the 5' end.
The primers were synthesised by the Biomolecular Resource Facility at the John Curtin 
School of Medical Research (Australian National University) and were supplied in 
ammonium hydroxide. Prior to use the primers were vacuum dried, washed and 
resuspended in PCR-grade water to the desired concentration.
The PCR was run using a FTS-1 Thermal Sequencer (Corbett Research, Sydney, 
Australia) under the following conditions. Samples were denatured at 94°C for 3 
minutes followed by 40 cycles of denaturation at 96°C for 5 seconds, annealing at 50°C 
for 5 seconds and extension at 72°C for 1 minute. The reaction was then concluded with 
a 5 minutes extension at 72°C.
VI.2.3.1.2.2 Hypoxanthine riboytransferase polymerase chain reaction.
Hypoxanthine riboysltransferase (HPRT) was used as a house keeping gene for semi 
quantitation of eotaxin mRNA expression as previously described (Svetic et al., 1991).
cDNA (5 pi of 1/80 dilution of lung samples and 1/20 dilution of membrane samples in 
PCR-grade water) was added to a 20 pi reaction mix containing 5 pmol of each of the 
forward primer (HPRT FI) and reverse primer (HPRT R l), 1 x AmpliTaq buffer 
(Perkin Elmer, Roche Molecular Systems, Inc., Branchburg, NJ., USA.), 1 unit of 
AmpliTaq DNA polymerase (Perkin Elmer, Roche Molecular Systems, Inc.,
Branchburg, NJ., USA.) and 250 pM each of dGTP, dCTP, dATP and dTTP 
(Promega, Madison, WI., USA.). To control for contamination, a water control was 
also included and consisted of 5 pi of PCR-grade water instead of 5 pi of sample.
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The non-degenerate PCR primers HPRT FI (5' HEX-GATTCAACTTGCGCTCATCTT 
AGGC 3’) and HPRTR1 (5' GTTGGATACAGGCCAGACTTTGTTG 3') homologous 
to 5' (514-538 bases) and 3' (complementary to 652-678 bases) regions of the murine 
HPRT gene were previously designed (Svetic et a l, 1991). The primers were 
synthesised by the Biomolecular Resource Facility at the John Curtin School of Medical 
Research (Australian National University) and were supplied in ammonium hydroxide. 
HPRT FI was synthesised with a 5' HEX fluorescent label. Prior to use the primers 
were vacuum dried, washed and resuspended in PCR-grade water to the desired 
concentration. The PCR was run using a FTS-1 Thermal Sequencer (Corbett Research, 
Sydney, Australia) under the following conditions. Sampled were denatured at 94°C for 3 
minutes followed by 40 cycles of denaturation at 96°C for 1 minute, annealing at 50°C 
for 1 minute and extension at 72°C for 2 minutes . The reaction was then concluded with 
a 5 minutes extension at 12°C.
VI.2.3.1.3 Analysis of polymerase chain reaction products.
HPRT and eotaxin PCR products (1 |Ltl each) were combined and analysed by the 
Biomolecular Resource Facility of the John Curtin School of Medical Research 
(Australian National University). Briefly, the PCR products were electrophoresed 
through a 2% polyacrylamide gel and the fluorescence of individual DNA fragments 
quantified using the GeneScan Analysis 2.0.2 software package. Peaks of fluorescence 
corresponding to HEX (HPRT) and 6-FAM (eotaxin) emissions were detected at the 
expected PCR product sizes (165 and 533 bp respectively). Eotaxin levels were 
determined in relation to the levels of HPRT by dividing the peak fluorescent area of the 
eotaxin PCR product by peak fluorescent area of the HPRT PCR product.
The PCR products were also analysed by PAGE (see section III.2.1.6.2.1) for 
comparative purposes.
VI.2.3.2 Determination of the role of IL-4, IL-5 and IFNy on eotaxin 
mRNA expression at skin and lung sites of allergic inflammation.
IL-4_/', IL-5‘/_, IFNy/_ and the corresponding wild type mice were analysed for eotaxin 
mRNA expression (see section VI.2.3), relative to HPRT mRNA expression at skin and 
lung sites of allergic inflammation at times of peak eotaxin expression in the tissues 
[previously determined in wild type mice (3 and 6 hours respectively, see section 
V I.2.3.1)].
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VI.2.4 Eotaxin deficiency and eosinophilic responses during cutaneous 
late-phase reaction.
Eotaxin+/+ and eotaxin'/' mice were sensitised to Ova by i.p injection on days 0 and 12 
(see section V.2.1.1). Control groups received 1 mg of Alhydrogel (CSL, Parkville, 
Melbourne, Australia) in 0.2 mis of saline. On day 24 the sensitised mice received a s.c. 
injection of 50 jig of Ova plus 0.9 mis of air and the non-sensitised controls received a 
s.c. injection of 0.1 mis of saline and 0.9 mis of air. The accumulation of eosinophils at 
s.c. injection sites were quantified at 6 and 24 hours after s.c. injections (see section
V. 2.1.2). The levels of eosinophils in the blood and bone marrow of these mice were 
also determined at 0, 6 and 24 hours post s.c. injection (see sections II.2.2 and II.2.3, 
respectively).
VI. 2.5 The effect of eotaxin deficiency on pulmonary eosinophilia and 
the induction of airways hyperreactivity during allergic airways 
inflammation.
Eotaxin+/+ and eotaxin'/' mice were sensitised to Ova by i.p. injection on days 0 and 12 
(see section V.2.1.1). Non-sensitised controls received 1 mg Alhydrogel in 0.2 mis of 
saline only. On days 24 and 26 the sensitised mice were exposed to Ova aerosol (10 
mg/ml) in 0.9% saline for 3 x 30 minutes with 30 minute rests between exposures. The 
non-sensitised controls were exposed to saline aerosol only. On day 27,24 hours after 
the last aerosol exposure, groups were analysed for airways reactivity to i.v. ß- 
methylcholine (see section IÜ.2.11). This was immediately followed by the quantitation 
of BALF leukocyte levels (see section III.2.9). Circulating leukocytes were quantified 
on blood smears (section V.2.1.4), prepared from samples taken on days 23, 25 and 27 
(prior to the analysis of airways hyperreactivity).
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VI.3 RESULTS.
VI.3.1 Eotaxin'/" mice display abnormal blood and bone marrow levels 
following i.v. administration of eotaxin and IL-5, respectively.
In contrast to previous reports (Rothenberg et a i, 1996), eotaxin"/" mice did not have 
reduced basal levels of eosinophils in the circulation when compared with eotaxin+/+ 
mice (figure VI. 1). The i.v. administration of eotaxin (1.2 nmol/kg), IL-5 (100 
pmol/kg) or both of these cytokines together, induced a pronounced blood eosinophilia 
in eotaxin'/_ and eotaxin+/+ mice (129 Svev strain)(figure VI. 1), supporting previous 
observations in C57BL/6 mice (see section II.3.1). The level of eosinophilia induced by 
IL-5 was similar in eotaxin'/" and eotaxin+/+ mice (figure VI. 1). In contrast, eotaxin (1.2 
nmol/kg) induced a greater increase the level of eosinophils in the blood of eotaxin'/' 
mice than in the eotaxin+/+ mice (figure VI. 1). The i.v. coadministration of IL-5 (100 
pmol/kg) and eotaxin (1.2 nmol/kg) significantly elevated the levels of eosinophils in the 
circulation of eotaxin+/+ and eotaxin'/" mice above that induced by either of these 
cytokines alone (figure VI. 1).
The i.v. administration of eotaxin to eotaxin+/+ and eotaxin'/' mice did not affect the 
levels of eosinophils in the bone marrow when they were analysed at the peak of the 
blood eosinophilia. These results were similar to the observations of previous 
experiments in IL-5+/+ and IL-5'/' mice (section IV.3.1). The i.v. administration of IL-5 
(100 pmol/kg) to eotaxin+/+ mice caused a significant decrease in the level of eosinophils 
in the bone marrow when measured at the peak of the blood eosinophilia (30 minutes 
post i.v. injection). Although eosinophilic responses to i.v. IL-5 in the blood were not 
affected in the absence of eotaxin (figure VI. 1), there was an increase in the level of 
eosinophils in the bone marrow (figure VI.2). The i.v. coadministration of eotaxin and 
IL-5 did not alter the effect of IL-5 on eosinophil levels in the bone marrow of either the 
eotaxin+/+ or eotaxin'/' groups (figure VI.2). In order to clarify the mechanism involved 
in the elevation in eosinophils levels in the bone marrow of eotaxin-/" mice following i.v. 
administration of IL-5, bone marrow cells were lavaged from the right femurs of 
eotaxin+/+ and eotaxin-/' mice and were cultured with 30 nM rmIL-5 (a gift from 
Professor I. G. Young, John Curtin School of Medical Research, Australian National 
University) (figure VI.3). In the presence of IL-5, the levels of eosinophils in cultures 
of bone marrow cells from eotaxin+/+ mice were unaffected over 3 hours (figure VI.3).
In contrast, an increased proportion of eosinophils was observed in the cultures of bone 
marrow cells from eotaxin"/' mice (figure VI.3). Moreover, the increases in the 
percentage of eosinophils in these cultures were evident as early as 30 minutes after the
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Figure VI.l The effects of intravenous IL-5 and/or eotaxin 
administration on circulating eosinophil levels in mice in the absence of 
endogenous eotaxin.
Eotaxin+/+ and eotaxin*/* mice were injected i.v. with IL-5 (100 pmol/kg), 
eotaxin (1.2 nmol/kg), a combination of both of these cytokines or control 
vehicle [100 (il of 10 mM PBS/0.1% BSA (pH 7.4) ]. Blood samples were 
taken before, at 30 minutes and hourly after i.v. injection of the cytokines 
or control vehicle for differential quantification of leukocytes (Data 
shown for 0 and 30 minutes only at peak of eosinophilia). The i.v. 
administration of IL-5 and/or eotaxin induced a significant increase in 
circulating eosinophil levels. Responses to i.v. eotaxin, but not i.v. IL-5
were further amplified in the eotaxin*/' mice. The i.v. coadministration of 
IL-5 and eotaxin induced a significant increase in circulating eosinophil 
levels that was significantly greater than that induced by these cytokines 
alone. Results represent mean eosinophils/ml of blood ± SEM of groups 
of 5 mice. The significance of differences between experimental groups 
was analysed using the Student's unpaired Mest. Differences in means 
were considered significant if P <  0.05. < 0.02 compared with
eotaxin+/+ mice under the same conditions and **P < 0.05 compared with 
eotaxin or IL-5 alone in mice of the same genotype.
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Figure VI.2 The effect of intravenous IL-5 and/or eotaxin administration on 
the level of eosinophils residing in bone marrow.
Eotaxin+/+ and eotaxin'/' mice were injected i.v. with IL-5 (100 pmol/kg), 
eotaxin (1.2 nmol/kg) or control vehicle [100 fil of 10 mM PBS/0.1% BSA (pH 
7.4)]. Bone marrow eosinophil levels were quantified at the peak of the blood 
eosinophilia (30 minutes post i.v administration). Administration of i.v. IL-5 
induced a significant decreased in the level of eosinophils in the bone marrow of
the eotaxin+/+ mice. In contrast, i.v IL-5 induced a significant increase in the
level of eosinophils in the bone marrow of eotaxin"/' mice. The i.v. 
administration of eotaxin did not significantly effect the level of eosinophils in 
the bone marrow. Furthermore, eotaxin did not affect IL-5-induced mobilisation
of eosinophils in either the eotaxin"/' or eotaxin+/+ mice. Results represent mean 
percentage of eosinophils of total femur marrow cells of groups of 8 femurs 
from 4 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired t-test. Differences in means were
considered significant if P < 0.05. * P < 0.05 compared with eotaxin+/+ mice
given control vehicle i.v and **P < 0.01 compared with eotaxin'/' given control 
vehicle i.v. No significant differences were detected between means of the 
groups that received eotaxin plus IL-5 i.v and those that received IL-5 alone.
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Figure VI.3 The culture of bone marrow cells isolated from eotaxin^' mice 
with IL-5 leads to a rapid increase in eosinophil levels.
Bone marrow cells obtained from the femurs of eotaxin+/+ and eotaxin'/_ mice 
were incubated with 30 nM rmIL-5. Elevated levels of eosinophils were 
detected in the bone marrow cultures from eotaxin*/' mice at 30 minutes after 
the addition of IL-5 but not in the control treatment. There were no changes in 
eosinophil levels in eotaxin+/+ bone marrow cultures in the presence of IL-5 or 
in the control cultures for the duration of the experiment (3 hours). Results 
represent mean percentage of eosinophils of total bone marrow culture cells ± 
SEM. Bone marrow cells were obtained from 2 mice/group and were assayed 
in triplicate. The significance of differences between experimental groups were 
analysed using the Student's unpaired r-test. Differences in means were 
considered significant if P < 0.05. *P < 0.05 when compared with either
eotaxin_/‘ control, eotaxin+/+ in the presence of IL-5 or the eotaxin+/+ control 
groups at the same time or when compared with the eotaxnr/_ cultures prior to 
IL-5 exposure. **P < 0.02 when compared with either , eotaxin+/+ in the 
presence of IL-5 or the eotaxin-/' and eotaxin+/+ control groups.
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addition of the DL-5 (figure VI.3). This phenomena was specific for IL-5 since no 
changes in the proportion of eosinophils in the bone marrow cultures from eotaxin+/+ or 
eotaxin'/' mice were observed in the control treatment (figure VI.3).
VI.3.2 Eotaxin mRNA expression is enhanced at sites of allergic 
inflammation and is differentially regulated at skin and lungs sites of 
allergic inflammation by IL-4 and IFNy.
Eotaxin mRNA was quantified at skin and lung sites of allergic inflammation using semi- 
quantitative PCR analysis with reference to mRNA expression of the house keeping 
gene, HPRT (Svetic et a l, 1991). Eotaxin was constitutively expressed in the skin 
(figure VI.4a) and lungs (figure VI.4b) of antigen sensitised and non-sensitised mice. 
Similar observations have been reported in naive guinea pigs and mice (Rothenberg et 
a l,  1995a; 1995b).
Significant elevations in eotaxin mRNA expression were observed in the skin of the 
sensitised mice following the s.c. administration of Ova (figure VI.4a). No elevation in 
eotaxin mRNA expression was detected in the skin of the non-sensitised control mice 
following the s.c. administration of saline (figure VI.4a) suggesting that eotaxin does not 
promote non-specific eosinophils trafficking in response to saline administration. As 
previously observed in the allergic lungs of guinea pigs (Rothenberg et a l, 1995b) and 
mice (Gonzalo et a l, 1996b), the expression of eotaxin mRNA in the skin was enhanced 
soon after allergen provocation and this expression was transient (figure VI.4a). A 
significant elevation in eotaxin mRNA was detected at 3 hours following the s.c. 
administration of Ova, but not at any another time.
An elevation in the expression of eotaxin mRNA was also detected in the lungs of the 
sensitised mice following aeroallergen (Ova) challenge (figure VI.4b). In contrast, no 
elevation in eotaxin mRNA expression was detected in the non-sensitised mice following 
exposure to an aerosol of saline (figure VI.4b). As observed at sites of CLPR, the 
elevations in eotaxin mRNA expression in the allergic lungs of mice were detectable soon 
after aeroallergen exposure. Interestingly, in contrast to allergic skin and the previous 
reports of eotaxin mRNA expression in the allergic lungs of guinea pigs (Rothenberg et 
a l, 1995b) and mice (Gonzalo et a l,  1996b), the elevated expression of eotaxin mRNA 
in the allergic lungs was sustained. A significant elevation in the levels eotaxin mRNA in 
the lungs was first detected at 6 hours following the exposure to aeroallergen and the 
levels remained elevated for the duration of the experiment (24 hours) (figure VI.4b).
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Figure VI.4 The kinetics of eotaxin expression at skin and lung sites of 
allergic inflammation in mice.
Mice were sensitised to Ova by i.p. injection on days 0 and 12 and on day 24 cutaneous 
or airways inflammation was induced in sensitised mice by s.c. Ova administration or by 
Ova aerosol exposure, respectively. The non-sensitised controls received s.c. saline or 
were exposed to an aerosol of saline instead of Ova exposure. The levels of eotaxin 
mRNA at skin and lung sites was monitored over a 24 hours. Eotaxin mRNA 
expression was compared with HPRT mRNA expression and was determined using 
semi quantitative RT-PCR. (a) Eotaxin mRNA was maximally expressed at 3 hours post 
Ova administration in the skin of sensitised mice and fell thereafter. No significant 
increase in eotaxin mRNA expression relative to HPRT mRNA expression was 
detectable in non-sensitised mice in response to s.c. administration of saline, (b)
Elevated levels of eotaxin mRNA were detectable in the lungs of sensitised mice 6 hours 
post Ova aerosol exposure and remained elevated for a further 18 hours. No significant 
increase in eotaxin mRNA expression relative to HPRT mRNA expression was 
detectable in the non-sensitised mice after exposure to saline aerosol. The significance of 
differences between experimental groups were analysed using the Student's unpaired t- 
test. Differences in means were considered significant if P < 0.05. (a) *P < 0.02 when 
compared with non-sensitised mice 3 hours post s.c. injection of saline, (b) *P < 0.02 
when compared with non-sensitised mice 6 hours post exposure to saline aerosol.
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Figure YI.5 The effect of IL-5, IL-4 or IFNy deficiency on eotaxin 
expression during allergy of the skin and lung.
IL-5'/_, IL-4_/', IFNy^‘ and the respective wild type mice were sensitised to Ova by i.p. 
injection on days 0 and 12 and on day 24 cutaneous or airways inflammation was 
induced in sensitised mice by s.c. Ova administration or Ova aerosol exposure, 
respectively. The non-sensitised controls received s.c. saline or were exposed to an 
aerosol of sahne instead of Ova exposure. The levels of eotaxin mRNA at skin and 
lungs sites of allergic inflammation were determined at peak eotaxin expression times [3 
hours (in the skin) and 6 hours (in the lung) post antigen provocation]. Eotaxin mRNA 
expression was compared with HPRT mRNA expression and was determined using 
semi-quantitative RT-PCR. (a) Significantly higher levels of eotaxin mRNA expression 
were detectable at skin sites of allergic inflammation in wild type mice when compared 
with their non-sensitised controls at s.c. sites of saline administration. These elevations 
in eotaxin expression at sites of cutaneous allergy were significantly reduced in the 
absence of IFNy, but not in the absence of IL-5 or IL-4. (b) Significantly higher levels 
of eotaxin mRNA expression were detectable at sites of allergic airways inflammation in 
wild type groups when compared with their non-sensitised controls, that were exposed 
to an aerosol of saline. The elevations in eotaxin expression at sites of allergic airways 
inflammation were significantly reduced in the absence of either IL-4 or IFNy, but not in 
the absence of IL-5. Results represent mean ratio of eotaxin : HPRT mRNA levels of 
expression ± SEM of groups of 4-8 animals. The significance of differences between 
experimental groups was analysed using the Student's unpaired r-test and differences in 
means were considered significant if P < 0.05. (a) < 0.05 when compared with non-
sensitised/saline s.c. injected mice and **P < 0.05 when compared with sensitised 
IFNy+/+ mice administered Ova s.c. (b) < 0.05 when compared with non-sensitised
mice exposed to sahne aerosol and **P < 0.01 when compared with the sensitised wild 
type mice exposed to Ova aerosol.
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Increased levels of eotaxin mRNA expression were also detected at skin and lung sites of 
allergic inflammation (at 3 and 6 hours post allergen provocation, respectively) in 
sensitised IL-5+/+ (C57BL6), IL-4+/+ (129Sv/C57BL6) and IFNy<7+ (129SvEv) mice 
(figure VI.5). Furthermore, the elevations were equivalent in all of these groups when 
compared at the same site and time of analysis (3 hours at skin sites and 6 hours at lung 
sites).
The increased expression of eotaxin mRNA at skin sites of allergic inflammation was not 
attenuated in IL-4'/' or IL-5'/' mice (figure VI.5). In contrast, the levels of eotaxin 
mRNA in the skin did not increase in IFN-y/’ mice following s.c. allergen provocation 
(figure VI.5). No increase in eotaxin mRNA above basal levels was observed in the 
lungs of sensitised IFNy/' mice when measure 6 hours after aeroallergen challenge.c 
However, unlike the preceding experiments in allergic skin, allergen-induced expresion 
of eotaxin mRNA in the lungs were abolished in sensitised IL-4'/' mice (figure VI.5).
No role for IL-5 in the regulation of eotaxin mRNA expression at skin or lung sites of 
allergic inflammation was demonstrated.
VI.3.3 Eotaxin deficiency alters eosinophilic responses during cutaneous 
late-phase reaction in mice.
V I.3.3.1 E o ta x in ‘,m mice have impaired eosinophilic responses during  
cutaneous late-phase reaction , but exhibit high responses to s.c. 
adm inistered saline.
The accumulation of eosinophils at skin sites of allergic inflammation is biphasic (see 
section V.3.1.1). When measured at peak eosinophil infiltration times [6 and 24 hours, 
as determined in C57BL6 (section V.3.1.1) or BALB/c strains of mice (Iwamoto et al., 
1992)] significantly greater levels of eosinophils accumulated at sites of Ova-induced 
CLPR in eotaxin+/+ mice in comparison to skin sites of saline administration in non- 
sensitised controls (figure VI.6). In the absence of eotaxin (as assessed in eotaxin'/' 
mice) significantly lower level of eosinophils accumulated at sites of CLPR at 6 and 24 
hours post s.c. administration of Ova when compared with the eotaxin+/+ mice of the 
same treatment (figure VI.6). Interestingly, significantly higher levels of eosinophils 
accumulated at skin sites of saline administration in the non-sensitised eotaxin'/' when 
compared with the wild type mice (figure VI.6). Furthermore, in eotaxin'/' mice, the 
accumulation of eosinophils at s.c. sites of saline administration in non-sensitised mice 
were significantly greater that those in sensitised mice at s.c. sites of Ova administration 
(figure VI.6).
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Figure VI.6 The role of eotaxin in eosinophil trafficking during CLPR in 
mice.
Eotaxin+/+ and eotaxin'/_ mice were sensitised to Ova by i.p injection on days 
0 and 12 and on day 24 were challenged with 50 fig Ova by s.c. injection in
100 (il saline. Non-sensitised mice received s.c. saline only. The 
accumulation of eosinophils at sites of CLPR at 6 (first phase) and 24 (second 
phase) hours was significantly reduced in the eotaxin_/* mice when compared 
with the wild types. Significantly greater levels of eosinophils accumulated at 
s.c. sites of saline administration in the non-sensitised eotaxin_/' mice 
compared with non-sensitised eotaxin+/+ mice at 6 and 24 hours.
Furthermore, higher levels of eosinophils accumulated at skin sites of saline 
administration in the non-sensitised eotaxin*/_ mice at 6 hours than at sites of 
CLPR in the eotaxin_/_ mice at the same time. Results represent mean
eosinophils/mm2 ± SEM of groups of 5 animals. The significance of 
difference between experimental groups was analysed using the Student's 
unpaired Mest. Differences in means were considered significant if P < 0.05.
*P < 0.02 when compared with non-sensitised eotaxin+/+ mice given s.c. 
saline, at the same time point and **P < 0.02 when compared with the 
sensitised eotaxin+/+ given s.c. Ova, at the same time point.
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Figure YI.7 Levels of circulating eosinophils in eotaxin+/+ and eotaxinm/~ mice 
during CLPR.
Eotaxin+/+ and eotaxin'/_ mice were sensitised to Ova by i.p injection on days 0 and 12
and on day 24 were challenged with 50 jig Ova by s.c. injection in 100 [i\ saline. Non-
sensitised mice received s.c. saline only. Sensitised mice displayed higher levels of 
eosinophils in the blood in comparison to the non-sensitised controls. Following the
induction of CLPR, eotaxin+/+ mice had significantly lower circulating eosinophil levels 
in comparison to the non-sensitised saline controls, when compared at the same time 
point. Circulating levels of eosinophils in these mice at 6 and 24 hours were also 
significantly lower than the levels in these mice prior to s.c. Ova provocation. In contrast, 
the sensitised eotaxin_/" mice had significantly higher levels of eosinophils in the blood at
6 hours post Ova administration than the non-sensitised saline eotaxnW- controls at the 
same time point. The elevated blood levels of eosinophils in these mice at 6 hours post 
Ova administration were significantly higher than the levels in these mice prior to the 
induction of CLPR. There were no differences between the circulating eosinophils levels 
in the non-sensitised saline controls and the non-treated control group. Results represent 
mean eosinophils/ml of blood ± SEM of groups of 5 animals. The significance of 
differences between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. < 0.05 when compared
with the non-sensitised eotaxin+/+ saline control at the same time p o i n t < 0.002 when
compared with the non-sensitised eotaxnr/_ saline controls at 6 hours post s.c. saline 
injection. There was no significant differenced between the means of the saline injected
non-sensitised eotaxin+/+ and eotaxin_/’ groups when compared at any given time.
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VI.3.3.2 E otaxinm,m mice exhibit blood eosinophilia during cutaneous 
late-phase reaction, in contrast to wild type mice.
The levels of eosinophils in the circulation of the sensitised eotaxin+/+ and eotaxin_/" mice 
were significantly higher than their respective non-sensitised controls (figure VI.7). As 
previously observed in IL-5+/+ mice (see section V .3.1.1), the blood levels of 
eosinophils in the sensitised eotaxin+/+ mice at 6 and 24 hours post s.c. antigen 
challenge were significantly reduced in comparison to the blood levels of eosinophils of 
the non-sensitised saline controls or when compared to the blood levels of eosinophils 
prior to the induction of CLPR (figure VI.7). In contrast, the sensitised eotaxin_/" mice 
developed a significant blood eosinophilia at 6 hours post s.c. Ova provocation (figure 
VI.7). At 24 hours post antigen administration these mice no longer exhibited blood 
eosinophilia compared to the non-sensitised eotaxin'/_ saline controls although the level 
of eosinophils in the blood of the mice were significantly higher than that in the 
sensitised eotaxin+/+ mice (figure VI.7).
VI.3.3.3 E oiaxinm,m mice have enhanced eosinophilic responses in the 
bone morrow during cutaneous late-phase reaction compared with wild 
type mice.
The levels of eosinophils in the bone marrow of eotaxin+/+ and eotaxin'/_ mice during 
CLPR were also examined (figure VI.8). The sensitisation of eotaxin+^+ mice to Ova 
induced an increase in the level of eosinophils in the bone marrow in comparison with 
the non-sensitised and non-treated eotaxin+/+ controls (figure VI. 8). There was also a 
reduction in the level of eosinophils in the bone marrow of the sensitised eotaxin+/+ mice 
24 hours after the s.c. administration of Ova (figure VI.8). In contrast, the s.c. 
administration of saline to the non-sensitised wild type controls had no effect of the 
levels of eosinophil in the bone marrow (figure VI.8).
In contrast to wild type mice, the non-sensitised and sensitised eotaxin‘/_ mice had 
significantly higher levels of eosinophils in the bone marrow compared to their non- 
treated groups (figure VI.8). There was a reduction in eosinophil levels in the bone 
marrow of the sensitised eotaxin'/_ mice 6 and 24 hours after the s.c. administration of 
Ova. Similar to the non-sensitised eotaxin+/+ mice there was no change in the levels of 
eosinophils in the bone marrow of the non-sensitised eotaxin_/" mice following the s.c. 
administration of sahne.
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Figure VI.8 Levels of eosinophils in the bone marrow of eotaxin+/+ and 
eotaxin'1' mice during CLPR.
Eotaxin+/+ and eotaxin'/_ mice were sensitised to Ova by i.p injection on days 0 
and 12 and on day 24 were challenged with 50 fig Ova by s.c. injection in 
100 [il saline. Non-sensitised mice received s.c. saline only. Ova sensitisation
increased eosinophil levels in bone marrow. Non-sensitised control eotaxin_/‘ 
mice also had significantly higher levels of eosinophils in bone marrow 
compared with non-treated mice. Eosinophil levels in bone marrow were
decreased in eotaxin'/' mice at 6 and 24 hours following s.c. Ova provocation.
Bone marrow eosinophil levels were also reduced in eotaxin+/+ mice following 
Ova provocation, but only at 24 hours. S.c. administration of saline to non- 
sensitised eotaxin+/+ and eotaxnr/_ mice did not effect levels of eosinophils in 
bone marrow. Results represent mean eosinophils/ml of blood ± SEM of 
groups of 5 animals. The significance of differences between experimental 
groups was analysed using the Student's unpaired Mest. Differences in means 
were considered significant if P < 0.05. *P < 0.05 when compare with levels in 
non-treated mice. **P < 0.01 when compare with levels prior to s.c. Ova 
provocation and ***P < 0.02 when compared with non-treated and non- 
sensitised groups.
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VI.3.4 Eotaxin deficiency does not effect the accumulation of 
eosinophils in the lungs or the induction of airways hyperreactivity 
following aeroallergen provocation.
Allergic airways inflammation was induced in eotaxin+/+ and eotaxin"/" mice to determine 
if this cytokine has any significant role in the accumulation of eosinophils in the lungs or 
the induction of airways hyperreactivity, during allergic airways inflammation. The 
exposure of sensitised eotaxin+/+ mice to an aerosol of Ova on days 24 and 26 induced a 
selective accumulation of eosinophils in the airways on day 27 (figure VI.9). In 
contrast, the non-sensitised eotaxin+/+ mice that were exposed to aerosol of saline for an 
equivalent duration did not have any significant levels of eosinophils in the BALF.
The sensitised eotaxin'/' mice that were exposed to an aerosol of Ova on days 24 and 26 
displayed an equivalent and selective (figure VL9$) elevation in the levels
of eosinophils in the BALF when compared to the wild type mice of the same treatment 
(figure VI.9). Similar to the observations in eotaxin+/+ mice, no significant levels of 
eosinophil were detectable in the BALF of the non-sensitised eotaxin'/“ mice after their 
exposure to saline aerosol (figure VI.9*). This was in contrast to observations in the 
skin where eotaxin deficiency was associated with a hypereosinophilic response at site of 
saline administration. No significant elevation in the levels of eosinophils in the blood of 
any of the groups were detected (results not shown).
The duration of aeroallergen exposure in these series of experiments was chosen based 
upon prior observations that indicated that this was the minimum period of antigen 
exposure in this model of allergic airways inflammation that was required for the 
induction of airways hyperreactivity. Associated with the elevation in the levels of 
eosinophils in the BALF of sensitised eotaxin+/+ and eotaxin'/' mice (figure VI.9Ä) was 
the development of airways hyperreactivity when compared with the non-sensitised 
saline aerosol controls of either genotype (figure VI. 10). Furthermore, the development 
of airways hyperreactivity was not impaired or enhanced in the absence of eotaxin.
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Figure VI.9 The levels o f leukocytes in BALF of eotaxin+/+ and 
eotaxin~,m mice following aeroallergen provocation.
Eotaxin+/+ and eotaxin'/' mice were sensitised to Ova by i.p. injection on days 0 
and 12 . On days 24 and 26 the sensitised mice were exposed to Ova aerosol and 
the non-sensitised controls were exposed to saline aerosol only. Leukocytes 
levels were quantified in the BALF 24 hours after the last aerosol exposure. Ova 
sensitised/challenged groups had significantly greater levels of eosinophils in 
BALF when compare with non-aonsitod/saline aerosol exposed controls. Levels 
of lymphocytes, neutrophils and macrophages were not increased in Ova 
sensitised/challenged groups when compared with non-sensitised/saline aerosol
exposed controls. Levels of leukocytes in eotaxin'/' groups were not different
from eotaxin+/+ groups of the same treatement. Results represent mean cells/ml 
of BALF ± SEM of groups of 5-6 animals. The significance of differences 
between experimental groups was analysed using the Student's unpaired r-test. 
Differences in means were considered significant if P < 0.05. *P < 0.001 when 
compared with levels in non-sensitised groups.
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Figure VI.10 Eotaxin+/+ and eotaxin~/m mice exhibit equivalent airways 
hyperreactivity following aeroallergen provocation.
Eotaxin+/+ and eotaxin_/_ mice were sensitised to Ova by i.p. injection on days 0 
and 12 . On days 24 and 26 the sensitised mice were exposed to Ova aerosol and 
the non-sensitised controls were exposed to saline aerosol only. Airways
hyperreactivity to i.v. ß-methylcholine was measured on day 27, 24 hours after the
final exposure to aerosol. Ova sensitised/challenged mice exhibited airways 
hypereactivity when compare with non-sensitised/saline aerosol exposed controls.
No significant differences in airways reactivity were detected between eotaxin+/+
and eotaxin‘/_ groups of the same treatment. Airways reactivity was measured by
monitoring i.v. ß-methylcholine-induced changes in respiratory overflow volume.
Data represents mean percentage airway occlusion ± SEM of groups of 5 mice. 
The significance of differences between experimental groups was analysed using 
the Student's unpaired Mest. Differences in means were considered significant if 
P < 0.05. *P < 0.05 and **P < 0:01 when compare with saline controls at the
same dose of ß-methylcholine.
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V I.4 DISCUSSION.
Mice constitutively express eotaxin in numerous tissues and it has been suggested that 
this chemokine may regulate the basal migration of eosinophils through tissues 
(Rothenberg et al., 1995b). Eotaxin"/' mice also have lower levels of eosinophils 
residing in the intestinal mucosa and in the thymus (levels have not been characterised in 
other tissues) (Mathews et al., 1998). In addition, eotaxin was thought to regulate basal 
levels of circulating eosinophils (Rothenberg et al., 1997), although the eotaxin"/' mice 
used in this study did not have lower circulating levels of eosinophils when compared 
with eotaxin+/+ mice. Interestingly, the i.v. administration of eotaxin to eotaxin'/' mice 
induced a blood eosinophilia that was significantly greater than that induced by this 
chemokine in wild type mice. Furthermore, the movement of eosinophils into the 
circulation of both eotaxin"/' and eotaxin+/+ mice in response to i.v. eotaxin did not 
require the mobilisation of bone marrow stores of this leukocyte. These results suggest 
that the enhanced blood eosinophilia in the eotaxin'/' mice in response to the i.v. eotaxin, 
involved a greater sequestrating of eosinophils out of tissues into the circulation. An 
explanation for the hypereosinophilic response to eotaxin in eotaxin-/* mice may involve 
sensitisation of signalling through the CCR3 receptor. C-C chemokines induce transient 
Ca2+ fluxes in eosinophils which are coupled with chemotactic responses and regulation 
of adhesion molecule expression (Forssmann et al., 1997). The exposure of eosinophils 
to eotaxin has been shown to desensitise these cells to subsequent Ca2+ responses 
elicited by eotaxin or other CCR3 binding CC-chemokines (Forssmann et al., 1997). In 
wild type mice, basal levels of eotaxin may modulate CCR3 signalling pathways that 
constitutively regulate chemotactic responsiveness of eosinophils. In the absence of such 
regulation, eosinophils may become hyperresponsive to chemokines that signal thorough 
CCR3. Thus, eotaxin may regulate eosinophil function by directly modulating CCR3 
function and subsequent migratory processes. Interestingly, the action of IL-5 on the 
induction of blood eosinophilia occurs independently of eotaxin, supporting the concept 
that these two cytokines may act via different mechanisms to induce blood eosinophilia in 
mice (Chapter IV).
In eotaxin-/" mice, IL-5-induced blood eosinophilia correlated with the mobilisation of 
eosinophils from the bone marrow and this response was not diminished in the absence 
of eotaxin. These results suggest that eotaxin is not required to mobilise this pool of 
eosinophils. However, the rapid induction of eosinophilia in the bone marrow of 
eotaxin'/" mice following the i.v. administration of IL-5 suggests that eotaxin may play a 
role in the regulation of IL-5-induced eosinophil differentiation. Notably, eosinophil 
progenitor cells from eotaxin"/" mice were hyperresponsiveness to IL-5 in vitro (figure 
VI.3). This suggests that eotaxin plays a regulatory role with IL-5 in eosinophil 
differentiation in the bone marrow. However, eotaxin-/' mice have normal resting levels
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of eosinophils in the bone marrow (compared to wild types mice), suggesting that 
eotaxin does not have an obligatory role in basal eosinophil differentiation.
In an attempt to determine what cytokines regulate eotaxin expression, at baseline and 
during allergy, levels of mRNA expression were characterised in factor deficient mice. 
Constitutive eotaxin mRNA expression was observed in the lungs and in the skin. 
Interestingly, other investigations have failed to detect mRNA for this chemokine in 
either of these tissues in mice (Gonzalo et al, 1996). Notably, eotaxin expression was 
upregulated at sites of allergic inflammation and increased expression occurred soon after 
antigen exposure, supporting a role for this chemokine in early eosinophil trafficking 
events (Rothenberg et al., 1997). The prolonged expression of eotaxin in the allergic 
lung compared to allergic skin suggests a differential temporal role for eotaxin in the 
regulation of eosinophil trafficking at different tissue sites of allergic disease. Notably, 
the elevations in expression of eotaxin mRNA at both sites of allergic inflammation were 
dependent on IFN-y and independent of IL-5. Interestingly, antigen-induced increases in 
eotaxin expression in the lung, but not in the skin, were also dependent on IL-4. Thus, 
IL-4 may selectively regulate the expression of eotaxin in the lungs. These results 
suggest that eotaxin expression may be differentially regulated by cytokines at mucosal 
(lung) and non-mucosal sites (skin) of allergic inflammation. The observation that the 
expression of eotaxin mRNA in allergic lungs did not increase in the absence of either 
IL-4 or IFNy, suggests that these molecules may act together to activate eotaxin 
expression.
Although the expression of eotaxin mRNA was upregulated in the skin and in the lungs 
at sites of antigen provocation, eosinophil recruitment at sites of allergic inflammation 
was dependent on eotaxin only in the skin. Elevated expression of eotaxin mRNA at 
sites of CLPR was observed in wild type mice at 3 hours post antigen administration, but 
not at later time points. Interestingly, the accumulation of eosinophils at sites of CLPR 
was impaired during both the early (6 hours) and late (24 hours) infiltration phases in 
eotaxin'/' mice. This suggest that either eotaxin is very stable and remains active at sites 
of cutaneous inflammation for long periods or that eotaxin activates a second pathway 
leading to the generation of other eosinophil chemoattractants. Furthermore, levels of 
circulating eosinophils at 6 and 24 hours post s.c. antigen administration in eotaxin'/' 
mice were not diminished in contrast to wild type mice indicating that eosinophil 
recruitment into sites of CLPR was impaired. In addition, there was a direct correlation 
between the decreased accumulation of eosinophils at sites of CLPR and an elevation in 
the levels of eosinophils in the circulation. Interestingly, there was a decrease in the 
levels of eosinophils in the bone marrow of eotaxin+/+ mice during the later stages, but 
not early stages of CLPR (figure VI.8). These results suggest that eosinophil trafficking 
during the early stages of CLPR does not solely rely on a pronounced mobilisation of
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eosinophils from the bone marrow, and thus may depend on the available circulating 
pool of eosinophils. In contrast, the levels of eosinophils in the bone marrow of eotaxin' 
/' mice were reduced during the early stages of CLPR as well as during the later stages. 
Early mobilisation of eosinophils from the bone marrow may account for the increased 
blood levels of eosinophils in the eotaxin'/' mice during the early phase of CLPR. These 
observations may reflect the hypersensitivity of eosinophil progenitor differentiation to 
IL-5 in eotaxin'/' mice that was observed in vitro (figure VI.3). However, Although 
additional inflammatory factors may act with IL-5 to facilitate eosinophil mobilisation 
from bone marrow during allergy since i.v. administration of IL-5, in isolation, 
enhanced eosinophil levels in the bone marrow, but not the blood, of these animals. 
These results suggests that eosinophil mobilisation from the bone marrow during allergy 
is regulated, in part, by eotaxin.
The accumulation of eosinophils at sites of CLPR was reduced in eotaxin'/' mice. 
Furthermore, blood eosinophil levels did not decrease in eotaxin'/" mice following 
antigen provocation (in contrast to wild type mice) indicating that eotaxin'/" mice had 
impaired eosinophil recruitment. Collectively, these data show a role for eotaxin in 
eosinophil trafficking during CLPR. Interestingly, non-sensitised eotaxin"/" mice 
accumulated high levels of eosinophils at skin sites of saline administration and these 
results suggest that eotaxin negatively regulates eosinophil trafficking in the skin in 
response to non-specific stimuli (such as tissue trauma). This is despite the observation 
that following s.c. administration of saline, eosinophil levels in the circulation of 
eotaxin'/' mice were not significantly different from those of wild type mice. 
Furthermore, the pronounced eosinophilic response at s.c. sites of sahne administration 
in eotaxin’/' mice was not associated with any decrease in the levels of eosinophils in the 
blood or bone marrow, unlike responses to s.c. Ova in sensitised eotaxin-/' mice. The 
accumulation of eosinophils at sites of sahne administration may involve the production 
of EL-5, LTB4 or IL-8 (Oliveira et al., 1996) and hypereosinophilic responses in eotaxin" 
/' mice may be due to increased sensitivity of eosinophils to these molecules. Although 
the mechanism underlying enhanced response to saline in eotaxin-/' mice remains to be 
elucidated, these observations further support a role for eotaxin in the regulation of 
eosinophil trafficking at base line and perhaps in response to tissue injury.
Unlike wild type mice, the i.p. injection of eotaxin-/- mice with adjuvant (Alhydrogel) in 
sahne (which serves as a control for the Ova i.p. sensitisation) induced an elevation in 
the level of eosinophils in the bone marrow. Intraperitoneal administration of saline to 
rats has been shown to induce a peritoneal eosinophilia which may be regulated by the 
local production of eosinophil chemoattractants, including IL-5 (Oliveira et a l, 1996). 
The production of IL-5 in response to sahne administration may induce eosinophil
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differentiation in the bone marrow of eotaxin'/' mice due to the haemopoietic sensitivity 
to this cytokine in these animals.
Interestingly, in contrast to the trafficking of eosinophils at sites of CLPR, no role for 
eotaxin in the accumulation of eosinophils to the allergic lung was observed. Previous 
experiments by Rothenberg et ai, (1997) also failed to find differences between the 
number of eosinophils recruited to the airways of eotaxin'/" and eotaxin+/+ mice during 
late-phase responses. However, the accumulation of eosinophils in the lungs during the 
early stage of allergic airways inflammation was significantly impaired in the absence o f 
eotaxin (Rothenberg et a i, 1997). Previously it was shown (Chapter V) that the 
development of airways hyperreactivity in both IL-5+/+ and IL-5'/' mice correlates with 
the levels of eosinophils and MBP in the BALF. This suggest that in this model of 
allergic airways inflammation, the development of airways hyperreactivity is mediated by 
eosinophils and is associated with the presence of MBP. Since allergic eotaxin+/+ and 
eotaxin_/' mice exhibited equivalent elevations in airways eosinophilia and 
responsiveness to ß-methylcholine (above the non-allergic controls), it was concluded 
that eotaxin has no obligatory role in eosinophil activation/degranulation and the 
induction of airways hyperreactivity during the late-phase reaction.
In conclusion, eotaxin regulates eosinophilic responses at basal states in the blood and in
tissues (in response to non-specific stimuli). This chemokine also modulates the e ffec t
of IL-5 on haeomopoiesis. During allergic responses, eotaxin is produced at sites of
inflammation and the stimulation of expression is differentially controlled by the
cytokines IFNy and IL-4 in the skin (non-mucosal) and the lung (mucosal). Eotaxin
promotes eosinophil recruitment to sites of CLPR, but is not required for the recruitm ent
of eosinophils into the lungs, nor for the development of airways hyperreactivity, d u rin g
e 3\V*jr easw\opm\ cWero<jttfoäa*fs as IL-S 
the later stages of allergic inflammation. Although these results indicate that eotaxin
regulates eosinophil function, this chemokine does not play an obligatory role in this <yeaVer ro\e
process.
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CHAPTER VII
THE ROLE OF IL-5, IL-4, TNF-cc and IL-lß IN 
EOSINOPHIL RECRUITMENT DURING 
ALLERGIC CUTANEOUS LATE-PHASE 
REACTIONS IN MICE
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VII.1 INTRODUCTION.
Elevated levels of IL-5 are found in the B ALF and sera of asthmatics and at sites of 
allergic inflammation in mice (Walker et al., 1992; Ohkawara et al., 1997). IL-5 has also 
been shown to play a key role in regulating blood eosinophilia and thus, subsequent 
tissue eosinophilia, during allergic responses in mice (Foster et al., 1996) demonstrating 
the importance of this molecule in eosinophil trafficking. Furthermore, eosinophil 
recruitment to sites of chemotactic stimuli (IL-5 and eotaxin, Chapter IV) and at base line 
is markedly attenuated in the absence of IL-5 suggesting that this cytokine may also play 
important roles in modulating the accumulation of eosinophils in tissues by activating 
homing and adhesion pathways.
However, although IL-5 may regulate eosinophil trafficking at various steps in the 
recruitment mechanism during allergy and during baseline, this cytokine does not play an 
obligatory role in eosinophil homing during allergic CLPR (section V.3.1).
A number of cytokines, through activation of adhesion molecules, may also play key 
roles in regulating eosinophil migration into tissues during allergic responses. In 
particular, IL-4, TNF-a and IL -lß have been implicated in vitro in the regulation of 
eosinophil transmigration by upregulating ICAM-1 and VCAM-1 expression on the 
vascular endothelium (Lamas et al., 1988; Schleimer et al., 1992; Ebisawa et al., 1992; 
Briscoe et al., 1992; Shimizu et al., 1992; Wardlaw, 1993; Acevedo et al., 1993; Pober et 
al., 1996). Eosinophil recruitment to sites of allergic inflammation in the lung is 
dependent on ICAM-1 and VCAM-1 in mice (Gonzalo et al., 1996a). Furthermore, 
elevated levels of IL-4 and TNF-a are observed in the sera and B ALF of sensitised mice 
following allergen provocation (Ohkawara et al., 1997) and this implies that these 
molecules activate adhesion systems during allergic responses.
Although IL-4, TNF-a and IL -lß upregulate adhesion pathways used by eosinophils and 
are found at sites of allergic inflammation, their combined and individual roles in 
regulating eosinophil migration to sites of allergen provocation are unknown. Recently, a 
role for IL-4, TNF-a and IL -lß individually (but not IL-5), in the promotion of 
eosinophil recruitment to sites of hapten administration in a murine model of 
cyclophosphamide-induced tissue eosinophilia was demonstrated (Satoh et al., 1997). 
These studies suggest that neither IL-4, TNF-a nor IL -lß are redundant in the trafficking 
of eosinophils, since mAbs to each of these cytokines inhibited eosinophil recruitment at 
sites of hapten administration. In contrast, anti-IL-5 mAb had no effect on the 
accumulation of eosinophils, suggesting that local IL-5 is not required for eosinophil 
homing or that this cytokine is not involved in hapten-induced eosinophilia. Humeral 
responses are strongly inhibited by cyclophosphamide and the adhesion pathways utilised
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during hapten-induced eosinophilia may differ from those required for allergic 
eosinophilia.
The aim of experiments in this chapter was to define the role that IL-4, TN F-a and IL-1 ß 
play in regulating tissue eosinophilia during CLPR, with a view to identifying the 
elemental signals regulating eosinophil homing during allergic responses. The 
relationship between IL-5 and these cytokines for eosinophil recruitment to sites of CLPR 
was also determined. In addition, since IL-5, IL-4, TNF-a and IL-lß have all been 
implicated in activating ICAM-1 and VCAM-1 adhesion systems, the usage of these two 
adhesion pathways by eosinophils during recruitment processes to sites of allergic CLPR 
was also determined.
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VII.2 MATERIALS AND METHODS.
VII.2.1 Dissecting the role of adhesion systems involved in eosinophil
recruitment during cutaneous late-phase reaction.
CLPR was induced in mice (C57BL6, male, 6-8 weeks of age) (see section V.2.1.1).
On day 24, the mice received a i.v. co-injection of 100 pg of rat anti-mouse ICAM-1 
(clone; YN1, a gift from Dr N. King, University of Sydney, Australia), and rat anti­
mouse VCAM-1 (clone; MK1.9, a gift from Dr M. E. Rothenberg, Childrens Hospital 
Medical Centre, Cincinnati, OH., USA.) or 100 pg of either of these anti-adhesion 
molecule antibodies plus 100 pg of the control IgG mAb (clone; GL113) to keep the total 
amount of antibody given constant. The control group received 200 pg of control rat IgG 
(GL113). Thirty minutes later, CLPR was induced by s.c. injection of 50 pg of Ova in 
100 pi of 0.9% sahne. The levels of eosinophils at skin sites of Ova administration and 
in the circulation of the mice were quantified 6 hours after the s.c. administration of Ova 
(see sections II.2.4 and II.2.2). The accumulation of eosinophils was measured at 6 
hours (the peak of the first phase of eosinophil infiltration into the skin) rather that at 24 
hours (the peak of the second phase of eosinophil recruitment) because eosinophil 
recruitment was reported to be partially independent of IL-5 at 6 hours and dependent on 
IL-5 at 24 hours (Iwamoto et a l ,  1994).
VII.2.2 Analysing the role of TNF-a, IL-4, and IL-lß in the recruitment 
of eosinophils at sites of cutaneous late-phase reaction in IL-5'/- mice.
IL-5"/' mice were sensitised to Ova by i.p. injection on days 0 and 12 (see section 
V.2.1.1). On day 24, the mice were given a s.c. administration of 0.9 mis of air and 50 
pg of Ova in 100 pi of saline containing 20 pg of rat anti-mouse TN F-a mAb (clone; 
G281-2626; Pharmingen, San Diago, CA., USA.) and/or 20 pg of rat anti-mouse IL-4 
mAb (11B11) and/or 20 pg of hamster anti-mouse IL-lß mAb (Genzyme, Cambridge, 
MA., USA.) or 60 pg of isotype control antibodies [40 pg of rat IgG, clone; GL113 and 
20 pg of hamster anti-TNP IgG (clone; G235-2356, Genzyme, Cambridge, MA., 
USA.)]. The total amount of antibody given to any one animal was maintained at 60 pg 
by substituting isotype control mAbs for the respective monoclonal rat anti-mouse 
TNF-a (rat IgG), rat anti-mouse IL-4 (rat IgG) or hamster anti-mouse IL-lß antibodies 
(hamster anti-TNP IgG). The accumulation of eosinophils at skin sites of Ova 
administration and eosinophil levels in the circulation were quantified at 6 hours post s.c. 
administration of Ova (see sections II.2.4 and II.2.2). Eosinophilic responses in the skin 
and in the blood were also analysed at 6 hours rather than at 24 hours post Ova 
administration as describe above, but also so that comparisons could be made between
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these cytokines and ICAM-1- and VCAM-1- dependent eosinophil recruitment pathways 
(as outlined in section VII.2.1.)
VII.2.3 Analysis of the role of TNF-a and IL-4 in eosinophil recruitment 
mechanisms during cutaneous late-phase reaction in wild type mice.
Since the treatment of IL-5'/_ mice with anti-TNF-cx or anti-IL-4 mAs reduced the 
accumulation of eosinophils in the skin at sites of Ova provocation, the role of these 
cytokines in eosinophil recruitment in wild type mice (ie. in the presence of IL-5) at sites 
of CLPR was also examined. CLPR was also induced (see section V.2.1.1) in TNF
receptor deficient (P55/P75'M mice, IL-4'/'mice and their wild type littermates (both
- A  V.rom AlUsW
129Sv/C57BL6 cross). P557P75'/_ and IL-4‘/_ mice were used preferentially in these 
experiment/instead of treating wild type mice with antibodies against TNF-a and IL-4. 
The accumulation of eosinophils at skin sites of Ova administration and eosinophil levels 
in the circulation were quantified at 6 hours post s.c. administration of Ova on day 24 
(see sections II.2.4 and II.2.2). Non-sensitised control received a s.c. injection of saline 
and the accumulation of eosinophils at injection sites and in the circulation were also 
quantified 6 hours later (see sections II.2.4 and n.2.2).
Since a reduction in the accumulation was observed at sites of CLPR in the IL-4'/_ mice, 
eosinophil homing to sites of CLPR was examined at 6 hours post s.c. injection on day 
24, by monitoring the homing of adoptively transferred H33342-labelled eosinophils to 
sites of Ova or saline administration (see section V.2.1.3).
Because anti-IL-4 and anti-TNF-a mAbs each reduced the accumulation of eosinophils at 
sites of CLPR in IL-5_/' mice (see section VII.3.2), but not in wild types (see section 
Vn.3.3), IL-4 and TNF-a may have overlapping functions with IL-5 in the promotion of 
eosinophil recruitment at sites of allergic inflammation. To determine if IL-5 could take 
the place of IL-4 and TNF-a to promote eosinophil recruitment at sites of allergic 
inflammation, eosinophil recruitment 6 hours after Ova provocation (CLPR, see section 
IV.2.2.1) was assessed in wild type mice treated with 20 pg of rat anti-mouse TN F-a 
mAb (Pharmingen, San Diago, CA., USA., clone; G281-2626) and 20 pig of rat anti­
mouse IL-4 (clone; 11B11). The control group received 40 pig of isotype control mAb 
(clone; GL113) and all of these mAbs were co-administered s.c. with the 50 pg of Ova. 
Antibody treatments were used in this experiment since mice deficient for both TNF-a 
and IL-4 were unavailable.
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VII.3 RESULTS.
VII.3.1 Eosinophils utilise both ICAM-1 and VCAM-1 adhesion pathways 
during recruitment at sites of cutaneous late-phase reaction.
Pretreatment of mice with anti-ICAM-1 or anti-VCAM-1 mAbs caused a significant 
reduction in the accumulation of eosinophils at sites of Ova-induced CLPR, when 
measured at 6 hours (figure VH. la). Furthermore, the simultaneous treatment of mice 
with both of these mAbs was significantly more effective at inhibiting the accumulation of 
eosinophils at sites of allergic inflammation in the skin than either one alone (figure 
VII. la). Treatment of mice with the control antibody had no effect on eosinophilic 
responses in the skin of mice when compared to groups that did not receive antibody 
(figure V n .la )
The levels of eosinophils in the blood of mice that received anti-VCAM-1, anti-ICAM-1 
or control mAbs i.v. were inversely proportional to level of accumulation of this cell at the 
site of CLPR, when measured at 6 hours. The mice that received anti-ICAM-1 and/or 
anti-VCAM-1 mAbs had significantly (P < 0.05) higher levels of eosinophils in the blood 
6 hours after the s.c. administration of Ova when compared with the control mAb treated 
mice. Eosinophilic responses in the blood of mice at 6 hours were not affected by control 
antibody treatment (figure VII.lb).
VII.3.2 IL-4 and TNF-a have important roles in eosinophil recruitment 
during cutaneous late-phase reaction.
The roles of IL-4, TN F-a and IL-lß in the recruitment of eosinophils at sites of CLPR 
were examined in IL-5'^' mice. The s.c. treatment of IL-5'^' mice with control mAb did 
not effect the accumulation of eosinophils at sites of CLPR at 6 hours (figure VII. 2a). 
Treatment with anti-IL-4 or anti-TNF-a mAbs significantly inhibited the accumulation of 
eosinophils at sites of Ova-induced CLPR at 6 hours. Interestingly, the effect of both of 
these mAbs together was not greater than the effect of either one of these mAbs alone.
The treatment of mice with anti-IL-lß mAb had no effect on the accumulation of 
eosinophils.
The levels of eosinophils in the blood of sensitised wild type and IL-5_/'  mice were 
significantly reduced following s.c. Ova provocation in the absence of antibody treatment 
(see section V.3.1). The s.c. administration of the control mAbs at sites of Ova 
provocation did not effect eosinophilic responses in the blood at 6 hours in IL-5'/_ mice 
(figure VE.2b).
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Figure VII.l Eosinophil recruitment at sites of cutaneous late-phase 
reaction in /L-5+/+ and IL-5',m mice is dependent on both ICAM-1 and 
VCAM-1 adhesion pathways .
IL-5+/+ and IL-5_/‘ mice were sensitised to Ova by i.p. injection on days 0 and 12. On 
day 24 the mice received an i.v. injection of (1) rat anti-mouse ICAM-1 (100 (ig) and rat 
anti-mouse VCAM-1 (100 fig); isotype control mAb (GL113, 200 gig); rat anti-mouse 
ICAM-1 and isotype control mAb (GL113, 100 (ig) or rat anti-mouse VCAM-1 (100 fig) 
and isotype control mAb (GL113, 100 fig). After administration of antibodies a s.c. co­
injection of 50 (ig of Ova in 100 |il of saline plus 900 (il of air was performed. To 
compare the effect of control antibody treatment on eosinophilic responses at s.c. 
injection sites and in the blood sensitised mice were given a s.c. injection Ova and air and 
non-sensitised mice were given a s.c injection of saline and air only in the absence of i.v. 
mAb. All groups were sacrificed at 6 hours post s.c. injections and eosinophils at skin 
sites and in the circulation quantified, (a) The treatment of IL-5+/+ and IL-5'/_ mice with 
anti-ICAM-1 or anti-VCAM-1 mAbs reduced the accumulation of eosinophils at sites of 
CLPR. Furthermore, in combination these antibodies further inhibited the accumulation 
of eosinophils at skin sites. Data represents mean eosinophils/mm2 ± SEM of groups of 
5 mice, (b) As above for (a) the Ova-induced reduction in the levels of eosinophils in the 
circulation at 6 hours. Data represents the mean eosinophils/ml blood ± SEM of groups 
of 5 animals. The significance of differences between experimental groups was analysed 
using the Student's unpaired r-test. Differences in means were considered significant if p 
< 0.05. (a) *P < 0.05 when compared with the mice that were treated with the isotype 
control mAb and ** p < 0.05 compared with the mice that received anti-ICAM-1 or anti- 
VCAM-1 mAbs. (b) *P < 0.05 when compared with eosinophil levels before s.c. 
administration of Ova.
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(a)
f ^ | no mAb i.v. + s.c. Ova
I I i.v. isotype control mAb 
+ s.c. Ova
EÜ i.v. aICAM -1 mAb + isotype 
control mAb + s.c. Ova
E23 i.v. otVCAM-1 mAb +
isotype control mAb + s.c. Ova
M  i.v. aICA M -1 mAb +
aVCAM -1 mAb + s.c. Ova 
no mAb i.v. + s.c. saline
DL-5"/_
I before s.c. Ova administration 
Yft no mAb i.v. + s.c. Ova 
no mAb i.v. + s.c. saline 
] i.v. control mAb + s.c. Ova
0
i.v. aICAM -1 mAb + isotype 
control mAb + s.c. Ova
i.v. aV CA M -1 mAb + 
isotype control mAb + s.c. Ova
i.v. aICAM -1 mAb + 
aVCAM -1 mAb + s.c. Ova
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Figure VII.2 Eosinophil recruitment during cutaneous late-phase reaction 
is inhibited in IL-5^'mice in the presence of anti-TNF-a or anti-IL-4 
mAbs.
IL-5'/_ mice were sensitised to Ova by i.p injection on days 0 and 12. On day 24 mice 
received a s.c. injection containing 50 p.g Ova and combinations of 20 pig of anti-IL-4 (or 
isotype control) mAb, 20 [ig of anti-TNF-a (or isotype control) mAb and 20 [ig of anti- 
IL-1 ß (or isotype control) mAb in saline. The accumulation of eosinophils at skin sites 
and eosinophil levels in the blood were determined 6 hours post s.c. injection with Ova. 
(a) Treatment of mice with anti-IL-4 or anti-TNF-a mAb reduced the accumulation of 
eosinophils in the skin. In contrast, anti-IL-1 ß mAb treatment did not effect the 
accumulation of eosinophils. The coadministration of IL-4 and TNF-a did not further 
reduce the accumulation of eosinophils at sites of CLPR when compared with responses 
induced by treatment with either of mAbs alone. Data represents mean eosinophils/mm2 
± SEM of groups of 5 animals, (b) Blood levels of eosinophils in mice treated with anti- 
IL-4 mAb and/or anti-TNF-a mAb and/or anti IL-1 ß mAb were inversely proportional to 
the levels of eosinophils that accumulated at skin sites of CLPR. The IL-5'/_ mice that 
received anti-IL-4 and/or anti-TNF-a mAbs had significantly higher levels of eosinophils 
in the blood compared with control antibody treated mice. Anti-IL-lß  mAb, but not anti- 
IL-4 or anti-TNF-a mAb treatments displayed similar eosinophil levels in the blood when 
compared with control antibody treated mice. Data represents mean eosinophils/ml blood 
± SEM of groups of 5 mice. The significance of differences between experimental 
groups was analysed using the Student's unpaired Ftest. Differences in means were 
considered significant if P < 0.05. < 0.05 compared with the isotype control mAb
treated mice.
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(a)
A - Isotype control mAbs 
B - anti-IL-4 mAb 
C - anti-TNFa mAb 
D - anti-IL-lß mAb
E - anti-TNFa + anti-IL-lß mAb 
F - anti-IL-4 + anti-IL-lß mAb 
G - anti-IL-4 + anti-TNFa mAb 
H - anti-IL-4 + anti-TNFa + anti-IL-1 ß mAb
A - Isotype control mAbs 
B - anti-IL-4 mAb 
C - anti-TNFa mAb 
D - anti-IL-1 ß mAb
E - anti-TNFa + anti-IL-1 ß mAb 
F - anti-IL-4 + anti-IL-1 ß mAb 
G - anti-IL-4 + anti-TNFa mAb 
H - anti-IL-4 + anti-TNFa + anti-IL-lß mAb
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The levels of eosinophils in the blood of IL-5"/_ mice in the presence of s.c. treatment with 
anti-IL-4, anti-TNF-a, anti-IL-lß or control mAbs, singularly or in combination with 
each other, were inversely proportional to the levels of eosinophils that accumulated at 
sites of CLPR. The s.c. treatment of IL-5"^ mice with the control mAbs or anti-IL-lß 
mAb (in the absence of the anti-IL-4 and or anti-IL-lß mAbs) simultaneously, did not 
effect eosinophilic responses in the blood in response to Ova. In contrast, the mice that 
received anti-IL-4 and/ or anti-TNF-a mAbs did not have reduced blood eosinophil levels 
6 hours after the s.c. administration of Ova , when compared with the blood eosinophil 
levels in these mice prior to s.c.administration of Ova (figure VII.2b).
VII.3.3 Eosinophil recruitment at sites of cutaneous late-phase reaction is 
not significantly inhibited in the absence of IL-4 and/or TNF-a function.
In the absence of TNF-a function [as engendered by the absence of the TNF RI (P55) 
and R2 (P75) receptors], the accumulation of eosinophils at sites of CLPR was not 
affected when measured 6 hours after s.c. Ova provocation (figure VII.3). Similarly, 
eosinophil levels in the blood prior to, or 6 hours after, s.c. Ova provocation were also 
not affected in absence of TNF-a function. As previously observed in IL -5 /_ and 
IL-5+/+ mice (Chapter V), there was a significant reduction in the levels of eosinophils in 
the blood of the sensitised P55/P75-/_ and P55/P75+/+ mice when compared with levels in 
these mice before s.c. administration of Ova .
In contrast to P55/P75'/_ mice, IL-4_/_ mice had impaired eosinophil accumulation at sites 
of CLPR when compared to their wild type counterparts (IL-4+/+)(figure VII.4a). 
Sensitised IL-4+/+ mice, but not sensitised IL-4"/_ mice had significantly (.P  < 0.05) 
higher eosinophil levels in the blood than the non sensitised controls. Furthermore, the 
blood levels of eosinophils in the sensitised IL-4_/_ mice were significantly ( P  < 0.05) 
lower that those observed in the sensitised wild type mice before s.c. Ova provocation. 
Since sensitised BL-4'/_ mice exhibited reduced circulating eosinophil levels (compared 
with the sensitised wild type mice) prior to the induction of CLPR, it was hypothesised 
that the reduced accumulation of eosinophils in these mice during CLPR may reflect a 
decreased circulating eosinophil pool rather than impaired eosinophil recruitment 
processes. In order to clarify the mechanism involved in the attenuation of tissue 
eosinophilia, sensitised and non-sensitised IL-4+/+ and IL-4_/' mice were given an i.v. 
adoptive transfer of 1 x 106 H33342 fluorescently labelled eosinophils 4 hours after the 
s.c. injection of Ova or saline. Two hours later the accumulation of fluorescent 
eosinophils was quantified at the s.c. site of injection.
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hours post s.c. injection
0  P55/P75+/+saline □  P55/P75+/+Ova
0  P55/P75-/- saline ■  P55/P75'7- Ova
Figure VII.3 The role of TNF-ain eosinophil trafficking during CLPR in 
mice.
P55/P75+/+ and P55/P75'/_ mice were sensitised to Ova by i.p injection on days 0 
and 12 and on day 24 were given a s.c. injection of 50 fig Ova in 100 fil saline
with 900 fil of air. Non-sensitised mice received s.c. saline only. Mice were
sacrificed 6 hours later and eosinophil numbers at s.c. sites and in the blood 
quantified. Eosinophilic responses to Ova at sites of CLPR (a) or in the blood (b)
were not affected in P55/P75_/_ mice when compared to P55/P75+/+ mice.
Results represent (a) mean eosinophils/mm2 ± SEM and (b) mean eosinophils/ml 
of blood ± SEM of groups of 6 mice. The significance of differences between 
experimental groups was analysed using the Student's unpaired /-test. Differences 
in means were considered significant if P < 0.05. (a) *P < 0.01 when compared 
with the saline controls, (b) *P < 0.05 when compared with the non-sensitised 
groups and **P <0.05 when compared with the saline controls. No significant 
difference in mean levels of eosinophil accumulation in the skin (a) or the mean
eosinophils levels in the blood (b) were detected between the P55/P75+/+ and 
P55/P75_/* mice groups of the same treatment.
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Figure VII.4 The role of IL-4 in eosinophil trafficking during cutaneous 
late-phase reaction.
IL-4+/+ mice and IL-4'/_ mice were sensitised to Ova by i.p injection on day 0 and 12 and 
on day 24 the mice received a s.c. injection of 50 pg Ova in 100 pi saline with 900 pi of 
air. Non-sensitised groups received s.c. saline and air only, (a) The accumulation of 
eosinophils at sites of CLPR at 6 hours was reduced in the IL -4 /_ mice. Results represent 
mean eosinophils/mm2 ± SEM of groups of 5-6 mice, (b) The levels of eosinophils in the 
blood of the sensitised IL-4'/'  mice were significantly lower than those in the sensitised 
IL-4+/+ mice prior to s.c. Ova administration. Eosinophil numbers in the blood 6 hours 
after the induction of CLPR were similar in IL-4'/_ and IL-4+/+ mice when compared 
between the same treatment. Data represents mean eosinophils/ml blood ± SEM of 
groups of 6 mice. The significance of differences between experimental groups was 
analysed using the Student's unpaired Mest. Differences in means were considered 
significant if P < 0.05. (a) P < 0.05 compared with saline controls at the same time point 
and **/) < 0.05 compared with sensitised IL-4+/+ mice at 6 hours post s.c. Ova 
administration and when compared with the saline controls, (b) *P < 0.05 compared with 
sensitised IL-4+/+ mice prior to s.c. Ova administration and **P < 0.05 compared with 
saline controls.
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Following the adoptive transfer of H33342 labelled eosinophils, fluorescent cells were 
detectable in the blood of the recipients. The levels of fluorescent cells in the circulation 
were equivalent in all groups of sensitised and non-sensitised IL-4+/+and IL-4'/_ mice 
when determined 10 minutes after i.v. adoptive transfer (figure VII.5a). As previously 
observed in IL-5+/+ mice (Chapter V), a significantly (P <0.01) greater number of 
fluorescent eosinophils accumulated at sites of Ova-induced CLPR in mice than at sites of 
saline administration (figure VII.5b). Moreover, the ability of fluorescent eosinophils to 
home to sites of CLPR or s.c. saline administration in mice was not effected in the 
absence of IL-4 (figure VII.5b).
To determine whether the apparent lack of effect of IL-4 or TNF-a in processes of 
eosinophil homing at sites of CLPR (as discussed above) was due to the overlapping 
function between these molecules, sensitised wild type mice were s.c. coadministered 
with anti-IL-4 and anti-TNF-a mAbs at sites of s.c. Ova administration. In contrast to 
similar studies (Satoh et al., 1997), the s.c. administration of anti-IL-4 and anti-TNF-a 
mAb had little effect on the eosinophilic responses in the skin (figure VII.6a) or the 
circulation (figure VII.6b) when measured at 6 hours after s.c. Ova provocation.
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Figure VII.5 The role of IL-4 in eosinophil homing to sites ofCLPR in mice.
IL-4+/+ mice and IL-4'7' mice were sensitised to Ova by i.p injection on days 0 and 12. 
On day 24 the mice received a s.c. injection of 50 fig Ova in 100 fil saline with 900 fil 
of air. Non-sensitised mice received s.c. saline only. Four hours after s.c. injections 
mice received an i.v. adoptive transfer of 1 x 106 H33342-labelled eosinophils. Mice
were sacrificed 2 hours later and the accumulation of fluorescent eosinophils/mm2 on 
s.c. membrane sections quantified, (a) Adoptively transferred H33342-labelled 
eosinophils accumulated at sites of CLPR at 6 hours post Ova provocation and the 
ability of these cells to accumulate was not affected in IL-4'7' mice. Significantly 
greater levels of H33342-labelled eosinophils accumulated at sites of CLPR than at 
sites of saline administration. Results represent mean fluorescent cells/mm2 ± SEM 
for groups of 5 animals, (b) Fluorescent cells in the blood at 10 minutes post i.v. 
adoptive transfer were equivalent in all groups of mice. Results represent mean 
fluorescent cells/ml of blood ± SEM of groups of 5 mice. The significance of 
differences between experimental groups was analysed using the Student's unpaired 
1-test. Differences in means were considered significant if P < 0.05. (a) No significant 
difference between the means of any group of mice receiving an adoptively transfer of 
eosinophils were detected, (b) *P < 0.01 when compared with saline controls. No
significant differences were detected between the means of IL-4+7+ and IL-4'7' groups 
when compared within the same treatment.
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(b)
hours post s.c. injecton
anti-IL-4 mAb + anti-TNF-a mAb, s.c. Ova 
non-mAb treated, s.c. saline
Figure VII.6 Treatment of mice with anti-IL-4 and anti-TNF-a mAbs has no 
effect on eosinophilic responses at sites of CLPR or in the blood of wild type mice.
IL-5+/+ mice (C57BL6) were sensitised to Ova by i.p injection on days 0 and 12. On 
day 24 mice received a s.c. injection of 900 fils of air with 50 pig of Ova in 100 fil of 
saline contained either 100 fig of anti-IL-4 mAb and 100 fig of anti-TNF-a mAb or 
200 fig of isotype control mAb (GL113). For comparison mice were also given a s.c.
injection of Ova in saline with 900 fil of air in the absence of mAb treatment. Mice
were sacrificed 6 hours later and the accumulation of eosinophils at sites of CLPR 
quantified. Eosinophil levels in the blood were also quantified at this time as well as 
prior to s.c. injection. Data represents (a) mean eosinophils/mm2 ± SEM and (b) 
mean eosinophils/ml blood ± SEM of groups of 5 mice. The significance of 
differences between experimental groups was analysed using the Student’s unpaired 
r-test. Differences in means were considered significant if P < 0.05. (a) < 0.01
when compare with all groups that received s.c. Ova. (b) *P < 0.01 compared with 
levels prior to s.c. injection of Ova. No significant differences were detected
between the means of the group treated with anti-IL-4 and anti-TNF-a mAbs, the
group treated with the isotype control mAb and the non-antibody treated group at 6 
hours post s.c. Ova provocation.
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VII.4 DISCUSSION.
Basal eosinophil recruitment into peripheral tissues is impaired in IL-5'/_ mice (Chapter V) 
and the nature of this impairment indicates that adhesion systems are defective in these 
animals. In contrast, the homing of eosinophil to sites of allergic inflammation is not 
inhibited in IL-5'^‘ mice (Chapter V) and thus, inflammatory mediators may restore 
adhesion systems in EL-5 deficient mice.
Previous observations of mice during allergic airways inflammation (Gonzalo et al, 
1996a) indicated that the recruitment of eosinophils at sites of inflammation is dependent 
on both ICAM-1 and VCAM-1 adhesion pathways. The results in this Chapter also 
support a role for these two adhesion pathways in eosinophil recruitment at sites of 
CLPR. The treatment of IL-5+/+ mice and IL-5_/' mice with anti-ICAM-1 and anti- 
VC AM-1 mAbs inhibited the accumulation of eosinophils at sites of CLPR 6 hours after 
antigen provocation. Thus, not only do these molecules participate in eosinophil 
recruitment into inflamed tissues, they are also activated independently of IL-5 during 
allergy. Since the treatment of mice with anti-ICAM-1 and anti-VCAM-1 mAbs was 
more effective at inhibiting the accumulation of eosinophils at sites of CLPR than either 
mAb alone, these adhesion molecules may promote eosinophil trafficking in tissues 
independently of one another. The i.v. treatment of mice with anti-VCAM-1 and anti- 
ICAM-1 mAbs also inhibited the reduction of eosinophil numbers in the blood that are 
associated with CLPR. This indicates that the inhibition of the accumulation of 
eosinophils at sites of allergic inflammation by these mAbs, was coupled to mechanisms 
regulating the sequestration of eosinophils from the circulation into inflammed tissues.
Eosinophil recruitment at sites of CLPR in IL-5"/_ mice was reduced in the presence of 
anti-IL-4 or anti-TNF-a mAbs, but not in the presence of anti-IL-lß mAb. Thus, 
although IL- lß  stimulates eosinophil adhesion and transmigration at the vascular 
endothelium in vitro (Ebisawa et al., 1992), this cytokine is redundant or not involved in 
eosinophil recruitment processes during allergy. Interestingly, previous reports indicated 
that the treatment of cyclophosphamide-treated mice with anti-IL-lß mAb reduced the 
accumulation of eosinophils at sites of hapten administration (Satoh et al., 1997). Thus, 
there may be a differential requirement for this cytokine in eosinophil trafficking in 
various eosinophilia models. Furthermore, the cyclophosphamide model of eosinophilia 
may not be suitable for the study of eosinophil trafficking during allergy.
The s.c. administration of both anti-IL-4 and anti-TNF-a mAbs to IL-5'/_ mice was no 
more effective at reducing the accumulation of eosinophils at sites of CLPR than either of 
these mAbs alone. Thus, IL-4 and TN F-a may act together to promote eosinophil 
recruitment at sites of allergic inflammation. Both IL-4 and TNF-a may promote
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eosinophil recruitment by activating adhesion systems that promote eosinophil tethering 
and transmigration at the vascular endothelium at the site of allergic inflammation (Briscoe 
et a l, 1992, Pober et al., 1996). In light of the recent demonstration that both IL-4 and 
TNF-a act in synergy to promote the expression of VCAM-1 on the vascular endothelium 
in vitro (Iademarco et al., 1995), it is possible that these cytokines act together to 
promote eosinophil recruitment at sites of allergic inflammation. Interestingly, in the 
absence of TNF-a function (as effected by the deletion of the receptors for this cytokine), 
mice exhibited normal eosinophilic responses at cutaneous sites of allergic inflammation. 
Thus, in the presence of EL-5, TNF-a may become redundant in processes that promote 
the accumulation of eosinophils at sites of allergic inflammation.
Although early (6 hours post antigen s.c. administration) eosinophilic responses in fL-4_/‘ 
mice were reduced at sites of CLPR, the signal for eosinophil homing at these sites in 
these mice was not impaired. Circulating eosinophil levels in IL-4'/_ mice do not increase 
during sensitisation to antigen (unlike their wild type counterparts) and thus decreased 
eosinophil recruitment at sites of CLPR may reflect the reduced circulating eosinophil 
pool. The inability of IL-4_/' mice to develop blood eosinophilia following sensitisation 
may involve the reduced capacity of these animals to produce IL-5 (effected by the 
inability of these mice to produce Th2 type responses) (Kopf et al., 1993, Gonzalo et al., 
1996).
Although a role for IL-4 or TNF-a in eosinophil recruitment to sites of allergic 
inflammation was demonstrated in IL-5"/_ mice, the treatment of wild type mice with both 
anti-IL-4 and anti-TNF-a mAbs had no significant effect on either the accumulation of 
eosinophils at sites of inflammation or antigen induced reductions in the circulating 
eosinophil pool. This indicates that in the presence of IL-5, both IL-4 and TNF-a 
become redundant in eosinophil recruitment processes at sites of allergic inflammation. 
These results are of considerable importance since they suggest that there are multiple 
pathways of eosinophil recruitment at sites of allergic inflammation. Thus, the 
therapeutic intervention of allergic disease by the specific targeting of individual 
molecules involved in eosinophil recruitment at sites of inflammation may not be 
possible. It would be interesting to verify the role of these cytokines in the activation of 
adhesion pathways at sites of inflammation, particularly mechanisms involving ICAM-1 
and VCAM-1. This could be accomplished by the immunohistochemical examination of 
the expression and activation of adhesion molecule subsets at cutaneous sites of allergic 
inflammation in IL-5+/+ and EL-5'/_ mice, in the presence and absence of anti-IL-4 and 
anti-TNF-a mAbs.
Results in this Chapter suggest of a role for IL-5 in eosinophil recruitment pathways 
during allergy. Furthermore, these experiments demonstrate that a high degree of
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redundancy may exist between inflammatory cytokines that are involved in the promotion 
of eosinophil recruitment to sites of allergic inflammation, possibly due to the overlapping 
action of these molecules on adhesion systems. In the absence of IL-5 (but not in it's 
presence) both IL-4 and TNF-a are required for eosinophil trafficking at sites of CLPR. 
This suggests that IL-5 has a similar action to IL-4 and TNF-a in the promotion of 
eosinophil trafficking. TNF-a is not considered to be an eosinophil chemoattractant and 
in light of the demonstration that eosinophil homing to sites of allergic inflammation is not 
impaired in IL-5'/_ mice (Chapter V), these cytokines may not act as eosinophil 
chemoattractants at sites of allergic inflammation. As IL-4, TNF-a and IL-5 all induce 
the expression of adhesion molecules in endothelial cultures, these cytokines probably 
promote eosinophil adhesion and transmigration at the vascular endothelium, possibly by 
regulating the expression and activational states of ICAM-1 and VCAM-1.
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CHAPTER VIII
SUMMARY AND CONCLUSIONS
214
VIII.1 INTRODUCTION.
Eosinophil trafficking and activation is a complex process that is potentially regulated by 
numerous cytokines, chemokines, lipid mediators and small bioactive peptides. 
Accumulating evidence supports a role for eotaxin and IL-5 as central mediators of 
selective eosinophil recruitment into tissues, and indicates that both of these cytokines 
may also regulate eosinophil activation. Recent literature suggests that under basal 
conditions, eotaxin and IL-5 may act cooperatively to regulate eosinophil homing and 
tissue accumulation (Collins etal., 1995; Rothenberg etal., 1996). Furthermore, both 
IL-5 and eotaxin have been shown to regulate the accumulation of eosinophils at sites of 
allergic inflammation (Foster et al., 1996; Rothenberg et al., 1997). In response to 
inflammatory stimuli, IL-5 provides the essential signal for the rapid mobilisation of a 
bone marrow pool of eosinophils and is required in the maintenance of blood eosinophilia 
(Coffman et al., 1989; Kopf et al., 1996; Foster et al., 1996). In contrast, eotaxin may 
regulate early-phases of eosinophil recruitment into tissues (Rothenberg et al., 1997). 
Although previous studies show cooperation between EL-5 and eotaxin in the regulation 
of eosinophil trafficking (Collins etal., 1995, Rothenberg, et al., 1996), the relationship 
between these cytokines in eosinophil recruitment and activation was unknown. It was 
the role of the research presented in this thesis to define the relationship between IL-5 and 
eotaxin in the regulation of eosinophilic responses in the circulation and in tissues; and to 
detennine if there is a requirement for these cytokines in eosinophil trafficking at basal 
states and at sites of allergic inflammation. Furthermore, the effect of these two cytokines 
on eosinophil-induced airways hyperreactivity was also examined.
VIII.2 SUMMARY OF EXPERIMENTAL FINDINGS.
Both IL-5 and eotaxin were found to be potent and selective regulators of eosinophilic 
responses in vivo. When administered systemically, eotaxin and IL-5 potently induced 
blood eosinophilia. IL-5 mobilised eosinophils from the bone marrow and eotaxin acted 
independently of this compartment. Systemic eotaxin may recruit eosinophils out of 
peripheral tissues. Therefore, two mechanism exist by which eosinophils can be rapidly 
mobilised into the circulation. Eotaxin is produced by tissues and IL-5 from T-cells 
following antigen provocation. Thus, eotaxin may augment the IL-5 signal by 
supplementing blood eosinophilia in the early phases of the inflammatory response as 
well as eliciting a selective chemoattractant signal for eosinophil polarisation and 
migration (Jose et al, 1994a; Rothenberg et al., 1996).
When administered to the skin, eotaxin and IL-5 potently induced tissue eosinophilia.
The effect of eotaxin was highly dose dependent indicating that the action of this molecule 
is tightly regulated. Furthermore, these cytokines acted in synergy. IL-5 also
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synergistically promoted the effects of RANTES and M IP-la on the accumulation of 
eosinophils in tissues, but not with lipid mediators (PAF and LTB4) or ECF-a (Val-Gly- 
Ser-Glu). Thus, not only is IL-5 a potent eosinophil chemoattractant in its own right, it 
also synergistically promotes eosinophil chemotaxis in response to CC-chemokines at 
concentrations that are suboptimal for these cytokines in isolation. Eotaxin, M IP-la and 
RANTES may all signal through the chemokine receptor CCR3 and IL-5 could potentiate 
this pathway. RANTES and M IP -la  also signal through other CCRs which may account 
for their action on a variety of other cell types. Thus, the unique relationship between IL- 
5 and CCR3 operation provides a fundamental mechanism for the amplification of signals 
selectively regulating eosinophil trafficking.
Eotaxin and IL-5 were also found to be potent and selective stimuli of the accumulation of 
eosinophils in the lungs of mice. Furthermore, these two cytokines acted in synergy.
This indicates that eotaxin and IL-5 may promote eosinophil trafficking in both mucosal 
(airways) and non-mucosal (skin) tissues as well as in the circulation. Although both 
eotaxin and IL-5 activate eosinophils in vitro (Kita et a l, 1992, Eisner et al., 1996), 
these cytokines in combination, did not induce eosinophils to release MBP in the airways. 
Furthermore, these cytokines alone or in combination did not promote airways 
hyperreactivity. The additional antigenic stimulus provided by repeated aero allergen 
exposure was required to induce the release MBP from eosinophils and for airways 
hyperreactivity to develop. Notably, the signals derrived from antigen stimulation could 
not induce airways hyperreactivity in the absence of airways eosinophilia. Interestingly, 
no damage to the airways was observed in those mice that developed airways 
hyperreactivity. Thus, airways damage does not necessarily precede the development of 
airways hyperreactivity. Furthermore, the repeated exposure of the mice to aeroallergen 
did not affect the levels of eosinophils in the airways. These results indicate that not only 
were the levels of eosinophils in the airways (in the absence of aeroallergen exposure) 
sufficient to induced airways hyperreactivity, but the activation of these cells is not solely 
effected by IL-5 and eotaxin. Interestingly, genetically manipulated mice that over
produce IL-5 specifically by airway epithelial cells, develop both airways eosinophilia, i
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IL-5 may not only potentiate eotaxin-induced eosinophil chemotaxis, but also provide an 
essential signal for basal eosinophil migration into tissues in response to eotaxin stimuli. 
The impaired nature of eotaxin signalling in the tissues of IL-5‘/_ mice indicates that basal 
levels of IL-5 control eosinophil transmigration events at the vascular endothelium and 
suggest a requirement for this cytokine in adhesion molecule function. These studies
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further emphasise the broad action of IL-5 on eosinophil function. Interestingly, eotaxin 
signalling in the blood occurs in the absence of IL-5. Since systemic eotaxin most 
probably draws eosinophils out of peripheral tissues and not from the bone marrow, 
eosinophil trafficking within tissues and the migration of this cell out of tissues in 
response to eotaxin does not require IL-5, in contrast to eosinophil migration into tissues. 
This suggests that there is a differential usage of adhesion processes between active 
migration in and transient margination mechanisms in tissues.
The demonstration that systemic eotaxin induces blood eosinophilia in the absence of 
IL-5 is novel and demonstrates the existence of a pool of eosinophils that can be 
mobilised independently of IL-5. However, although systemic eotaxin promoted blood 
eosinophilia it did not enhance eosinophilic responses in tissues, in contrast to IL-5. The 
systemic coadministration of IL-5 and eotaxin amplified eosinophilic responses in tissues 
to a greater extent than either of these cytokines alone. Thus, in addition to promoting 
blood eosinophilia, IL-5 may be required to activate (ie. prime) the eosinophils in the 
circulation, promoting increased responsiveness to chemotactic stimuli in tissues.
Although eotaxin or IL-5 -induced eosinophil homing in tissues at base line was impaired 
in EL-5"/' mice, eosinophil trafficking in tissues at sites of allergic inflammation was not. 
This indicates that inflammatory mediators may overcome any impairment in eosinophil 
homing that occur in the absence of DL-5 at basal states. IL-4 and TNF-a may contribute 
to this process since in the absence of IL-5 these molecules regulate the accumulation of 
eosinophils at sites of CLPR. Interestingly, IL-5 may also promote eosinophil trafficking 
at sites of CLPR since both IL-4 and TNF-a become redundant in this process in the 
presence of IL-5. These results indicate that there may be a high degree of redundancy 
between these cytokines in the events regulating eosinophil trafficking to sites of allergic 
inflammation. All of these molecules regulate the expression of adhesion molecules, and 
thus, the redundancy between these cytokines may reflect their overlapping activation of 
adhesion pathways at sites of allergic inflammation.
The development of airways eosinophilia and airways dysfunction during allergic airways 
inflammation was severely attenuated in IL-5_/' mice (Foster et al., 1996). However, 
eosinophil homing to the inflamed lungs is not impaired in IL-5"/_ mice (Chapter V).
Thus, the attenuation of the accumulation of eosinophils in the lungs IL-5‘/_ mice may 
reflect their inability to develop blood eosinophilia in response to antigenic stimuli. Not 
only was eosinophil recruitment at sites of antigen provocation independent of IL-5, this 
cytokine was not required for the development of airways hyperreactivity. Sensitised IL- 
5_/" mice developed increased airways responsiveness to the spasmogen, 
ß-methylcholine, following multiple exposures to aeroallergen. Furthermore, as in wild 
type mice, the degree of airways hyperreactivity correlated with the levels of eosinophils
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and the level of MBP in the airways. These results suggest that eosinophils and their 
products directly mediate airways hyperreactivity. Further studies showed that by 
amplifying circulating eosinophil levels in IL-5~/_ mice by adoptive transfer of eosinophils 
or by the systemic administration of eotaxin, both airways eosinophilia and airways 
hyperreactivity are enhanced. Interestingly, the adoptive transfer of eosinophils that had 
prior exposure to IL-5, increased airways reactivity to a greater level than the systemic 
administration of eotaxin; even though both treatments induced equivalent and specific 
increases in the levels of eosinophils in the airways. Thus, although IL-5 is not required 
for the induction of airways hyperreactivity following aeroallergen provocation, it does 
amplify it. This may involve the ability of this cytokine to prime eosinophils, inducing 
heightened sensitivity to degranulatory stimuli. The specific localisation of eosinophils in 
regions near the airways smooth muscle, but not in regions near the airways epithelium, 
suggests that eosinophils induce airways hyperreactivity by effecting airways smooth 
muscle function rather than through airways epithelial lining disruption. Furthermore, as 
previously observed, airways hyperreactivity occurred in the visible absence of airways 
damage, (including airway epithelial shedding) and thus, it is concluded that airways 
hyperreactivity precedes airways damage. The primary difference between studies by 
Foster et al., (1996) and those here is the amount and number of exposure of IL -5 /_ mice 
to aeroallergen. In investigations in this thesis, IL-5’^ " mice received an|f extra day of Ova 
Inhalation and the dose was 150 mg of Ova per 30 minute aerosol period [as opposed to 
100 mg per 30 minute aerosol period used by Foster et al., (1996)]. Thus, the antigen 
load to the airways regulates the number of eosinophils recruited to the lung and the 
subsequent impact of the eosinophil regulates airways hyperreactivity. In unpublished 
observations, IL-5_/' mice that are chronically exposed to Ova develop pronounced foci of 
airways eosinophils and airways hyperreactivity without developing a blood eosinophilia. 
Thus, in chronic models of allergic airways disease it would appear that pathophysiology 
can occur independently of IL-5.
In contrast to IL-5, eotaxin may direct eosinophil chemotaxis at cutaneous sites of allergic 
inflammation. Elevated levels of eotaxin mRNA were observed at skin and lung sites of 
allergic inflammation soon after antigen provocation and were dependent on IFNy. 
Interestingly, the expression of eotaxin in the lungs, but not in the skin at sites of allergic 
inflammation was also dependent on IL-4. Thus, the expression of this chemokine may 
be differentially regulated at non-mucosal and mucosal sites of allergic inflammation.
Eotaxin may not only regulate eosinophil trafficking at base line and during allergy, but 
may also regulate eosinophilic responses to non-allergic stimuli. Eotaxin deficient mice 
developed abnormally high levels of eosinophils at s.c. sites of saline administration. 
Eotaxin may also regulate the responsiveness of eosinophils to itself, as eosinophilia in 
the blood following the systemic administration of eotaxin was amplified in eotaxin~/_
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mice. This may reflect a down regulation of eotaxin signalling through CCR3, that has 
previously been observed in vitro (Rothenberg et a l, 1996). Although eotaxin does not 
appear to regulate IL-5 induced blood eosinophilia, it may participate in IL-5-induced 
eosinophil differentiation. In the absence of eotaxin, bone marrow eosinophil levels rise 
rapidly following the systemic administration of IL-5, and cultures of bone marrow cells 
from eotaxin"^' mice rapidly differentiate into eosinophils following the addition of IL-5. 
However, eotaxin is not significantly involved in eosinophil differentiation at resting 
states, as eotaxin deficient mice have normal levels of eosinophils in bone marrow. 
Eotaxin may also regulate eosinophil mobilisation from the bone marrow following 
antigen provocation, as bone marrow eosinophil mobilisation was heightened in eotaxin 
deficient mice during cutaneous allergy and this phenomena may involve an eosinophil 
hypersensitivity to IL-5.
VIII.3 THE PROPOSED ROLES OF IL-5 AND EOTAXIN IN 
EOSINOPHIL TRAFFICKING.
The results presented in this thesis demonstrates that both IL-5 and eotaxin are important 
regulators of eosinophil trafficking at basal states and during allergy. The following is a 
proposal of the suspected roles of IL-5 and eotaxin in these processes.
At resting states eosinophil differentiation may be regulated by a range of cytokines, 
including eotaxin and IL-5. EL-5 promotes eosinophil differentiation and eotaxin may 
regulate this process. However, these two cytokines do not play obligatory roles in 
eosinophil differentiation, as eosinophil differentiation occurs in their absence. In the 
circulation, eosinophil levels may be regulated by both IL-5 and eotaxin. The basal levels 
of expression of eotaxin in numerous tissues throughout the body (Rothenberg et a l, 
1995a, 1995b), suggests that eotaxin may also regulate resting state eosinophil 
recruitment through peripheral tissues. Basal levels of IL-5 may assist in this process by 
maintaining adhesion molecule function at the vascular endothelium. Furthermore, IL-5 
may act in synergy with eotaxin (and other C-C chemokines?) to promote eosinophil 
trafficking in tissues. This would allow each of these cytokines to effectively signal at 
concentrations that are suboptimal for the molecules individually. Eosinophil trafficking 
at resting state is summarised in figure VIII. 1.
The selective trafficking of eosinophils at sites of allergic inflammation may also be 
regulated by eotaxin and IL-5. Following antigen provocation, eotaxin is produced at 
sites of inflammation. Increased systemic levels of this cytokine may induce the 
migration of eosinophils out of non-inflamed tissues into the circulation. IL-5 produced 
at sites of inflammation (probably after eotaxin) also amplifies the circulating eosinophil 
pool, by mobilising eosinophils from the bone morrow into the circulation. Over longer
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Figure VIII. 1 The role of IL-5 and eotaxin in eosinophil trafficking at basal 
states.
IL-5 differentiates precursor cells into eosinophils in the bone marrow and eotaxin 
may regulate this process. Systemic IL-5 mobilises eosinophils into the circulation 
and primes them, leading to enhanced chemotactic responsiveness. In addition 
IL-5 may also activate adhesion molecule expression on the eosinophil and regulate 
the function of adhesion systems at the vascular endothelium. Eotaxin may also 
regulate eosinophil levels in the circulation by recruiting eosinophils out of tissues. 
In addition, IL-5 and eotaxin, may also regulate eosinophil trafficking in tissues as 
part of immune surveillance. Furthermore, in this capacity IL-5 may promote 
effective and selective eosinophil migration by enhancing the effects of CC-
chemokines.
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periods of time, systemic IL-5 may also promote! the differentiation of eosinophils in the 
bone marrow for the long term development and maintenance of blood eosinophilia. 
Furthermore, eotaxin may negatively regulate this process.
IL-5, in addition to IL-4 and TNF-ot may promote eosinophil transmigration at the 
vascular endothelium in inflamed tissues by inducing the expression of complementary 
adhesion molecules. Eosinophil polarisation and mobilisation in tissues is promoted by 
chemotactic gradients formed by the release of chemoattractants at the loci of 
inflammation. Eotaxin may promote eosinophil chemotaxis during the early stages of the 
inflammatory response, becoming redundant during the later stages of the inflammatory 
reaction due to the production of other eosinophil chemoattractants, such as RANTES and 
M IP -la  (Alam etal., 1996; Humbert et al., 1997). Interestingly, although IL-5 is 
chemotactic for eosinophils in vivo, this cytokine does not appear to be involved in 
eosinophil homing at sites of inflammation during allergy.
In the airways, eosinophils preferentially localise in regions near the airways smooth 
muscle in response to IL-5 and eotaxin expression by recombinant vaccinia viruses and 
following aeroallergen provocation. Inflammatory mediators may then activate 
eosinophils to degranulate and release MBP. IL-5 at sites of inflammation may not only 
prime eosinophils to respond to degranulatory stimuli, but at high concentrations and over 
long periods of time may itself promote eosinophil degranulation (Lee et al,, 1997).
MBP causes airways dysfunction by allosteric blocking of inhibitory pathways of smooth 
muscle contraction, leading to hypersensitivity to spasmogenic stimuli (Gleich et al., 
1995). Over prolonged periods eosinophils may also induce damage to the airways by 
amplifying the inflammatory response through the release of cytotoxic molecules, 
including cationic proteins and lipid mediators, in addition to the generation of highly 
reactive oxygen species (Bruijnzeel, 1989; Gleich, 1990; Gleich et al., 1994). The role 
of IL-5 and eotaxin in the regulation of eosinophil trafficking and activation at sites of 
allergic inflammation are summarised in figure VIII.2.
Interestingly, although IL-5 and eotaxin potently induce the recruitment of eosinophils 
into tissues; these molecules are not obligatory for eosinophil homing at sites of allergic 
inflammation. In the absence of eotaxin eosinophil homing is diminis^d however, 
indicating that this chemokine promotes eosinophil chemotaxis at sites of allergen 
provocation. During allergy, IL-5 appears to primarily promote eosinophil differentiation 
and the development of blood eosinophilia, as well as prime eosinophils for enhanced 
responsiveness to chemotactic and degranulatory stimuli. Thus, the inhibition of IL-5 as 
a therapy for allergic disease such as asthma may be effective, since it would reduce the 
available eosinophil pool. Eotaxin acts in synergy with IL-5 and plays a fundamental role
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Figure VIII.2 The role of IL-5 and eotaxin in the regulation of eosinophil 
trafficking at sites of allergic inflammation.
The secretion of IL-5 and eotaxin at sites of allergic inflammation elevates systemic levels 
of these cytokines. IL-5 induces mobilisation of bone marrow eosinophils into the 
circulation and eotaxin may sequester eosinophils out of non-inflamed tissues. IL-5 also 
induces eosinophil differentiation in the bone marrow. Eotaxin may regulate EL-5- 
induceA-eosinophil differentiation and the mobilisation from bone marrow. IL-5 in the 
circulation primes eosinophils for enhanced chemotactic responsiveness, and induces the 
expression of adhesion molecules on these cells. At sites of inflammation, the 
overlapping actions of IL-5, IL-4 and TNF-a may promote complementary adhesion 
molecule expression at the vascular endothelium and promote eosinophil 
adhesion/transmigration. Chemoattractant gradients generated at sites of inflammation 
induce cell polarisation and migration towards the inflammation site. Eotaxin may 
promote eosinophil chemotaxis during the early stages of inflammation.
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in regulating eosinophil chemotaxis. Targetting the action of both molecules would 
provide a powerful therapeutic approach to downregulating tissue eosinophilia.
In conclusion, IL-5 and eotaxin play fundamental roles in the regulation of eosinophil 
function. Notably both cytokines can regulate blood and tissues eosinophilia in response
to allergic stimuli. In particular, the migration of eosinophils is regulated by a unique
aclvvfofce.
signalling arrangement between IL-5 and chemokines that oppe.rate.CCR3 which provides 
a mechanism that synergistically and selectively potentiates eosinophilia. Modulation of 
IL-5 and eotaxin signalling may provide a significant advance in the treatment of 
eosinophil derived pathophysiology in allergic disease.
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